Melanin concentrating hormone receptor antagonist

ABSTRACT

Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I  
                 
 
wherein A, W, X, Z, R 1 -R 3 , and R 8  are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

BACKGROUND OF THE INVENTION

In 1999, 61% of adults, 13% of children aged 6 to 11 years and 14% of adolescents aged 12 to 19 years in the United States were overweight. Increases in occurrence of overweight and obesity has been seen in all age, racial and ethnic groups, and in both men and women.

Epidemiological studies show an increase in mortality associated with overweight and obesity. Individuals who are obese (body mass index (“BMI”)>30) have a 50-100% increased risk of premature death from all causes compared to individuals with a BMI in the range of 20 to 25. BMI is calculated according to the formula: ${BMI} = {\frac{{Weight}\quad{in}\quad{pounds}}{\left( {{Height}\quad{in}\quad{inches}} \right)^{2}} \times 703}$

An estimated 300,000 deaths a year in the United States may be attributable to obesity. Overweight and obesity are associated with an increased risk for coronary heart disease; type 2 diabetes; endometrial, colon, postmenopausal breast, and other cancers; and certain musculoskeletal disorders, such as knee osteoarthritis.

Both modest and large weight gains are associated with significantly increased risk of disease. For example, a weight gain of 11 to 18 pounds increases a person's risk of developing type 2 diabetes to twice that of individuals who have not gained weight, while those who gain 44 pounds or more have four times the risk of type 2 diabetes. A gain of approximately 10 to 20 pounds results in an increased risk of coronary heart disease (nonfatal myocardial infarction and death) of 1.25 times in women and 1.6 times in men. Higher levels of body weight gain of 22 pounds in men and 44 pounds in women result in an increased coronary heart disease risk of 1.75 and 2.65, respectively. In women with a BMI of 34 or greater, the risk of developing endometrial cancer is increased by more than six times. Overweight and obesity are also known to exacerbate many chronic conditions such as hypertension and elevated cholesterol. Overweight and obese individuals also may suffer from social stigmatization, discrimination, and poor body image. Although obesity-associated morbidities occur most frequently in adults, important consequences of excess weight as well as antecedents of adult disease occur in overweight children and adolescents. Overweight children and adolescents are more likely to become overweight or obese adults; this concern is greatest among adolescents. Type 2 diabetes, high blood lipids, and hypertension as well as early maturation and orthopedic problems also occur with increased frequency in overweight youth. A common consequence of childhood overweight is psychosocial-specifically discrimination. See The Surgeon General's Call To Action To Prevent and Decrease Overweight and Obesity, U.S. Dept. of Health and Human Services, 2001. Thus, the need exists for methods of controlling weight and treating obesity.

Melanin-concentrating hormone (MCH) is a cyclic, 19-amino acid hypothalamic neuropeptide derived from a larger pro-hormone precursor of MCH, Pmch. Pmch-deficient mice are lean, hypophagic, and have an increased metabolic rate. Transgenic mice over-expressing Pmch are hyperphagic and develop mild obesity. Consequently, MCH has been implicated in the regulation of energy homeostasis, through actions on motor activity, metabolism, food intake and neuroendocrine function.

Two receptors have been identified in MCH, and are designated MCH 1 receptor and MCH 2 receptor. The MCH 1 and MCH 2 receptors are G protein-coupled receptors (GPCRs) believed to be responsible for the actions of MCH. G proteins are heterotrimeric proteins that control cellular responses to stimuli by cycling between a GTP-bound active state, which regulates the activity of a number of effector proteins, and a GDP-bound inactive state. GPCRs accelerate activation of the G protein by increasing the GDP/GTP exchange rate.

MCH 1 receptor-deficient mice have normal body weights, yet are lean and have reduced fat mass. Surprisingly, MCH 1 receptor-deficient mice are hyperphagic when maintained on regular chow, and their leanness is a consequence of hyperactivity and altered metabolism. Consistent with the hyperactivity, MCH 1 receptor-deficient mice are less susceptible to diet-induced obesity. Importantly, chronic central infusions of MCH induce hyperphagia and mild obesity in wild-type mice, but not in MCH 1 receptor-deficient mice. Marsh et al., Proc. Nat. Acad. Sci., 99(5), 3241 (2002).

Because MCH has been shown to be an important regulator of food intake and energy balance, compounds capable of modulating the activity of MCH receptors, particularly MCH 1 receptors, are highly desirable for the treatment of eating disorders and metabolic disorders.

PCT Publication No. WO 02/04433 describes phenylcycloalkylmethylamino and phenylalkenylamino derivatives as modulators of MCH 1 receptors useful in the treatment of certain metabolic, feeding and sexual disorders.

U.S. Pat. No. 6,472,394 describes the use of amide derivatives of 1,4-disubstituted piperidine as MCH antagonists for the treatment of obesity and diabetes.

SUMMARY OF THE INVENTION

Among the several objects of certain embodiments of the present invention, therefore, may be noted the provision of melanin concentrating hormone receptor antagonists; the provision of pharmaceutical compositions comprising melanin concentrating hormone receptor antagonists; the provision of methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject; the provision of methods for treating, preventing or otherwise ameliorating obesity in a subject; and the provision of methods of achieving sustained body weight loss in a subject.

Briefly therefore, the present invention is directed to a melanin concentrating hormone receptor antagonist of Formula I as defined herein.

The present invention is also directed to pharmaceutical compositions comprising a compound of Formula I, as defined herein, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

The present invention is also directed to a method of inhibiting a GPCR, comprising contacting a compound of Formula I, as defined herein, with a GPCR, wherein the compound of Formula I is present at a concentration sufficient to inhibit the binding of a GPCR ligand in vitro. This method includes inhibiting a GPCR in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of a ligand to the GCPR in vitro. Examples of GPCRs which may be inhibited according to the present invention include, but are not limited to the following GPCR families: Acetylcholine muscarinic, Adenosine, adrenergic, adrenergic, alpha-adrenergic, angiotensin, AR, Cannabinoid, DA, dopamine, His, imidazoline, Leukotriene, mAch, MCH, Opioid, serotonergic, serotonin, and Somatostatin.

Inhibition of the binding of a GPCR ligand to GPCRs is useful in the treatment of numerous disorders, including digestive tract disorders; mucolytic asthma; arrhythmia; ischemia; reperfusion injury; bronchospasm associated with asthma, emphysema and chronic bronchitis; acute and chronic respiratory diseases, including cystic fibrosis; cardiostimulant; chronic bronchitis; neurological depression; heart failure; benign prostate hypertrophy; diabetes; muscle spasm; myocardial infarction; stroke; Alzheimer's disease; anorexia; cachexia; multiple sclerosis; hyperprolactinemia; psychotropism; mydriasis in ocular examination and surgery; deficitary and productive schizophrenia, psychasthenia and non-endogenous depression; kidney disease; vasodilation; chronic gastritis; glaucoma; depression; rhinitis, including allergic rhinitis; pain, including cancer pain, musculoskeletal pain, post-operative pain; eye disease; dyspepsia; cough; ulcer, including gastrointestinal, gastric and esophageal ulcers; helicobacter pylori prophylaxis infection; oesophagitis; allergies, including non-asthma allergies; cold; asthma; conjuctivitis; urticaria; diarrhea; Creutzfeldt-Jakob disease; dysmenorrhoea; drug addiction and drug overdose; septic shock treatment; cerebral ischaemia; drug posoning; head trauma; inflammation; pruritus; tardive dyskinesia; emesis; anxiety; motility dysfunction; cluster headaches; hypertension; cancer; irritable bowel syndrome; hemotherapy-induced nausea and vomiting; thrombosis; dementia; opiate-induced nausea and vomiting; bipolar depression; migraine; sleep disorders; traumatic shock; gastritis; gastro-oesophageal reflux; psychosis; Parkinson disease; Dependence treatment; Pre-eclampsia; Raynaud's disease; Vasospasm; haemostasis; nausea and vomiting; spasms; post-operative nausea and vomiting; alcoholism, alcohol addiction; bulimia; nicotine addiction; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; premenstrual syndrome; and dermatitis, including allergic dermatitis.

The present invention is also directed to methods of inhibiting the binding of MCH to MCH receptors comprising contacting a compound of Formula I with cells expressing MCH receptors, wherein the compound is present at a concentration sufficient to inhibit MCH binding to MCH receptors in vitro. This method includes inhibiting the binding of MCH to MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptors in vitro. The amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptor in vitro may be readily determined via a MCH receptor binding assay, such as the assay described hereinbelow in Example 7.

The present invention is also directed to methods for altering the signal-transducing activity of MCH receptors, particularly the MCH receptor-mediated release of intracellular calcium, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention. This method includes altering the signal-transducing activity of MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to alter the signal-transducing activity of MCH receptors in vitro. The amount of a compound that would be sufficient to alter the signal-transducing activity of MCH receptors may be determined via a MCH receptor signal transduction assay, such as the calcium mobilization assay described hereinbelow in Example 6.

The present invention is also directed to methods of using compounds of Formula I and appropriately labeled derivatives thereof as standards and reagents in determining the ability of a potential pharmaceutical to bind to MCH receptor.

The present invention is also directed to methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating or preventing obesity in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating or preventing conditions such as feeding disorders, including obesity, bulimia and bulimia nervosa; sexual or reproductive disorders; depression and anxiety; epileptic seizure; hypertension; cerebral hemorrhage; congestive heart failure; sleep disturbances; or any condition in which antagonism of an MCH receptor is beneficial.

The present invention is also directed to methods of treating eating disorders, particularly obesity and bulimia nervosa, comprising administering to a subject in need of such treatment a compound of Formula I in combination with leptin, a leptin receptor agonist, or a melanocortin receptor 4 (MC4) agonist.

The present invention is also directed to methods of using compounds of Formula I as positive controls in assays for activity of GPCRs, particularly MCH.

The present invention is also directed to methods of using appropriately labeled compounds of Formula I as probes for the localization of GPCRs, particularly MCH, in tissue sections.

Other objects and features will be in part apparent and in part pointed out hereinafter.

Abbreviations and Definitions

The term “alkyl”, where used alone or within other terms such as “haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl” and “hydroxyalkyl”, is a linear or branched radical having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), pentyl (e.g., n-pentyl and iso-amyl), hexyl, and the like.

The term “cycloalkyl” is a saturated carbocyclic radical having three to twelve carbon atoms. The cycloalkyl radical may be mono-, bi-, or tricyclic. More preferred cycloalkyl radicals are “lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “alkenyl” is a linear or branched radical having at least one carbon-carbon double bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are “lower alkenyl” radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, butenyl and 4-methylbutenyl. The terms “alkenyl” and “lower alkenyl”, also are radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.

The term “cycloalkenyl”, is a partially unsaturated carbocyclic radical having three to twelve carbon atoms. The cycloalkenyl radicals may be mono-, bi-, or tricyclic. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl.

The term “alkynyl” is a linear or branched radical having at least one carbon-carbon triple bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are “lower alkynyl” radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.

The terms “carboxy” or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, is —CO₂H.

The term “carboxyalkyl” is an alkyl radical as defined above substituted with a carboxy radical. More preferred are “lower carboxyalkyl” radicals, which are lower alkyl radicals as defined above substituted with a carboxy radical, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl.

The term “halo” is a halogen such as fluorine, chlorine, bromine or iodine.

The term “haloalkyl” is an alkyl radical as defined above wherein any one or more of the carbon atoms is substituted with halo as defined above. Specifically included are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. More preferred haloalkyl radicals are “lower haloalkyl” having one to six carbon atoms. Examples of lower haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

The terms “alkoxy” and “alkyloxy” are linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are “lower haloalkoxy” radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

The term “alkoxyalkyl” is an alkyl radical having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and polyalkoxyalkyl radicals. More preferred alkoxyalkyl radicals are “lower alkoxyalkyl” radicals having two to twelve carbon atoms. Examples of such radicals include methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, dimethoxymethyl, dimethoxyethyl, methoxy(ethoxy)ethyl, dimethoxypropyl, and methoxy(ethoxy)propyl.

The term “alkoxycarbonyl” is a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical, i.e., an ester radical. More preferred are “lower alkoxycarbonyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.

The term “hydroxyalkyl” is a linear or branched alkyl radical having one to about ten carbon atoms, any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are “lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl.

The term “alkylamino” is an amino group that has been substituted with one or two alkyl radicals. Preferred are “lower N-alkylamino” radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be mono- or dialkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.

The term “alkylaminoalky” is a radical having one or more alkyl radicals attached to the nitrogen atom of an aminoalkyl radical.

The term “alkylaminocarbonyl” is an aminocarbonyl group that has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are “N-alkylaminocarbonyl” “N,N-dialkylaminocarbonyl” radicals. More preferred are “lower N-alkylaminocarbonyl” and “lower N,N-dialkylaminocarbonyl” radicals with lower alkyl portions as defined above.

The term “alkylthio” is a radical containing an alkyl radical of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are “lower alkylthio” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio.

The term “alkylthioalkyl” is a radical containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl radicals are “lower alkylthioalkyl” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl, methylthioethyl, ethylthioethyl, and ethylthiopropyl.

The term “alkylsulfinyl” is a radical containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent —S(═O)— radical. More preferred alkylsulfinyl radicals are “lower alkylsulfinyl” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl.

The term “aminoalkyl” is an alkyl radical substituted with one or more amino radicals. More preferred are “lower aminoalkyl” radicals of one to six carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.

The term “aminocarbonyl” is an amide group of the formula —C(═O)NH₂.

The term “carbonyl”, whether used alone or with other terms, such as “alkoxycarbonyl”, is —(C═O)—.

The term “aryl”, alone or in combination, is a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused, and wherein at least one of the rings is aromatic. The term “aryl” includes aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl.

The terms “heterocyclyl” and “heterocyclo” are saturated or partially unsaturated heteroatom-containing ring-shaped radicals having one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl and heterocyclo radicals include saturated 3- to 6-membered heteromonocylic radicals containing one to four nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., morpholinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl and heterocyclo radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.

The term “heteroaryl” is an aromatic heteroatom-containing ring-shaped radical having one, two, or three rings wherein at least one ring is aromatic. Examples of heteroaryl radicals include unsaturated 3- to 6-membered heteromonocyclic group containing one to four nitrogen atoms, e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing one to five nitrogen atoms, e.g., indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3- to 6-membered heteromonocyclic group containing an oxygen atom, e.g., pyranyl, furyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing a sulfur atom, e.g., thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms, e.g., oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms, e.g., thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term “heteroaryl” also includes radicals where heteroaryl radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said heterocyclyl group may be substituted at a substitutable position with one or more substituents selected independently from alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino.

The terms “heterocyclylalkyl” and “heterocycloalkyl” are saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.

The term “acyl” is a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals.

The term “alkanoyl” or “alkylcarbonyl” are alkyl radicals as defined herein attached to a carbonyl radical. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and trifluoroacetyl.

The terms “arylcarbonyl” (also called “aroyl”) and “aralkylcarbonyl” include radicals having aryl or aralkyl radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted phenylcarbonyl, naththoyl, and benzylcarbonyl. The aryl in said aroyl and aralkylcarbonyl radicals may be additionally substituted.

The term “aralkoxy” is an aralkyl radical as defined herein attached through an oxygen atom to other radicals.

The term “aralkoxyalkyl” is an aralkoxy radical as defined herein attached through an oxygen atom to an alkyl radical.

The terms “aralkyl” and “arylalkyl” are aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable.

The term “aralkylamino” is an aralkyl radical as defined herein attached through an amino nitrogen atom to other radicals. The terms “N-arylaminoalkyl” and “N-aryl-N-alkyl-aminoalkyl” are amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-methylaminomethyl.

The term “aralkylthio” is an aralkyl radical attached to a sulfur atom.

The term “aralkylthioalkyl” is an aralkylthio radical attached through a sulfur atom to an alkyl radical.

The term “arylamino” is an amino group that has been substituted with one or two aryl radicals. An example of such arylamino radicals is N-phenylamino. The “arylamino” radicals may be further substituted on the aryl ring portion of the radical.

The term “aryloxyalkyl” is a radical having an aryl radical attached to an alkyl radical through a divalent oxygen atom.

The term “arylthioalkyl” is a radical having an aryl radical attached to an alkyl radical through a divalent sulfur atom.

The term “sulfonyl”, whether used alone or linked to other terms such as alkylsulfonyl, is a divalent —SO₂— radical.

The term “alkylsulfonyl” is an alkyl radical attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are “lower alkylsulfonyl” radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The “alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals.

The terms “sulfamyl”, “aminosulfonyl” and “sulfonamidyl” are —SO₂NH₂.

The term “pharmaceutically acceptable” is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product; that is the “pharmaceutically-acceptable” material is relatively safe and/or non-toxic, though not necessarily providing a separable therapeutic benefit by itself. Pharmaceutically-acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiologically-acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

The term “prodrug” refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject.

The term “subject” for purposes of treatment or prevention includes any human or animal subject who is in need of treatment. The subject can be a domestic livestock species, a laboratory animal species, a zoo animal or a companion animal. In one embodiment, the subject is a mammal. In another embodiment, the mammal is a human being.

The term “PBS” stands for phosphate buffered saline.

The term “HEPES” stands for N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid.

The term “BSA” stands for bovine serum albumin.

The term “STI” stands for soybean trypsin inhibitor.

The term “Pefabloc” stands for (4-(2-aminoethyl)benzenesulfonylfluoride, HCl salt.

The term “Phosphoramidon” stands for N-α-L-rhamnopyranosyloxy(hydroxyphosphinyl)-L-leucyl-L-tryptophan.

The term “FCC” stands for flash column chromatography.

The term “K_(i)” stands for inhibitory rate constant.

The term “FLIPR” stands for fluorometric imaging plate reader.

The term “HEK 293” stands for the human embryonic kidney 293 cell line.

The term “Boc” stands for tert-butoxycarbonyl.

The term “DIC” stands for diisopropylcarbodiimide.

The term “DCM” stands for dichloromethane.

The term “DBU” stands for 1,8-diazabicyclo[5.4.0]undec-7-ene.

The term “phosgene” stands for COCl₂.

The term “DCE” stands for dichloroethane.

The term “DMF” stands for dimethylformamide.

The term “EtOAc” stands for ethyl acetate.

The term “HOBt” stands for 1-Hydroxybenzotriazole hydrate.

The term “MeOH” stands for methanol.

The term “TFA” stands for trifluoroacetic acid.

The MCH receptor antagonists employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d- and l-isomers, the racemic mixtures thereof and other mixtures thereof. Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention. The terms “cis” and “trans”, as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond and each substituted by a hydrogen and another group, will each have a hydrogen atom on the same side of the double bond (“cis”) or on opposite sides of the double bond (“trans”). Some of the compounds described herein contain alkenyl groups, and are meant to include both cis and trans or “E1” and “Z” geometric forms. Furthermore, some of the compounds described herein contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

The MCH receptor antagonists utilized in the present invention may be in the form of free bases or pharmaceutically-acceptable acid addition salts thereof. The term “pharmaceutically-acceptable salts” are salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt may vary, provided that it is pharmaceutically acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds for use in the present methods may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of use in the present methods include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of any Formula set forth herein.

The MCH receptor antagonists useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically, in dosage unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, e.g., Hoover, Remington's Pharmaceutical Sciences, (1975), and Liberman & Lachman, Eds., Pharmaceutical Dosage Forms, (1980).

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the MCH receptor antagonist will vary depending upon the patient and the particular mode of administration. In general, the pharmaceutical compositions may contain an MCH receptor antagonist in the range of about 1 to about 250 mg, more typically, in the range of about 10 to about 200 mg and still more typically, between about 25 to about 150 mg. A daily dose of about 0.01 to about 80 mg/kg body weight, or more typically, between about 0.5 to about 50 mg/kg body weight and even more typically, from about 1 to about 25 mg/kg body weight, may be appropriate. The daily dose can be administered in one to about four doses per day.

The MCH receptor antagonists are administered in such an amount as will be therapeutically effective in the treatment, control, or prevention of the disorder or condition being treated. It will be appreciated that the amount of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount, as the necessary effective amount could be reached by administration of a number of individual doses. Those skilled in the art will appreciate that the quantity of active MCH receptor antagonist to be administered will vary depending upon the age, sex, and body weight of the subject to be treated, the type of disease, or syndrome to be treated, the particular method and scheduling of administration, and what other MCH receptor antagonist, if any, is co-administered. Dosage amounts for an individual patient may thus be above or below the typical dosage ranges. Generally speaking, the MCH receptor antagonist can be employed in any amount known to be effective at treating, preventing or controlling the disorder or condition being treated. The doses may be single doses or multiple doses per day, with the number of doses taken per day and the time allowed between doses varying depending on the individual needs of the patient. Optimization of treatment, including dosage amount, method and time of administration, is thus best determined by a skilled practitioner through close monitoring of patients on an individual basis. Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 9th Ed. (1996), App. II, pp. 1707-1711 and from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 10th Ed. (2001), App. II, pp. 475-493.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In one embodiment of the present invention, the MCH receptor antagonist is a compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, having the following structure:

-   -   wherein     -   A is selected from the group consisting of heteroaryl, —C(═O)—,         and —C(═O)NH—;     -   W is selected from the group consisting of a bond, —C(═O)—,         alkyl, alkenyl, aryl, aralkenyl and heterocyclo;     -   X is selected from the group consisting of XA:     -   Z is selected from the group consisting of a bond, alkyl,         cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo;     -   R¹ is selected from the group consisting of alkyl, aryl,         aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of alkyl,         hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, alkyl,         cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and         aralkoxy, or R² and R⁸ together with the atom to which they are         both attached form a 5- or 6-membered cycloalkyl or heterocyclo         group, wherein R² or the cycloalkyl or heterocyclo group formed         with R⁸ is optionally substituted by one or more substituents         selected from the group consisting of alkoxy, aryloxy,         haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy,         hydroxyalkoxy, alkoxycarbonyl, alkylthio,         N-(alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³         is optionally substituted by one or more substituents selected         from the group consisting of halo, aryl, haloaryl, alkoxy,         alkyl, carboxyl, aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consiting of hydrogen, alkyl, and halo; and     -   R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to         which they are both attached form a 5- or 6-membered cycloalkyl         or heterocyclo group;     -   provided that Z is not methyl when X is XB or XC, further         provided that W is not pyrrolidyl when X is XC, and further         provided that R³ is not aryl- or haloaryl-substituted indolyl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of 5- or 6-membered heteroaryl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         lower alkyl, lower alkenyl, aryl, aralkenyl and 3- to         10-membered heterocyclo;     -   Z is selected from the group consisting of a bond, lower alkyl,         lower cycloalkyl, aryl, aralkyl and 3-to 10-membered         heterocyclo;     -   R¹ is selected from the group consisting of lower alkyl, aryl,         aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo,         aryloxy, 3- to 10-membered heteroaryl, and lower         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of lower         alkyl, hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, lower         alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered         heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R²         and R⁸ together with the atom to which they are both attached         form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein         R² or the cycloalkyl or heterocyclo group formed with R⁸ is         optionally substituted by one or more substituents selected from         the group consisting of lower alkoxy, aryloxy, lower haloalkyl,         halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano,         hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower         alkylthio, N-(lower alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl,         imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, and (3- to 10-membered         heterocyclo)carbonyl, wherein R³ is optionally substituted by         one or more substituents selected from the group consisting of         halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl,         aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consiting of hydrogen, lower alkyl, and halo; and     -   R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the         atom to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl,         allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, phenylethenyl, phenylpropenyl, phenylallyl,         phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl,         piperidinyl, piperazinyl, morpholinyl, thiazolidinyl,         dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl,         and tetrahydrofuryl;     -   Z is selected from the group consisting of a bond, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl;     -   R¹ is selected from the group consisting of methyl, ethyl,         propyl, butyl, pentyl, hexyl, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl,         triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl,         ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,         pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,         tetrazolyl, benzodioxolyl, monomethylphosphonate,         dimethylphosphonate, monoethylphosphonate, diethylphosphonate,         monopropylphosphonate, and dipropylphosphonate, wherein R¹ is         optionally substituted by one or more substituents selected from         the group consisting of methyl, ethyl, propyl, butyl, pentyl,         hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and         keto;     -   R² is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, phenylcarbonyl, naphthylcarbonyl,         tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and         phenylhexyloxy, or R² and R⁸ together with the atom to which         they are both attached form a 5- or 6-membered cycloalkyl or         heterocyclo group selected from the group consisting of         cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,         piperidinyl, piperazinyl, morpholinyl, thiazolidinyl,         dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl,         and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo         group formed with R⁸ is optionally substituted by one or more         substituents selected from the group consisting of methoxy,         ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy,         naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl,         difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,         trichloromethyl, trichloromethyl, pentafluoroethyl,         heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,         difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl,         fluoro, chloro, bromo, iodo, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl,         phenylallyl, phenylbutenyl, phenylpentenyl, benzyl,         diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,         methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl,         difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl,         dichloromethylphenyl, trichloromethylphenyl,         trichloromethylphenyl, bis(fluoromethyl)phenyl,         bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,         bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,         bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl,         chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy,         dibromophenoxy, difluorophenoxy, chlorobromophenoxy,         chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy,         ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy,         dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy,         propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy,         dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy,         propylbiphenylyloxy, dimethylbiphenylyloxy,         diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl,         pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,         oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl,         oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano,         hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy,         hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy,         methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,         butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,         ethylthio, propylthio, butylthio, pentylthio, hexylthio,         N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,         N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,         N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, phenyl,         naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy,         propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy,         phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl,         isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,         benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,         piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,         thiazolidinylcarbonyl, dihydrothienylcarbonyl,         dihydropyranylcarbonyl, dihydrofurylcarbonyl,         dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein         R³ is optionally substituted by one or more substituents         selected from the group consisting of fluoro, chloro, bromo,         iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,         chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl,         dibromophenyl, difluorophenyl, chlorobromophenyl,         chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy,         butoxy, pentyloxy, hexyloxy, methyl, ethyl, propyl, butyl,         pentyl, hexyl, carboxyl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl,         hexyl, fluoro, chloro, bromo, and iodo; and     -   R⁸ is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together         with the atom to which they are both attached form a 5- or         6-membered cycloalkyl or heterocyclo group selected from the         group consisting of cyclopropyl, cyclobutyl, cyclopentyl,         cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         alkyl, alkenyl, aryl, aralkenyl and heterocyclo;     -   X is selected from the group consisting of XA:     -   Z is selected from the group consisting of a bond, alkyl,         cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo;     -   R¹ is selected from the group consisting of alkyl, aryl,         aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of alkyl,         hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, alkyl,         cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and         aralkoxy, or R² and R⁸ together with the atom to which they are         both attached form a 5- or 6-membered cycloalkyl or heterocyclo         group, wherein R² or the cycloalkyl or heterocyclo group formed         with R⁸ is optionally substituted by one or more substituents         selected from the group consisting of alkoxy, aryloxy,         haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy,         hydroxyalkoxy, alkoxycarbonyl, alkylthio,         N-(alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³         is optionally substituted by one or more substituents selected         from the group consisting of halo, aryl, haloaryl, alkoxy,         alkyl, carboxyl, aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consiting of hydrogen, alkyl, and halo; and     -   R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to         which they are both attached form a 5- or 6-membered cycloalkyl         or heterocyclo group;     -   provided that Z is not methyl when X is XB or XC, further         provided that W is not pyrrolidyl when X is XC, and further         provided that R³ is not aryl- or haloaryl-substituted indolyl;     -   or a pharmaceutically-acceptable salt, tautomer or prodrug         thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         lower alkyl, lower alkenyl, aryl, aralkenyl and 3- to         10-membered heterocyclo;     -   Z is selected from the group consisting of a bond, lower alkyl,         lower cycloalkyl, aryl, aralkyl and 3-to 10-membered         heterocyclo;     -   R¹ is selected from the group consisting of lower alkyl, aryl,         aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo,         aryloxy, 3- to 10-membered heteroaryl, and lower         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of lower         alkyl, hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, lower         alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered         heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R²         and R⁸ together with the atom to which they are both attached         form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein         R² or the cycloalkyl or heterocyclo group formed with R⁸ is         optionally substituted by one or more substituents selected from         the group consisting of lower alkoxy, aryloxy, lower haloalkyl,         halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano,         hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower         alkylthio, N-(lower alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl,         imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, and (3- to 10-membered         heterocyclo)carbonyl, wherein R³ is optionally substituted by         one or more substituents selected from the group consisting of         halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl,         aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consiting of hydrogen, lower alkyl, and halo; and     -   R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the         atom to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula II:

-   -   wherein     -   A is selected from the group consisting of furyl, thienyl,         pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,         oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl,         oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and         —C(═O)NH—;     -   W is selected from the group consisting of a bond, —C(═O)—,         alkyl, alkenyl, aryl, aralkenyl and heterocyclo;     -   Z is selected from the group consisting of a bond, alkyl,         cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo;     -   R¹ is selected from the group consisting of alkyl, aryl,         aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of alkyl,         hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, alkyl,         cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and         aralkoxy, or R² and R⁸ together with the atom to which they are         both attached form a 5- or 6-membered cycloalkyl or heterocyclo         group, wherein R² or the cycloalkyl or heterocyclo group formed         with R⁸ is optionally substituted by one or more substituents         selected from the group consisting of alkoxy, aryloxy,         haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy,         hydroxyalkoxy, alkoxycarbonyl, alkylthio,         N-(alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³         is optionally substituted by one or more substituents selected         from the group consisting of halo, aryl, haloaryl, alkoxy,         alkyl, carboxyl, aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, and R⁷ are independently selected from the group         consiting of hydrogen, alkyl, and halo; and     -   R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to         which they are both attached form a 5- or 6-membered cycloalkyl         or heterocyclo group;     -   provided that R³ is not aryl- or haloaryl-substituted indolyl;     -   or a pharmaceutically-acceptable salt, tautomer or prodrug         thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of 5- or 6-membered heteroaryl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         lower alkyl, lower alkenyl, aryl, aralkenyl and 3- to         10-membered heterocyclo;     -   Z is selected from the group consisting of a bond, lower alkyl,         lower cycloalkyl, aryl, aralkyl and 3-to 10-membered         heterocyclo;     -   R¹ is selected from the group consisting of lower alkyl, aryl,         aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo,         aryloxy, 3- to 10-membered heteroaryl, and lower         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of lower         alkyl, hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, lower         alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered         heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R²         and R⁸ together with the atom to which they are both attached         form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein         R² or the cycloalkyl or heterocyclo group formed with R⁸ is         optionally substituted by one or more substituents selected from         the group consisting of lower alkoxy, aryloxy, lower haloalkyl,         halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano,         hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower         alkylthio, N-(lower alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl,         imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, and (3- to 10-membered         heterocyclo)carbonyl, wherein R³ is optionally substituted by         one or more substituents selected from the group consisting of         halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl,         aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, and R⁷ are independently selected from the group         consiting of hydrogen, lower alkyl, and halo; and     -   R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the         atom to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

-   -   W is selected from the group consisting of a bond, —C(═O)—,         methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl,         allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, phenylethenyl, phenylpropenyl, phenylallyl,         phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl,         piperidinyl, piperazinyl, morpholinyl, thiazolidinyl,         dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl,         and tetrahydrofuryl;     -   Z is selected from the group consisting of a bond, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl;     -   R¹ is selected from the group consisting of methyl, ethyl,         propyl, butyl, pentyl, hexyl, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl,         triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl,         ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,         pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,         tetrazolyl, benzodioxolyl, monomethylphosphonate,         dimethylphosphonate, monoethylphosphonate, diethylphosphonate,         monopropylphosphonate, and dipropylphosphonate, wherein R¹ is         optionally substituted by one or more substituents selected from         the group consisting of methyl, ethyl, propyl, butyl, pentyl,         hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and         keto;     -   R² is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, phenylcarbonyl, naphthylcarbonyl,         tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and         phenylhexyloxy, or R² and R⁸ together with the atom to which         they are both attached form a 5- or 6-membered cycloalkyl or         heterocyclo group selected from the group consisting of         cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,         piperidinyl, piperazinyl, morpholinyl, thiazolidinyl,         dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl,         and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo         group formed with R⁸ is optionally substituted by one or more         substituents selected from the group consisting of methoxy,         ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy,         naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl,         difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,         trichloromethyl, trichloromethyl, pentafluoroethyl,         heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,         difluoroethyl; difluoropropyl, dichloroethyl, dichloropropyl,         fluoro, chloro, bromo, iodo, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl,         phenylallyl, phenylbutenyl, phenylpentenyl, benzyl,         diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,         methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl,         difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl,         dichloromethylphenyl, trichloromethylphenyl,         trichloromethylphenyl, bis(fluoromethyl)phenyl,         bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,         bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,         bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl,         chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy,         dibromophenoxy, difluorophenoxy, chlorobromophenoxy,         chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy,         ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy,         dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy,         propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy,         dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy,         propylbiphenylyloxy, dimethylbiphenylyloxy,         diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl,         pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,         oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl,         oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano,         hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy,         hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy,         methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,         butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,         ethylthio, propylthio, butylthio, pentylthio, hexylthio,         N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,         N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,         N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, phenyl,         naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy,         propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy,         phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl,         isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,         benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,         piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,         thiazolidinylcarbonyl, dihydrothienylcarbonyl,         dihydropyranylcarbonyl, dihydrofurylcarbonyl,         dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein         R³ is optionally substituted by one or more substituents         selected from the group consisting of fluoro, chloro, bromo,         iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,         chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl,         dibromophenyl, difluorophenyl, chlorobromophenyl,         chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy,         butoxy, pentyloxy, hexyloxy, methyl, ethyl, propyl, butyl,         pentyl, hexyl, carboxyl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, and R⁷ are independently selected from the group         consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl,         hexyl, fluoro, chloro, bromo, and iodo; and     -   R⁸ is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together         with the atom to which they are both attached form a 5- or         6-membered cycloalkyl or heterocyclo group selected from the         group consisting of cyclopropyl, cyclobutyl, cyclopentyl,         cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula III:

-   -   wherein     -   W is selected from the group consisting of a bond, —C(═O)—,         alkyl, alkenyl, aryl, aralkenyl and heterocyclo;     -   Z is selected from the group consisting of a bond, alkyl,         cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo;     -   R¹ is selected from the group consisting of alkyl, aryl,         aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of alkyl,         hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, alkyl,         cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and         aralkoxy, or R² and R⁸ together with the atom to which they are         both attached form a 5- or 6-membered cycloalkyl or heterocyclo         group, wherein R² or the cycloalkyl or heterocyclo group formed         with R⁸ is optionally substituted by one or more substituents         selected from the group consisting of alkoxy, aryloxy,         haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy,         hydroxyalkoxy, alkoxycarbonyl, alkylthio,         N-(alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³         is optionally substituted by one or more substituents selected         from the group consisting of halo, aryl, haloaryl, alkoxy,         alkyl, carboxyl, aryloxy, keto, and hydroxy;     -   R⁴, R⁵, R⁶, and R⁷ are independently selected from the group         consiting of hydrogen, alkyl, and halo; and     -   R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to         which they are both attached form a 5- or 6-membered cycloalkyl         or heterocyclo group;     -   provided that R³ is not aryl- or haloaryl-substituted indolyl;     -   or a pharmaceutically-acceptable salt, tautomer or prodrug         thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen, and wherein W is selected from the group consisting of a bond, —C(═O)—, lower alkyl, lower alkenyl, aryl, aralkenyl and 3-to 10-membered heterocyclo;

-   -   Z is selected from the group consisting of a bond, lower alkyl,         lower cycloalkyl, aryl, aralkyl and 3-to 10-membered         heterocyclo;     -   R¹ is selected from the group consisting of lower alkyl, aryl,         aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo,         aryloxy, 3- to 10-membered heteroaryl, and lower         alkylphosphonate, wherein R¹ is optionally substituted by one or         more substituents selected from the group consisting of lower         alkyl, hydroxy, carboxyl, halo, cyano and keto;     -   R² is selected from the group consisting of hydrogen, lower         alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered         heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R²         and R⁸ together with the atom to which they are both attached         form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein         R² or the cycloalkyl or heterocyclo group formed with R⁸ is         optionally substituted by one or more substituents selected from         the group consisting of lower alkoxy, aryloxy, lower haloalkyl,         halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,         haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano,         hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower         alkylthio, N-(lower alkylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, aryl,         lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl,         imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, and (3- to 10-membered         heterocyclo)carbonyl, wherein R³ is optionally substituted by         one or more substituents selected from the group consisting of         halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl,         aryloxy, keto, and hydroxy;     -   R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the         atom to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen, and wherein W is selected from the group consisting of a bond, —C(═O)—, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl;

-   -   Z is selected from the group consisting of a bond, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl;     -   R¹ is selected from the group consisting of methyl, ethyl,         propyl, butyl, pentyl, hexyl, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl,         triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl,         ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,         pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,         tetrazolyl, benzodioxolyl, monomethylphosphonate,         dimethylphosphonate, monoethylphosphonate, diethylphosphonate,         monopropylphosphonate, and dipropylphosphonate, wherein R¹ is         optionally substituted by one or more substituents selected from         the group consisting of methyl, ethyl, propyl, butyl, pentyl,         hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and         keto;     -   R² is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl,         cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl,         biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,         diphenylethyl, phenylcarbonyl, naphthylcarbonyl,         tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl,         imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,         thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,         dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl,         pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,         benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,         dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and         phenylhexyloxy, or R² and R⁸ together with the atom to which         they are both attached form a 5- or 6-membered cycloalkyl or         heterocyclo group selected from the group consisting of         cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,         piperidinyl, piperazinyl, morpholinyl, thiazolidinyl,         dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl,         and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo         group formed with R⁸ is optionally substituted by one or more         substituents selected from the group consisting of methoxy,         ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy,         naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl,         difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,         trichloromethyl, trichloromethyl, pentafluoroethyl,         heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,         difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl,         fluoro, chloro, bromo, iodo, phenyl, naphthyl,         tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl,         phenylallyl, phenylbutenyl, phenylpentenyl, benzyl,         diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,         methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl,         difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl,         dichloromethylphenyl, trichloromethylphenyl,         trichloromethylphenyl, bis(fluoromethyl)phenyl,         bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,         bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,         bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl,         chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy,         dibromophenoxy, difluorophenoxy, chlorobromophenoxy,         chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy,         ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy,         dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy,         propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy,         dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy,         propylbiphenylyloxy, dimethylbiphenylyloxy,         diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl,         pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,         oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl,         oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano,         hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy,         hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy,         methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,         butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,         ethylthio, propylthio, butylthio, pentylthio, hexylthio,         N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,         N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,         N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;     -   R³ is selected from the group consisting of hydrogen, phenyl,         naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy,         propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy,         phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy,         phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl,         isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,         benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,         piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,         thiazolidinylcarbonyl, dihydrothienylcarbonyl,         dihydropyranylcarbonyl, dihydrofurylcarbonyl,         dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein         R³ is optionally substituted by one or more substituents         selected from the group consisting of fluoro, chloro, bromo,         iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,         chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl,         dibromophenyl, difluorophenyl, chlorobromophenyl,         chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy,         butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy,         tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy;     -   R⁸ is selected from the group consisting of hydrogen, methyl,         ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together         with the atom to which they are both attached form a 5- or         6-membered cycloalkyl or heterocyclo group selected from the         group consisting of cyclopropyl, cyclobutyl, cyclopentyl,         cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl,         piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,         dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and         tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula IV:

-   -   wherein     -   Z is selected from the group consisting of a bond, alkyl, aryl,         aralkyl, heteroaralkyl, and heterocyclo;     -   R¹ is selected from the group consisting of alkoxycarbonyl,         alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, and heterocyclo,         wherein R¹ is optionally substituted by one or more substituents         selected from the group consisting of alkyl, halo, and keto;     -   R² is selected from the group consisting of alkyl, aryl,         heterocyclo, and heteroaryl, or R² and R⁸ together with the atom         to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or         heterocyclo group formed with R⁸ is optionally substituted by         one or more substituents selected from the group consisting of         alkoxy, alkyl, alkylaryloxy, alkylthio, aralkenyl, aralkoxy,         aralkyl, aryloxy, cyano, halo, haloalkyl, haloalkylaryl,         haloaryloxy, heteroaryl, hydroxy, hydroxyalkoxy,         N-(alkylcarbonyl)amino, and nitro;     -   R⁴, R⁵, R⁶, and R⁷ are independently selected from the group         consisting of hydrogen, alkyl and halo; and     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         alkyl, hydroxy, and alkoxy;     -   or a pharmaceutically-acceptable salt, tautomer or prodrug         thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein Z is selected from the group consisting of a bond, lower alkyl, aryl, lower aralkyl, lower heteroaralkyl, and 3- to 10-membered heterocyclo;

-   -   R¹ is selected from the group consisting of lower         alkoxycarbonyl, lower alkyl, lower cycloalkyl, lower aralkyl,         aryl, 3- to 10-membered heteroaryl, and 3- to 10-membered         heterocyclo, wherein R¹ is optionally substituted by one or more         substituents selected from the group consisting of lower alkyl,         halo, and keto;     -   R² is selected from the group consisting of lower alkyl, aryl,         3- to 10-membered heterocyclo, and 3- to 10-membered heteroaryl,         or R² and R⁸ together with the atom to which they are both         attached form a 5- or 6-membered cycloalkyl or heterocyclo         group, wherein R² or the cycloalkyl or heterocyclo group formed         with R⁸ is optionally substituted by one or more substituents         selected from the group consisting of lower alkoxy, lower alkyl,         lower alkylaryloxy, lower alkylthio, lower aralkenyl, lower         aralkoxy, lower aralkyl, aryloxy, cyano, halo, lower haloalkyl,         lower haloalkylaryl, haloaryloxy, 3- to 10-membered heteroaryl,         hydroxy, lower hydroxyalkoxy, N-(lower alkylcarbonyl)amino, and         nitro;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consiting of hydrogen, lower alkyl, and halo; and     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         lower alkyl, hydroxy, and lower alkoxy.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein Z is selected from the group consisting of a bond, methyl, ethyl, propyl, t-butyl, phenyl, tetrahydronaphthyl, biphenyl, naphthyl, phenylpropyl, indolylethyl, and piperidyl;

-   -   R¹ is selected from the group consisting of methoxycarbonyl,         ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl,         cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl,         phenyl, tetrahydronaphthyl, indolyl, tetrahydrofuryl,         pyrrolidinyl, and morpholinyl, wherein R¹ is optionally         substituted by one or more substituents selected from the group         consisting of methyl, ethyl, propyl, bromo, fluoro, chloro, and         keto;     -   R² is selected from the group consisting of methyl, phenyl,         biphenyl, naphthyl, tetrahydrofuryl, pyrrolidinyl, morpholinyl,         piperidyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together         with the atom to which they are both attached form a piperidyl         or cyclohexyl group, wherein R² or the piperidyl or cyclohexyl         group formed with R⁸ is optionally substituted by one or more         substituents selected from the group consisting of methoxy,         ethoxy, methyl, ethyl, isopropyl, isobutyl, methylphenoxy,         methylthio, phenylethenyl, benzyloxy, phenylethoxy, benzyl,         phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl,         trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole,         hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro;     -   R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group         consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,         fluoro, chloro, and bromo; and     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         methyl, hydroxy, and methoxy.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula V:

-   -   wherein     -   Z is selected from the group consisting of a bond, alkyl,         aralkyl, heteroaralkyl, and heterocyclo;     -   R¹ is selected from the group consisting of alkoxycarbonyl,         alkyl, aralkyl, aryl, heteroaryl, and heterocyclo, wherein R¹ is         optionally substituted by one or more substituents selected from         the group consisting of alkyl, halo, and keto;     -   R² is selected from the group consisting of alkyl, aryl, and         heteroaryl, or R² and R⁸ together with the atom to which they         are both attached form a 5- or 6-membered cycloalkyl or         heterocyclo group, wherein R² or the cycloalkyl or heterocyclo         group formed with R⁸ is optionally substituted by one or more         substituents selected from the group consisting of alkoxy,         alkyl, alkylaryloxy, alkylthio, aralkenyl, aralkoxy, aralkyl,         aryloxy, cyano, halo, haloalkyl, haloalkylaryl, haloaryloxy,         heteroaryl, hydroxy, hydroxyalkoxy, N-(alkylcarbonyl) amino, and         nitro;     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         alkyl, hydroxy, and alkoxy;     -   or a pharmaceutically-acceptable salt, tautomer or prodrug         thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein Z is selected from the group consisting of a bond, lower alkyl, lower aralkyl, lower heteroaralkyl, and 3- to 10-membered heterocyclo;

-   -   R¹ is selected from the group consisting of lower         alkoxycarbonyl, lower alkyl, lower aralkyl, aryl, 3-to         10-membered heteroaryl, and 3- to 10-membered heterocyclo,         wherein R¹ is optionally substituted by one or more substituents         selected from the group consisting of lower alkyl, halo, and         keto;     -   R² is selected from the group consisting of lower alkyl, aryl,         and 3- to 10-membered heteroaryl, or R² and R⁸ together with the         atom to which they are both attached form a 5- or 6-membered         cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or         heterocyclo group formed with R⁸ is optionally substituted by         one or more substituents selected from the group consisting of         lower alkoxy, lower alkyl, lower alkylaryloxy, lower alkylthio,         lower aralkenyl, lower aralkoxy, lower aralkyl, aryloxy, cyano,         halo, lower haloalkyl, lower haloalkylaryl, haloaryloxy, 3- to         10-membered heteroaryl, hydroxy, lower hydroxyalkoxy, N-(lower         alkylcarbonyl)amino, and nitro;     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         lower alkyl, hydroxy, and lower alkoxy.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein Z is selected from the group consisting of a bond, methyl, ethyl, propyl, t-butyl, phenylpropyl, indolylethyl, and piperidyl;

-   -   R¹ is selected from the group consisting of methoxycarbonyl,         ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl,         benzyl, phenyl, tetrahydronaphthyl, indolyl, tetrahydrofuryl,         pyrrolidinyl, and morpholinyl, wherein R¹ is optionally         substituted by one or more substituents selected from the group         consisting of methyl, chloro, and keto;     -   R² is selected from the group consisting of methyl, phenyl,         biphenyl, naphthyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸         together with the atom to which they are both attached form a         piperidyl or cyclohexyl group, wherein R² or the piperidyl or         cyclohexyl group formed with R⁸ is optionally substituted by one         or more substituents selected from the group consisting of         methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl,         methylphenoxy, methylthio, phenylethenyl, benzyloxy,         phenylethoxy, benzyl, phenoxy, cyano, fluoro, chloro, bromo,         trifluoromethyl, trifluoromethylphenyl, dichlorophenoxy,         imidazole, benzodioxole, hydroxy, hydroxyethoxy,         N-(methylcarbonyl)amino, and nitro;     -   R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are         independently selected from the group consisting of hydrogen,         methyl, hydroxy, and methoxy.

In another embodiment, the compound of Formula I is selected from the group of compounds listed in Table TABLE 1 Com- pound No. Structure 1

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5- yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW 464.62 4

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5- yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW 464.62 11

1-{biphenyl-4-yl-[1-(2,6-dimethyiphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW 540.2 12

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3- phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 557.32 (M + H); MW 556.7 14

1-[(1-tert-butyl-1H-tetrazol-s-yl)phenylmethyl]- 4-(3-phenylallyl)piperazine MS m/z 417.3 (M + H); MW 416.6 15

1-[(1-benzyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3- phenylallyl)piperazine MS m/z 451.28 (M + H); MW 450.6 16

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)acetic acid methyl ester MS m/z 433.26 (M + H); MW 432.5 17

1-[(1-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3- phenylallyl)piperazine MS m/z 417.31 (M + H); MW 416.6 19

1-[(1-isopropyl-1H-tetrazol-5-yl)phenylmethyl]-4- (3-phenylallyl)piperazine MS m/z 403.28 (M + H); MW 402.5 20

5-5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)-1H-indole MS m/z 276.28 (M + H); MW 475.6 21

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl[methyl}tetrazol-1-yl)acetic acid ethyl ester MS m/z 447.29 (M + H); MW 446.6 22

1-(3-phenylallyl)-4-{phenyl-[1-(1,1,3,3- tetramethylbutyl)-1H-tetrazol-5- yl]methyl}piperazine MS m/z 473.37 (M + H); MW 472.7 24

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)acetic acid tert-butyl ester MS m/z 475.3 (M + H); MW 474.6 26

3-phenyl-2-(5-{phenyl-[4-(3- phenylallyl)piperazin-1-yl]methyl}tetrazol-1- yl)propionic acid methyl ester MS m/z 523.32 (M + H); MW 522.7 27

1-{[1-(3,3-diphenylpropyl)-1H-tetrazol-5- yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 555.4 (M + H); MW 554.7 28

1-{[1-(1-benzylpiperidin-4-yl)-1H-tetrazol-5- yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 534.37 (M+ H); MW 533.7 29

3-[2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)ethyl]-1H-indole MS m/z 504.33 (M + H); MW 503.7 30

1-{[1-(3,4-dichlorobenzyl)-1H-tetrazol-5- yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 519.22 (M + H); MW 519.5 31

3-(1H-indol-3-yl)-2-(5-{phenyl-[4-(3- phenylallyl)piperazin-1-yl]methyl}tetrazol-1- yl)propioriic acid methyl ester MS m/z 562.34 (M + H); MW 561.7 33

1-(3-phenylallyl)-4-{phenyl-[1-(tetrahydrofuran- 2-ylmethyl)-1H-tetrazol-5-yl]methyl}piperazine MS m/z 445.31 (M + H); MW 444.6 35

1-[(1-phenethyl-1H-tetrazol-5-yl)phenylmethyl]-4- (3-phenylallyl) piperazine MS m/z 465.29 (M + H); MW 464.6 36

1-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)propyl]pyrrolidin-2-one MS m/z 486.34 (M + H); MW 485.6 37

1-({1-[2-(1-methyl-pyrrolidin-2-yl)ethyl]-1H- tetrazol-5-yl}phenylmethyl)-4-(3- phenylallyl)piperazine MS m/z 472.35 (M + H); MW 471.6 38

1-(3-phenylallyl)-4-{phenyl-[1-(5,6,7,8- tetrahydronaphthalen-1-yl)-1H-tetrazol-5- yl]methyl}piperazine MS m/z 491.33 (M + H); MW 490.7 39

1-({1-[2-(4-chlorophenyl)ethyl]-1H-tetrazol-5- yl}phenylmethyl)-4-(3-phenylallyl)piperazine MS m/z 499.27 (M + H); MW 499.1 42

4-[3-5-{phenyl-[4-(3-phenylallyll)piperazin-1- yl]methyl}tetrazol-1-yl)propyl]morpholine MS m/z 488.35 (M + H); MW 487.6 46

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5- yl]naphthalen-1-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 567.35 (M + H); MW 566.7 48

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3- fluorophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 483.3 (M + H); MW 482.6 52

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- styrylphenyl)methyl]-4-(3-phenylallyl)piperazirie MS m/z 567.35 (M + H); MW 566.7 53

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5- yl]thiophen-2-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 471.25 (M + H); MW 470.6 55

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-p- tolylmethyl]-4-(3-phenylallyl)piperazine MS m/z 479.32 (M + H); MW 478.6 56

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethyiphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.31 (M + H); MW 532.6 57

1-{(4-chlorophenyl)-[1-(2,6-dimethyiphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 499.25 (M + H); MW 499.1 58

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- fluorophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 483.3 (M + H); MW 482.6 60

1-{(3,4-dichlorophenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 533.23 (M + H); MW 533.5 61

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-m- tolylmethyl}-4-(3-phenylallyl) piperazine MS m/z 479.33 (M + H); MW 478.6 62

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]naphthalen-2-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 515.32 (M + H); MW 514.7 63

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.31 (M + H); MW 532.6 64

1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 541.33 (M + H); MW 540.7 65

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(1- methyl-1H-pyrrol-2-yl)methyl]-4-(3- phenylallyl)piperazine MS m/z repeat (M + H); MW 467.6 66

1-{(2-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 571.34 (M + H); MW 570.7 67

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(2- methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H); MW 494.6 68

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[5- (3-trifluoromethylphenyl)furan-2-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 599.32 (M + H); MW 598.7 69

1-{2-benzyloxy-1-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]ethyl}-4-(3-phenylallyl)piperazine MS m/z 509.3 (M + H); MW 508.7 70

1-{(4-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 571.35 (M + H); MW 570.7 71

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(6- methylpyridin-2-yl)methyl]-4-(3- phenylallyl)piperazine MS m/z 480.31 (M + H); MW 479.6 72

1-{[3-(3,4-dichlorophenoxy)phenyl]-[1-(2,6- dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl) piperazine MS m/z 625.26 (M + H); MW 625.6 73

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- p-tolyloxyphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 571.3 (M + H); MW 570.7 74

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-3-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 466.3 (M + H); MW 465.6 75

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-2-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 466.3 (M + H); MW 465.6 76

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 557.3 (M + H); MW 556.7 77

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H); MW 494.6 78

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.3 (M + H); MW 530.7 79

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4- (3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.28 (M + H); MW 489.6 80

2-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4- (3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.31 (M + H); MW 489.6 81

1-{benzo[1,3]diaxol-4-yl-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z repeat (M + H); MW 508 82

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4- (3-phenylallyl)piperazin-1-yl]methyl}phenol MS m/z 481.3 (M + H); MW 480.6 83

1-{benzo[1,3]dioxol-5-yl-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 509.3 (M + H); MW 508.6 84

2-(3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]- [4-(3-phenylallyl)piperazin-1- yl]methyl}phenoxy)ethanol MS m/z repeat (M + H); MW 524.67 85

1-{1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-2- phenethyloxyethyl}-4-(3-phenylallyl)piperazine MS m/z 523.35 (M + H); MW 522.7 86

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-4-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 466.31 (M + H); MW 465.6 87

1-{[3-(3,5-dichloro-phenoxy)-phenyl]-[1-(2,6- dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 625.25 (M + H); MW 625.6 91

1-{1-benzyl-4-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]piperidin-4-yl}-4-(3- phenylallyl)piperazine MS m/z xxxx (M + H); MW 547.7 92

1-{1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]cyclohexyl)-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW 456.64 99

1-{4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-1- methylpiperidin-4-yl}-4-(3-phenylallyl)piperazine MS m/z xxxx (M + H); MW 471.6 103

1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.2 (M + H); MW 543.5 116

1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.2 (M + H); MW 543.5 118

1-{(4-chiorophenyl)-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 499.27 (M + H); MW 499.1 119

1-(3-phenylallyl)-4-[phenyl-(1-phenyl-1H- tetrazol-5-yl) methyl]piperazine MS m/z 503.3 (M + H); MW 436.5 121

1-[(4-imidazol-1-ylphenyl)-(1-phenyl-1H-tetrazol- 5-yl)methyl]-4-(3-phenylallyl)piperazine MS m/z 503.3 (M + H); MW 502.6 122

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H); MW 494.6 123

1-{(3,4-dimethylphenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 493.31 (M + H); MW 492.7 124

1-{(3,4-difluoraphenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 501.27 (M + H); MW 500.6 125

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- isopropylphenyl)methyl}-4-(3- phenylallyl)piperazine MS m/z 507.34 (M + H); MW 506.7 126

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- methylsulfanylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 511.28 (M + H); MW 510.7 127

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- ethylphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 493.32 (M + H); MW 492.7 128

1-{(3,4-dimethoxyphenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 525.33 (M + H); MW 524.7 129

1-{(4-benzyloxy-3-methoxyphenyl)-[1-(2,6- dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 601.35 (M + H); MW 600.8 130

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- isobutylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 521.35 (M + H); MW 520.7 131

n-(4-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]- [4-(3-phenylallyl)piperazin-1- yl]methyl}phenyl)acetamide MS m/z 522.31 (M + H); MW 521.7 133

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4- (3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.300 (M + H); MW 489.6 134

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.33 (M + H); MW 530.7 135

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.33 (M + H); MW 530.7 136

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4- ethoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 509.32 (M + H); MW 508.7 137

1-{(3,5-dichlorophenyl)-[1-(2,6-dimethylphenyl)- 1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 533.23 (M + H); MW 533.5 138

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- nitrophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 510.29 (M + H); MW 509.6 139

1-{(3-bromophenyl)-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.22 (M + H); MW 543.5 140

1-{(3-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 500.26 (M + H); MW 499.1 142

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.27 (M + H); MW 532.6 143

1-{biphenyl-3-yl-[1-(2,6-dimethylphenyl)-1H- tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 541.34 (M + H); MW 540.7 144

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]-4-(3,3- diphenylallyl)piperazine MS m/z 609.32 (M + H); MW 608.7 147

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]-4-[3-(4- methoxyphenyl)allyl]piperazine MS m/z 563.29 (M + H); MW 562.6 148

2-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]- (3-trifluoromethylphenyl)methyl]piperazin-1- ylmethyl}-1-methyl-1H-indole MS m/z 560.32 (M + H); MW 559.6 150

3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]- (3-trifluoromethylphenyl)methyl]piperazin-1- ylmethyl}-1H-indole MS m/z 417.23 (M + H); MW 545.6 151

2-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]-(3-trifluoromethylphenyl)methyl]piperazin-1- yl}propenyl)phenol MS m/z 549.30 (M + H); MW 548.6 154

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]-4-(3- phenylpropyl)piperazine MS m/z 535.3 (M + H); MW 534.6 156

1-benzo[1,3]dioxol-5-ylmethyl-4-[[1-(2,6- dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]piperazine MS m/z 551.25 (M + H); MW 550.6 162

(1-benzylpyrrolidin-3-yl)-[[1-(2,6- dimethylphenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]ethylamine MS m/z 535.29 (M + H); MW 534.6 163

4-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]-(3-trifluoromethylphenyl)methyl]piperazin-1- yl}propenyl)-2-methoxyphenol MS m/z 579.31 (M + H); MW 578.6 164

1-[[1-(2,6-dichlorophenyl)-1H-tetrazol-5-yl]-(3- trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z xxxx (M + H); MW 573.4

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the formula

wherein R^(1a), R^(1b), R^(2a), R^(2b), and R^(2c) are as defined in Table 2. TABLE 2 Compound No. R^(1a) R^(1b) R^(2a) R^(2b) R^(2c) 200 H CH₃ CH₃ H H 201 H CH₃ CH₃ CH₃ H 202 H CH₃ CH₃ OCH₃ H 203 H CH₃ CH₃ Cl H 204 H CH₃ CH₃ Br H 205 H CH₃ CH₃ F H 206 H CH₃ CH₃ H CH₃ 207 H CH₃ CH₃ CH₃ CH₃ 208 H CH₃ CH₃ H OCH₃ 209 H CH₃ CH₃ CH₃ OCH₃ 210 H CH₃ CH₃ OCH₃ OCH₃ 211 H CH₃ CH₃ Cl OCH₃ 212 H CH₃ CH₃ Br OCH₃ 213 H CH₃ CH₃ F OCH₃ 214 H CH₃ CH₃ H Cl 215 H CH₃ CH₃ CH₃ Cl 216 H CH₃ CH₃ OCH₃ Cl 217 H CH₃ CH₃ Cl Cl 218 H CH₃ CH₃ Br Cl 219 H CH₃ CH₃ F Cl 220 H CH₃ CH₃ H Br 221 H CH₃ CH₃ CH₃ Br 222 H CH₃ CH₃ OCH₃ Br 223 H CH₃ CH₃ Cl Br 224 H CH₃ CH₃ Br Br 225 H CH₃ CH₃ F Br 226 H CH₃ CH₃ H F 227 H CH₃ CH₃ CH₃ F 228 H CH₃ CH₃ OCH₃ F 229 H CH₃ CH₃ Cl F 230 H CH₃ CH₃ Br F 231 H CH₃ CH₃ F F 232 H CH₃ OCH₃ H H 233 H CH₃ OCH₃ CH₃ H 234 H CH₃ OCH₃ OCH₃ H 235 H CH₃ OCH₃ Cl H 236 H CH₃ OCH₃ Br H 237 H CH₃ OCH₃ F H 238 H CH₃ OCH₃ H CH₃ 239 H CH₃ OCH₃ CH₃ CH₃ 240 H CH₃ OCH₃ OCH₃ CH₃ 241 H CH₃ OCH₃ Cl CH₃ 242 H CH₃ OCH₃ Br CH₃ 243 H CH₃ OCH₃ F CH₃ 244 H CH₃ OCH₃ H OCH₃ 245 H CH₃ OCH₃ OCH₃ OCH₃ 246 H CH₃ OCH₃ H Cl 247 H CH₃ OCH₃ CH₃ Cl 248 H CH₃ OCH₃ OCH₃ Cl 249 H CH₃ OCH₃ Cl Cl 250 H CH₃ OCH₃ Br Cl 251 H CH₃ OCH₃ F Cl 252 H CH₃ OCH₃ H Br 253 H CH₃ OCH₃ CH₃ Br 254 H CH₃ OCH₃ OCH₃ Br 255 H CH₃ OCH₃ Cl Br 256 H CH₃ OCH₃ Br Br 257 H CH₃ OCH₃ F Br 258 H CH₃ OCH₃ H F 259 H CH₃ OCH₃ CH₃ F 260 H CH₃ OCH₃ OCH₃ F 261 H CH₃ OCH₃ Cl F 262 H CH₃ OCH₃ Br F 263 H CH₃ OCH₃ F F 264 H CH₃ Cl H H 265 H CH₃ Cl CH₃ H 266 H CH₃ Cl OCH₃ H 267 H CH₃ Cl Cl H 268 H CH₃ Cl Br H 269 H CH₃ Cl F H 270 H CH₃ Cl H CH₃ 271 H CH₃ Cl CH₃ CH₃ 272 H CH₃ Cl OCH₃ CH₃ 273 H CH₃ Cl Cl CH₃ 274 H CH₃ Cl Br CH₃ 275 H CH₃ Cl F CH₃ 276 H CH₃ Cl H OCH₃ 277 H CH₃ Cl CH₃ OCH₃ 278 H CH₃ Cl OCH₃ OCH₃ 279 H CH₃ Cl Cl OCH₃ 280 H CH₃ Cl Br OCH₃ 281 H CH₃ Cl F OCH₃ 282 H CH₃ Cl H Cl 283 H CH₃ Cl Cl Cl 284 H CH₃ Cl H Br 285 H CH₃ Cl CH₃ Br 286 H CH₃ Cl OCH₃ Br 287 H CH₃ Cl Cl Br 288 H CH₃ Cl Br Br 289 H CH₃ Cl F Br 290 H CH₃ Cl H F 291 H CH₃ Cl CH₃ F 292 H CH₃ Cl OCH₃ F 293 H CH₃ Cl Cl F 294 H CH₃ Cl F F 295 H CH₃ Br H H 296 H CH₃ Br CH₃ H 297 H CH₃ Br OCH₃ H 298 H CH₃ Br Cl H 299 H CH₃ Br Br H 300 H CH₃ Br F H 301 H CH₃ Br H CH₃ 302 H CH₃ Br CH₃ CH₃ 303 H CH₃ Br OCH₃ CH₃ 304 H CH₃ Br Cl CH₃ 305 H CH₃ Br Br CH₃ 306 H CH₃ Br F CH₃ 307 H CH₃ Br H OCH₃ 308 H CH₃ Br CH₃ OCH₃ 309 H CH₃ Br OCH₃ OCH₃ 310 H CH₃ Br Cl OCH₃ 311 H CH₃ Br Br OCH₃ 312 H CH₃ Br F OCH₃ 313 H CH₃ Br H Cl 314 H CH₃ Br CH₃ Cl 315 H CH₃ Br OCH₃ Cl 316 H CH₃ Br Cl Cl 317 H CH₃ Br Br Cl 318 H CH₃ Br F Cl 319 H CH₃ Br H Br 320 H CH₃ Br Br Br 321 H CH₃ Br H F 322 H CH₃ Br CH₃ F 323 H CH₃ Br OCH₃ F 324 H CH₃ Br Cl F 325 H CH₃ Br Br F 326 H CH₃ Br F F 327 H CH₃ F H H 328 H CH₃ F CH₃ H 329 H CH₃ F OCH₃ H 330 H CH₃ F Cl H 331 H CH₃ F Br H 332 H CH₃ F F H 333 H CH₃ F H CH₃ 334 H CH₃ F CH₃ CH₃ 335 H CH₃ F OCH₃ CH₃ 336 H CH₃ F Cl CH₃ 337 H CH₃ F Br CH₃ 338 H CH₃ F F CH₃ 339 H CH₃ F H OCH₃ 340 H CH₃ F CH₃ OCH₃ 341 H CH₃ F OCH₃ OCH₃ 342 H CH₃ F Cl OCH₃ 343 H CH₃ F Br OCH₃ 344 H CH₃ F F OCH₃ 345 H CH₃ F H Cl 346 H CH₃ F CH₃ Cl 347 H CH₃ F OCH₃ Cl 348 H CH₃ F Cl Cl 349 H CH₃ F Br Cl 350 H CH₃ F F Cl 351 H CH₃ F H Br 352 H CH₃ F CH₃ Br 353 H CH₃ F OCH₃ Br 354 H CH₃ F Cl Br 355 H CH₃ F Br Br 356 H CH₃ F F Br 357 H CH₃ F H F 358 H CH₃ F F F 359 H OCH₃ CH₃ H H 360 H OCH₃ CH₃ H CH₃ 361 H OCH₃ CH₃ H OCH₃ 362 H OCH₃ CH₃ H Cl 363 H OCH₃ CH₃ H Br 364 H OCH₃ CH₃ H F 365 H OCH₃ CH₃ CH₃ H 366 H OCH₃ CH₃ CH₃ CH₃ 367 H OCH₃ CH₃ CH₃ OCH₃ 368 H OCH₃ CH₃ CH₃ Cl 369 H OCH₃ CH₃ CH₃ Br 370 H OCH₃ CH₃ CH₃ F 371 H OCH₃ CH₃ OCH₃ H 372 H OCH₃ CH₃ OCH₃ OCH₃ 373 H OCH₃ CH₃ OCH₃ Cl 374 H OCH₃ CH₃ OCH₃ Br 375 H OCH₃ CH₃ OCH₃ F 376 H OCH₃ CH₃ Cl H 377 H OCH₃ CH₃ Cl OCH₃ 378 H OCH₃ CH₃ Cl Cl 379 H OCH₃ CH₃ Cl Br 380 H OCH₃ CH₃ Cl F 381 H OCH₃ CH₃ Br H 382 H OCH₃ CH₃ Br OCH₃ 383 H OCH₃ CH₃ Br Cl 384 H OCH₃ CH₃ Br Br 385 H OCH₃ CH₃ Br F 386 H OCH₃ CH₃ F H 387 H OCH₃ CH₃ F OCH₃ 388 H OCH₃ CH₃ F Cl 389 H OCH₃ CH₃ F Br 390 H OCH₃ CH₃ F F 391 H OCH₃ OCH₃ H H 392 H OCH₃ OCH₃ H CH₃ 393 H OCH₃ OCH₃ H OCH₃ 394 H OCH₃ OCH₃ H Cl 395 H OCH₃ OCH₃ H Br 396 H OCH₃ OCH₃ H F 397 H OCH₃ OCH₃ CH₃ H 398 H OCH₃ OCH₃ CH₃ CH₃ 399 H OCH₃ OCH₃ CH₃ Cl 400 H OCH₃ OCH₃ CH₃ Br 401 H OCH₃ OCH₃ CH₃ F 402 H OCH₃ OCH₃ OCH₃ H 403 H OCH₃ OCH₃ OCH₃ CH₃ 404 H OCH₃ OCH₃ OCH₃ OCH₃ 405 H OCH₃ OCH₃ OCH₃ Cl 406 H OCH₃ OCH₃ OCH₃ Br 407 H OCH₃ OCH₃ OCH₃ F 408 H OCH₃ OCH₃ Cl H 409 H OCH₃ OCH₃ Cl CH₃ 410 H OCH₃ OCH₃ Cl Cl 411 H OCH₃ OCH₃ Cl Br 412 H OCH₃ OCH₃ Cl F 413 H OCH₃ OCH₃ Br H 414 H OCH₃ OCH₃ Br CH₃ 415 H OCH₃ OCH₃ Br Cl 416 H OCH₃ OCH₃ Br Br 417 H OCH₃ OCH₃ Br F 418 H OCH₃ OCH₃ F H 419 H OCH₃ OCH₃ F CH₃ 420 H OCH₃ OCH₃ F Cl 421 H OCH₃ OCH₃ F Br 422 H OCH₃ OCH₃ F F 423 H OCH₃ Cl H H 424 H OCH₃ Cl H CH₃ 425 H OCH₃ Cl H OCH₃ 426 H OCH₃ Cl H Cl 427 H OCH₃ Cl H Br 428 H OCH₃ Cl H F 429 H OCH₃ Cl CH₃ H 430 H OCH₃ Cl CH₃ CH₃ 431 H OCH₃ Cl CH₃ OCH₃ 432 H OCH₃ Cl CH₃ Br 433 H OCH₃ Cl CH₃ F 434 H OCH₃ Cl OCH₃ H 435 H OCH₃ Cl OCH₃ CH₃ 436 H OCH₃ Cl OCH₃ OCH₃ 437 H OCH₃ Cl OCH₃ Br 438 H OCH₃ Cl OCH₃ F 439 H OCH₃ Cl Cl H 440 H OCH₃ Cl Cl CH₃ 441 H OCH₃ Cl Cl OCH₃ 442 H OCH₃ Cl Cl Cl 443 H OCH₃ Cl Cl Br 444 H OCH₃ Cl Cl F 445 H OCH₃ Cl Br H 446 H OCH₃ Cl Br CH₃ 447 H OCH₃ Cl Br OCH₃ 448 H OCH₃ Cl Br Br 449 H OCH₃ Cl F H 450 H OCH₃ Cl F CH₃ 451 H OCH₃ Cl F OCH₃ 452 H OCH₃ Cl F Br 453 H OCH₃ Cl F F 454 H OCH₃ Br H H 455 H OCH₃ Br H CH₃ 456 H OCH₃ Br H OCH₃ 457 H OCH₃ Br H Cl 458 H OCH₃ Br H Br 459 H OCH₃ Br H F 460 H OCH₃ Br CH₃ H 461 H OCH₃ Br CH₃ CH₃ 462 H OCH₃ Br CH₃ OCH₃ 463 H OCH₃ Br CH₃ Cl 464 H OCH₃ Br CH₃ F 465 H OCH₃ Br OCH₃ H 466 H OCH₃ Br OCH₃ CH₃ 467 H OCH₃ Br OCH₃ OCH₃ 468 H OCH₃ Br OCH₃ Cl 469 H OCH₃ Br OCH₃ F 470 H OCH₃ Br Cl H 471 H OCH₃ Br Cl CH₃ 472 H OCH₃ Br Cl OCH₃ 473 H OCH₃ Br Cl Cl 474 H OCH₃ Br Cl F 475 H OCH₃ Br Br H 476 H OCH₃ Br Br CH₃ 477 H OCH₃ Br Br OCH₃ 478 H OCH₃ Br Br Cl 479 H OCH₃ Br Br Br 480 H OCH₃ Br Br F 481 H OCH₃ Br F H 482 H OCH₃ Br F CH₃ 483 H OCH₃ Br F OCH₃ 484 H OCH₃ Br F Cl 485 H OCH₃ Br F F 486 H OCH₃ F H H 487 H OCH₃ F H CH₃ 488 H OCH₃ F H OCH₃ 489 H OCH₃ F H Cl 490 H OCH₃ F H Br 491 H OCH₃ F H F 492 H OCH₃ F CH₃ H 493 H OCH₃ F CH₃ CH₃ 494 H OCH₃ F CH₃ OCH₃ 495 H OCH₃ F CH₃ Cl 496 H OCH₃ F CH₃ Br 497 H OCH₃ F OCH₃ H 498 H OCH₃ F OCH₃ CH₃ 499 H OCH₃ F OCH₃ OCH₃ 500 H OCH₃ F OCH₃ Cl 501 H OCH₃ F OCH₃ Br 502 H OCH₃ F Cl H 503 H OCH₃ F Cl CH₃ 504 H OCH₃ F Cl OCH₃ 505 H OCH₃ F Cl Cl 506 H OCH₃ F Cl Br 507 H OCH₃ F Br H 508 H OCH₃ F Br CH₃ 509 H OCH₃ F Br OCH₃ 510 H OCH₃ F Br Cl 511 H OCH₃ F Br Br 512 H OCH₃ F F H 513 H OCH₃ F F CH₃ 514 H OCH₃ F F OCH₃ 515 H OCH₃ F F Cl 516 H OCH₃ F F Br 517 H OCH₃ F F F 518 H Cl CH₃ H H 519 H Cl CH₃ H CH₃ 520 H Cl CH₃ H OCH₃ 521 H Cl CH₃ H Cl 522 H Cl CH₃ H Br 523 H Cl CH₃ H F 524 H Cl CH₃ CH₃ H 525 H Cl CH₃ CH₃ CH₃ 526 H Cl CH₃ CH₃ OCH₃ 527 H Cl CH₃ CH₃ Cl 528 H Cl CH₃ CH₃ Br 529 H Cl CH₃ CH₃ F 530 H Cl CH₃ OCH₃ H 531 H Cl CH₃ OCH₃ OCH₃ 532 H Cl CH₃ OCH₃ Cl 533 H Cl CH₃ OCH₃ Br 534 H Cl CH₃ OCH₃ F 535 H Cl CH₃ Cl H 536 H Cl CH₃ Cl OCH₃ 537 H Cl CH₃ Cl Cl 538 H Cl CH₃ Cl Br 539 H Cl CH₃ Cl F 540 H Cl CH₃ Br H 541 H Cl CH₃ Br OCH₃ 542 H Cl CH₃ Br Cl 543 H Cl CH₃ Br Br 544 H Cl CH₃ Br F 545 H Cl CH₃ F H 546 H Cl CH₃ F OCH₃ 547 H Cl CH₃ F Cl 548 H Cl CH₃ F Br 549 H Cl CH₃ F F 550 H Cl OCH₃ H H 551 H Cl OCH₃ H CH₃ 552 H Cl OCH₃ H OCH₃ 553 H Cl OCH₃ H Cl 554 H Cl OCH₃ H Br 555 H Cl OCH₃ H F 556 H Cl OCH₃ CH₃ H 557 H Cl OCH₃ CH₃ CH₃ 558 H Cl OCH₃ CH₃ Cl 559 H Cl OCH₃ CH₃ Br 560 H Cl OCH₃ CH₃ F 561 H Cl OCH₃ OCH₃ H 562 H Cl OCH₃ OCH₃ CH₃ 563 H Cl OCH₃ OCH₃ OCH₃ 564 H Cl OCH₃ OCH₃ Cl 565 H Cl OCH₃ OCH₃ Br 566 H Cl OCH₃ OCH₃ F 567 H Cl OCH₃ Cl H 568 H Cl OCH₃ Cl CH₃ 569 H Cl OCH₃ Cl Cl 570 H Cl OCH₃ Cl Br 571 H Cl OCH₃ Cl F 572 H Cl OCH₃ Br H 573 H Cl OCH₃ Br CH₃ 574 H Cl OCH₃ Br Cl 575 H Cl OCH₃ Br Br 576 H Cl OCH₃ Br F 577 H Cl OCH₃ F H 578 H Cl OCH₃ F CH₃ 579 H Cl OCH₃ F Cl 580 H Cl OCH₃ F Br 581 H Cl OCH₃ F F 582 H Cl Cl H H 583 H Cl Cl H CH₃ 584 H Cl Cl H OCH₃ 585 H Cl Cl H Cl 586 H Cl Cl H Br 587 H Cl Cl H F 588 H Cl Cl CH₃ H 589 H Cl Cl CH₃ CH₃ 590 H Cl Cl CH₃ OCH₃ 591 H Cl Cl CH₃ Br 592 H Cl Cl CH₃ F 593 H Cl Cl OCH₃ H 594 H Cl Cl OCH₃ CH₃ 595 H Cl Cl OCH₃ OCH₃ 596 H Cl Cl OCH₃ Br 597 H Cl Cl OCH₃ F 598 H Cl Cl Cl H 599 H Cl Cl Cl CH₃ 600 H Cl Cl Cl OCH₃ 601 H Cl Cl Cl Cl 602 H Cl Cl Cl Br 603 H Cl Cl Cl F 604 H Cl Cl Br H 605 H Cl Cl Br CH₃ 606 H Cl Cl Br OCH₃ 607 H Cl Cl Br Br 608 H Cl Cl F H 609 H Cl Cl F CH₃ 610 H Cl Cl F OCH₃ 611 H Cl Cl F Br 612 H Cl Cl F F 613 H Cl Br H H 614 H Cl Br H CH₃ 615 H Cl Br H OCH₃ 616 H Cl Br H Cl 617 H Cl Br H Br 618 H Cl Br H F 619 H Cl Br CH₃ H 620 H Cl Br CH₃ CH₃ 621 H Cl Br CH₃ OCH₃ 622 H Cl Br CH₃ Cl 623 H Cl Br CH₃ F 624 H Cl Br OCH₃ H 625 H Cl Br OCH₃ CH₃ 626 H Cl Br OCH₃ OCH₃ 627 H Cl Br OCH₃ Cl 628 H Cl Br OCH₃ F 629 H Cl Br Cl H 630 H Cl Br Cl CH₃ 631 H Cl Br Cl OCH₃ 632 H Cl Br Cl Cl 633 H Cl Br Cl F 634 H Cl Br Br H 635 H Cl Br Br CH₃ 636 H Cl Br Br OCH₃ 637 H Cl Br Br Cl 638 H Cl Br Br Br 639 H Cl Br Br F 640 H Cl Br F H 641 H Cl Br F CH₃ 642 H Cl Br F OCH₃ 643 H Cl Br F Cl 644 H Cl Br F F 645 H Cl F H H 646 H Cl F H CH₃ 647 H Cl F H OCH₃ 648 H Cl F H Cl 649 H Cl F H Br 650 H Cl F H F 651 H Cl F CH₃ H 652 H Cl F CH₃ CH₃ 653 H Cl F CH₃ OCH₃ 654 H Cl F CH₃ Cl 655 H Cl F CH₃ Br 656 H Cl F OCH₃ H 657 H Cl F OCH₃ CH₃ 658 H Cl F OCH₃ OCH₃ 659 H Cl F OCH₃ Cl 660 H Cl F OCH₃ Br 661 H Cl F Cl H 662 H Cl F Cl CH₃ 663 H Cl F Cl OCH₃ 664 H Cl F Cl Cl 665 H Cl F Cl Br 666 H Cl F Br H 667 H Cl F Br CH₃ 668 H Cl F Br OCH₃ 669 H Cl F Br Cl 670 H Cl F Br Br 671 H Cl F F H 672 H Cl F F CH₃ 673 H Cl F F OCH₃ 674 H Cl F F Cl 675 H Cl F F Br 676 H Cl F F F 677 H Br CH₃ H H 678 H Br CH₃ H CH₃ 679 H Br CH₃ H OCH₃ 680 H Br CH₃ H Cl 681 H Br CH₃ H Br 682 H Br CH₃ H F 683 H Br CH₃ CH₃ H 684 H Br CH₃ CH₃ CH₃ 685 H Br CH₃ CH₃ OCH₃ 686 H Br CH₃ CH₃ Cl 687 H Br CH₃ CH₃ Br 688 H Br CH₃ CH₃ F 689 H Br CH₃ OCH₃ H 690 H Br CH₃ OCH₃ OCH₃ 691 H Br CH₃ OCH₃ Cl 692 H Br CH₃ OCH₃ Br 693 H Br CH₃ OCH₃ F 694 H Br CH₃ Cl H 695 H Br CH₃ Cl OCH₃ 696 H Br CH₃ Cl Cl 697 H Br CH₃ Cl Br 698 H Br CH₃ Cl F 699 H Br CH₃ Br H 700 H Br CH₃ Br OCH₃ 701 H Br CH₃ Br Cl 702 H Br CH₃ Br Br 703 H Br CH₃ Br F 704 H Br CH₃ F H 705 H Br CH₃ F OCH₃ 706 H Br CH₃ F Cl 707 H Br CH₃ F Br 708 H Br CH₃ F F 709 H Br OCH₃ H H 710 H Br OCH₃ H CH₃ 711 H Br OCH₃ H OCH₃ 712 H Br OCH₃ H Cl 713 H Br OCH₃ H Br 714 H Br OCH₃ H F 715 H Br OCH₃ CH₃ H 716 H Br OCH₃ CH₃ CH₃ 717 H Br OCH₃ CH₃ Cl 718 H Br OCH₃ CH₃ Br 719 H Br OCH₃ CH₃ F 720 H Br OCH₃ OCH₃ H 721 H Br OCH₃ OCH₃ CH₃ 722 H Br OCH₃ OCH₃ OCH₃ 723 H Br OCH₃ OCH₃ Cl 724 H Br OCH₃ OCH₃ Br 725 H Br OCH₃ OCH₃ F 726 H Br OCH₃ Cl H 727 H Br OCH₃ Cl CH₃ 728 H Br OCH₃ Cl Cl 729 H Br OCH₃ Cl Br 730 H Br OCH₃ Cl F 731 H Br OCH₃ Br H 732 H Br OCH₃ Br CH₃ 733 H Br OCH₃ Br Cl 734 H Br OCH₃ Br Br 735 H Br OCH₃ Br F 736 H Br OCH₃ F H 737 H Br OCH₃ F CH₃ 738 H Br OCH₃ F Cl 739 H Br OCH₃ F Br 740 H Br OCH₃ F F 741 H Br Cl H H 742 H Br Cl H CH₃ 743 H Br Cl H OCH₃ 744 H Br Cl H Cl 745 H Br Cl H Br 746 H Br Cl H F 747 H Br Cl CH₃ H 748 H Br Cl CH₃ CH₃ 749 H Br Cl CH₃ OCH₃ 750 H Br Cl CH₃ Br 751 H Br Cl CH₃ F 752 H Br Cl OCH₃ H 753 H Br Cl OCH₃ CH₃ 754 H Br Cl OCH₃ OCH₃ 755 H Br Cl OCH₃ Br 756 H Br Cl OCH₃ F 757 H Br Cl Cl H 758 H Br Cl Cl CH₃ 759 H Br Cl Cl OCH₃ 760 H Br Cl Cl Cl 761 H Br Cl Cl Br 762 H Br Cl Cl F 763 H Br Cl Br H 764 H Br Cl Br CH₃ 765 H Br Cl Br OCH₃ 766 H Br Cl Br Br 767 H Br Cl F H 768 H Br Cl F CH₃ 769 H Br Cl F OCH₃ 770 H Br Cl F Br 771 H Br Cl F F 772 H Br Br H H 773 H Br Br H CH₃ 774 H Br Br H OCH₃ 775 H Br Br H Cl 776 H Br Br H Br 777 H Br Br H F 778 H Br Br CH₃ H 779 H Br Br CH₃ CH₃ 780 H Br Br CH₃ OCH₃ 781 H Br Br CH₃ Cl 782 H Br Br CH₃ F 783 H Br Br OCH₃ H 784 H Br Br OCH₃ CH₃ 785 H Br Br OCH₃ OCH₃ 786 H Br Br OCH₃ Cl 787 H Br Br OCH₃ F 788 H Br Br Cl H 789 H Br Br Cl CH₃ 790 H Br Br Cl OCH₃ 791 H Br Br Cl Cl 792 H Br Br Cl F 793 H Br Br Br H 794 H Br Br Br CH₃ 795 H Br Br Br OCH₃ 796 H Br Br Br Cl 797 H Br Br Br Br 798 H Br Br Br F 799 H Br Br F H 800 H Br Br F CH₃ 801 H Br Br F OCH₃ 802 H Br Br F Cl 803 H Br Br F F 804 H Br F H H 805 H Br F H CH₃ 806 H Br F H OCH₃ 807 H Br F H Cl 808 H Br F H Br 809 H Br F H F 810 H Br F CH₃ H 811 H Br F CH₃ CH₃ 812 H Br F CH₃ OCH₃ 813 H Br F CH₃ Cl 814 H Br F CH₃ Br 815 H Br F OCH₃ H 816 H Br F OCH₃ CH₃ 817 H Br F OCH₃ OCH₃ 818 H Br F OCH₃ Cl 819 H Br F OCH₃ Br 820 H Br F Cl H 821 H Br F Cl CH₃ 822 H Br F Cl OCH₃ 823 H Br F Cl Cl 824 H Br F Cl Br 825 H Br F Br H 826 H Br F Br CH₃ 827 H Br F Br OCH₃ 828 H Br F Br Cl 829 H Br F Br Br 830 H Br F F H 831 H Br F F CH₃ 832 H Br F F OCH₃ 833 H Br F F Cl 834 H Br F F Br 835 H Br F F F 836 H F CH₃ H H 837 H F CH₃ H CH₃ 838 H F CH₃ H OCH₃ 839 H F CH₃ H Cl 840 H F CH₃ H Br 841 H F CH₃ H F 842 H F CH₃ CH₃ H 843 H F CH₃ CH₃ CH₃ 844 H F CH₃ CH₃ OCH₃ 845 H F CH₃ CH₃ Cl 846 H F CH₃ CH₃ Br 847 H F CH₃ CH₃ F 848 H F CH₃ OCH₃ H 849 H F CH₃ OCH₃ OCH₃ 850 H F CH₃ OCH₃ Cl 851 H F CH₃ OCH₃ Br 852 H F CH₃ OCH₃ F 853 H F CH₃ Cl H 854 H F CH₃ Cl OCH₃ 855 H F CH₃ Cl Cl 856 H F CH₃ Cl Br 857 H F CH₃ Cl F 858 H F CH₃ Br H 859 H F CH₃ Br OCH₃ 860 H F CH₃ Br Cl 861 H F CH₃ Br Br 862 H F CH₃ Br F 863 H F CH₃ F H 864 H F CH₃ F OCH₃ 865 H F CH₃ F Cl 866 H F CH₃ F Br 867 H F CH₃ F F 868 H F OCH₃ H H 869 H F OCH₃ H CH₃ 870 H F OCH₃ H OCH₃ 871 H F OCH₃ H Cl 872 H F OCH₃ H Br 873 H F OCH₃ H F 874 H F OCH₃ CH₃ H 875 H F OCH₃ CH₃ CH₃ 876 H F OCH₃ CH₃ Cl 877 H F OCH₃ CH₃ Br 878 H F OCH₃ CH₃ F 879 H F OCH₃ OCH₃ H 880 H F OCH₃ OCH₃ CH₃ 881 H F OCH₃ OCH₃ OCH₃ 882 H F OCH₃ OCH₃ Cl 883 H F OCH₃ OCH₃ Br 884 H F OCH₃ OCH₃ F 885 H F OCH₃ Cl H 886 H F OCH₃ Cl CH₃ 887 H F OCH₃ Cl Cl 888 H F OCH₃ Cl Br 889 H F OCH₃ Cl F 890 H F OCH₃ Br H 891 H F OCH₃ Br CH₃ 892 H F OCH₃ Br Cl 893 H F OCH₃ Br Br 894 H F OCH₃ Br F 895 H F OCH₃ F H 896 H F OCH₃ F CH₃ 897 H F OCH₃ F Cl 898 H F OCH₃ F Br 899 H F OCH₃ F F 900 H F Cl H H 901 H F Cl H CH₃ 902 H F Cl H OCH₃ 903 H F Cl H Cl 904 H F Cl H Br 905 H F Cl H F 906 H F Cl CH₃ H 907 H F Cl CH₃ CH₃ 908 H F Cl CH₃ OCH₃ 909 H F Cl CH₃ Br 910 H F Cl CH₃ F 911 H F Cl OCH₃ H 912 H F Cl OCH₃ CH₃ 913 H F Cl OCH₃ OCH₃ 914 H F Cl OCH₃ Br 915 H F Cl OCH₃ F 916 H F Cl Cl H 917 H F Cl Cl CH₃ 918 H F Cl Cl OCH₃ 919 H F Cl Cl Cl 920 H F Cl Cl Br 921 H F Cl Cl F 922 H F Cl Br H 923 H F Cl Br CH₃ 924 H F Cl Br OCH₃ 925 H F Cl Br Br 926 H F Cl F H 927 H F Cl F CH₃ 928 H F Cl F OCH₃ 929 H F Cl F Br 930 H F Cl F F 931 H F Br H H 932 H F Br H CH₃ 933 H F Br H OCH₃ 934 H F Br H Cl 935 H F Br H Br 936 H F Br H F 937 H F Br CH₃ H 938 H F Br CH₃ CH₃ 939 H F Br CH₃ OCH₃ 940 H F Br CH₃ Cl 941 H F Br CH₃ F 942 H F Br OCH₃ H 943 H F Br OCH₃ CH₃ 944 H F Br OCH₃ OCH₃ 945 H F Br OCH₃ Cl 946 H F Br OCH₃ F 947 H F Br Cl H 948 H F Br Cl CH₃ 949 H F Br Cl OCH₃ 950 H F Br Cl Cl 951 H F Br Cl F 952 H F Br Br H 953 H F Br Br CH₃ 954 H F Br Br OCH₃ 955 H F Br Br Cl 956 H F Br Br Br 957 H F Br Br F 958 H F Br F H 959 H F Br F CH₃ 960 H F Br F OCH₃ 961 H F Br F Cl 962 H F Br F F 963 H F F H H 964 H F F H CH₃ 965 H F F H OCH₃ 966 H F F H Cl 967 H F F H Br 968 H F F H F 969 H F F CH₃ H 970 H F F CH₃ CH₃ 971 H F F CH₃ OCH₃ 972 H F F CH₃ Cl 973 H F F CH₃ Br 974 H F F OCH₃ H 975 H F F OCH₃ CH₃ 976 H F F OCH₃ OCH₃ 977 H F F OCH₃ Cl 978 H F F OCH₃ Br 979 H F F Cl H 980 H F F Cl CH₃ 981 H F F Cl OCH₃ 982 H F F Cl Cl 983 H F F Cl Br 984 H F F Br H 985 H F F Br CH₃ 986 H F F Br OCH₃ 987 H F F Br Cl 988 H F F Br Br 989 H F F F H 990 H F F F CH₃ 991 H F F F OCH₃ 992 H F F F Cl 993 H F F F Br 994 H F F F F 995 CH₃ CH₃ CH₃ H H 996 CH₃ CH₃ CH₃ CH₃ H 997 CH₃ CH₃ CH₃ OCH₃ H 998 CH₃ CH₃ CH₃ Cl H 999 CH₃ CH₃ CH₃ Br H 1000 CH₃ CH₃ CH₃ F H 1001 CH₃ CH₃ CH₃ H CH₃ 1002 CH₃ CH₃ CH₃ CH₃ CH₃ 1003 CH₃ CH₃ CH₃ H OCH₃ 1004 CH₃ CH₃ CH₃ CH₃ OCH₃ 1005 CH₃ CH₃ CH₃ OCH₃ OCH₃ 1006 CH₃ CH₃ CH₃ Cl OCH₃ 1007 CH₃ CH₃ CH₃ Br OCH₃ 1008 CH₃ CH₃ CH₃ F OCH₃ 1009 CH₃ CH₃ CH₃ H Cl 1010 CH₃ CH₃ CH₃ CH₃ Cl 1011 CH₃ CH₃ CH₃ OCH₃ Cl 1012 CH₃ CH₃ CH₃ Cl Cl 1013 CH₃ CH₃ CH₃ Br Cl 1014 CH₃ CH₃ CH₃ F Cl 1015 CH₃ CH₃ CH₃ H Br 1016 CH₃ CH₃ CH₃ CH₃ Br 1017 CH₃ CH₃ CH₃ OCH₃ Br 1018 CH₃ CH₃ CH₃ Cl Br 1019 CH₃ CH₃ CH₃ Br Br 1020 CH₃ CH₃ CH₃ F Br 1021 CH₃ CH₃ CH₃ H F 1022 CH₃ CH₃ CH₃ CH₃ F 1023 CH₃ CH₃ CH₃ OCH₃ F 1024 CH₃ CH₃ CH₃ Cl F 1025 CH₃ CH₃ CH₃ Br F 1026 CH₃ CH₃ CH₃ F F 1027 CH₃ CH₃ OCH₃ H H 1028 CH₃ CH₃ OCH₃ CH₃ H 1029 CH₃ CH₃ OCH₃ OCH₃ H 1030 CH₃ CH₃ OCH₃ Cl H 1031 CH₃ CH₃ OCH₃ Br H 1032 CH₃ CH₃ OCH₃ F H 1033 CH₃ CH₃ OCH₃ H CH₃ 1034 CH₃ CH₃ OCH₃ CH₃ CH₃ 1035 CH₃ CH₃ OCH₃ OCH₃ CH₃ 1036 CH₃ CH₃ OCH₃ Cl CH₃ 1037 CH₃ CH₃ OCH₃ Br CH₃ 1038 CH₃ CH₃ OCH₃ F CH₃ 1039 CH₃ CH₃ OCH₃ H OCH₃ 1040 CH₃ CH₃ OCH₃ OCH₃ OCH₃ 1041 CH₃ CH₃ OCH₃ H Cl 1042 CH₃ CH₃ OCH₃ CH₃ Cl 1043 CH₃ CH₃ OCH₃ OCH₃ Cl 1044 CH₃ CH₃ OCH₃ Cl Cl 1045 CH₃ CH₃ OCH₃ Br Cl 1046 CH₃ CH₃ OCH₃ F Cl 1047 CH₃ CH₃ OCH₃ H Br 1048 CH₃ CH₃ OCH₃ CH₃ Br 1049 CH₃ CH₃ OCH₃ OCH₃ Br 1050 CH₃ CH₃ OCH₃ Cl Br 1051 CH₃ CH₃ OCH₃ Br Br 1052 CH₃ CH₃ OCH₃ F Br 1053 CH₃ CH₃ OCH₃ H F 1054 CH₃ CH₃ OCH₃ CH₃ F 1055 CH₃ CH₃ OCH₃ OCH₃ F 1056 CH₃ CH₃ OCH₃ Cl F 1057 CH₃ CH₃ OCH₃ Br F 1058 CH₃ CH₃ OCH₃ F F 1059 CH₃ CH₃ Cl H H 1060 CH₃ CH₃ Cl CH₃ H 1061 CH₃ CH₃ Cl OCH₃ H 1062 CH₃ CH₃ Cl Cl H 1063 CH₃ CH₃ Cl Br H 1064 CH₃ CH₃ Cl F H 1065 CH₃ CH₃ Cl H CH₃ 1066 CH₃ CH₃ Cl CH₃ CH₃ 1067 CH₃ CH₃ Cl OCH₃ CH₃ 1068 CH₃ CH₃ Cl Cl CH₃ 1069 CH₃ CH₃ Cl Br CH₃ 1070 CH₃ CH₃ Cl F CH₃ 1071 CH₃ CH₃ Cl H OCH₃ 1072 CH₃ CH₃ Cl CH₃ OCH₃ 1073 CH₃ CH₃ Cl OCH₃ OCH₃ 1074 CH₃ CH₃ Cl Cl OCH₃ 1075 CH₃ CH₃ Cl Br OCH₃ 1076 CH₃ CH₃ Cl F OCH₃ 1077 CH₃ CH₃ Cl H Cl 1078 CH₃ CH₃ Cl Cl Cl 1079 CH₃ CH₃ Cl H Br 1080 CH₃ CH₃ Cl CH₃ Br 1081 CH₃ CH₃ Cl OCH₃ Br 1082 CH₃ CH₃ Cl Cl Br 1083 CH₃ CH₃ Cl Br Br 1084 CH₃ CH₃ Cl F Br 1085 CH₃ CH₃ Cl H F 1086 CH₃ CH₃ Cl CH₃ F 1087 CH₃ CH₃ Cl OCH₃ F 1088 CH₃ CH₃ Cl Cl F 1089 CH₃ CH₃ Cl F F 1090 CH₃ CH₃ Br H H 1091 CH₃ CH₃ Br CH₃ H 1092 CH₃ CH₃ Br OCH₃ H 1093 CH₃ CH₃ Br Cl H 1094 CH₃ CH₃ Br Br H 1095 CH₃ CH₃ Br F H 1096 CH₃ CH₃ Br H CH₃ 1097 CH₃ CH₃ Br CH₃ CH₃ 1098 CH₃ CH₃ Br OCH₃ CH₃ 1099 CH₃ CH₃ Br Cl CH₃ 1100 CH₃ CH₃ Br Br CH₃ 1101 CH₃ CH₃ Br F CH₃ 1102 CH₃ CH₃ Br H OCH₃ 1103 CH₃ CH₃ Br CH₃ OCH₃ 1104 CH₃ CH₃ Br OCH₃ OCH₃ 1105 CH₃ CH₃ Br Cl OCH₃ 1106 CH₃ CH₃ Br Br OCH₃ 1107 CH₃ CH₃ Br F OCH₃ 1108 CH₃ CH₃ Br H Cl 1109 CH₃ CH₃ Br CH₃ Cl 1110 CH₃ CH₃ Br OCH₃ Cl 1111 CH₃ CH₃ Br Cl Cl 1112 CH₃ CH₃ Br Br Cl 1113 CH₃ CH₃ Br F Cl 1114 CH₃ CH₃ Br H Br 1115 CH₃ CH₃ Br Br Br 1116 CH₃ CH₃ Br H F 1117 CH₃ CH₃ Br CH₃ F 1118 CH₃ CH₃ Br OCH₃ F 1119 CH₃ CH₃ Br Cl F 1120 CH₃ CH₃ Br Br F 1121 CH₃ CH₃ Br F F 1122 CH₃ CH₃ F H H 1123 CH₃ CH₃ F CH₃ H 1124 CH₃ CH₃ F OCH₃ H 1125 CH₃ CH₃ F Cl H 1126 CH₃ CH₃ F Br H 1127 CH₃ CH₃ F F H 1128 CH₃ CH₃ F H CH₃ 1129 CH₃ CH₃ F CH₃ CH₃ 1130 CH₃ CH₃ F OCH₃ CH₃ 1131 CH₃ CH₃ F Cl CH₃ 1132 CH₃ CH₃ F Br CH₃ 1133 CH₃ CH₃ F F CH₃ 1134 CH₃ CH₃ F H OCH₃ 1135 CH₃ CH₃ F CH₃ OCH₃ 1136 CH₃ CH₃ F OCH₃ OCH₃ 1137 CH₃ CH₃ F Cl OCH₃ 1138 CH₃ CH₃ F Br OCH₃ 1139 CH₃ CH₃ F F OCH₃ 1140 CH₃ CH₃ F H Cl 1141 CH₃ CH₃ F CH₃ Cl 1142 CH₃ CH₃ F OCH₃ Cl 1143 CH₃ CH₃ F Cl Cl 1144 CH₃ CH₃ F Br Cl 1145 CH₃ CH₃ F F Cl 1146 CH₃ CH₃ F H Br 1147 CH₃ CH₃ F CH₃ Br 1148 CH₃ CH₃ F OCH₃ Br 1149 CH₃ CH₃ F Cl Br 1150 CH₃ CH₃ F Br Br 1151 CH₃ CH₃ F F Br 1152 CH₃ CH₃ F H F 1153 CH₃ CH₃ F F F 1154 CH₃ OCH₃ CH₃ H H 1155 CH₃ OCH₃ CH₃ H CH₃ 1156 CH₃ OCH₃ CH₃ H OCH₃ 1157 CH₃ OCH₃ CH₃ H Cl 1158 CH₃ OCH₃ CH₃ H Br 1159 CH₃ OCH₃ CH₃ H F 1160 CH₃ OCH₃ CH₃ CH₃ H 1161 CH₃ OCH₃ CH₃ CH₃ CH₃ 1162 CH₃ OCH₃ CH₃ CH₃ OCH₃ 1163 CH₃ OCH₃ CH₃ CH₃ Cl 1164 CH₃ OCH₃ CH₃ CH₃ Br 1165 CH₃ OCH₃ CH₃ CH₃ F 1166 CH₃ OCH₃ CH₃ OCH₃ H 1167 CH₃ OCH₃ CH₃ OCH₃ OCH₃ 1168 CH₃ OCH₃ CH₃ OCH₃ Cl 1169 CH₃ OCH₃ CH₃ OCH₃ Br 1170 CH₃ OCH₃ CH₃ OCH₃ F 1171 CH₃ OCH₃ CH₃ Cl H 1172 CH₃ OCH₃ CH₃ Cl OCH₃ 1173 CH₃ OCH₃ CH₃ Cl Cl 1174 CH₃ OCH₃ CH₃ Cl Br 1175 CH₃ OCH₃ CH₃ Cl F 1176 CH₃ OCH₃ CH₃ Br H 1177 CH₃ OCH₃ CH₃ Br OCH₃ 1178 CH₃ OCH₃ CH₃ Br Cl 1179 CH₃ OCH₃ CH₃ Br Br 1180 CH₃ OCH₃ CH₃ Br F 1181 CH₃ OCH₃ CH₃ F H 1182 CH₃ OCH₃ CH₃ F OCH₃ 1183 CH₃ OCH₃ CH₃ F Cl 1184 CH₃ OCH₃ CH₃ F Br 1185 CH₃ OCH₃ CH₃ F F 1186 CH₃ OCH₃ OCH₃ H H 1187 CH₃ OCH₃ OCH₃ H CH₃ 1188 CH₃ OCH₃ OCH₃ H OCH₃ 1189 CH₃ OCH₃ OCH₃ H Cl 1190 CH₃ OCH₃ OCH₃ H Br 1191 CH₃ OCH₃ OCH₃ H F 1192 CH₃ OCH₃ OCH₃ CH₃ H 1193 CH₃ OCH₃ OCH₃ CH₃ CH₃ 1194 CH₃ OCH₃ OCH₃ CH₃ Cl 1195 CH₃ OCH₃ OCH₃ CH₃ Br 1196 CH₃ OCH₃ OCH₃ CH₃ F 1197 CH₃ OCH₃ OCH₃ OCH₃ H 1198 CH₃ OCH₃ OCH₃ OCH₃ CH₃ 1199 CH₃ OCH₃ OCH₃ OCH₃ OCH₃ 1200 CH₃ OCH₃ OCH₃ OCH₃ Cl 1201 CH₃ OCH₃ OCH₃ OCH₃ Br 1202 CH₃ OCH₃ OCH₃ OCH₃ F 1203 CH₃ OCH₃ OCH₃ Cl H 1204 CH₃ OCH₃ OCH₃ Cl CH₃ 1205 CH₃ OCH₃ OCH₃ Cl Cl 1206 CH₃ OCH₃ OCH₃ Cl Br 1207 CH₃ OCH₃ OCH₃ Cl F 1208 CH₃ OCH₃ OCH₃ Br H 1209 CH₃ OCH₃ OCH₃ Br CH₃ 1210 CH₃ OCH₃ OCH₃ Br Cl 1211 CH₃ OCH₃ OCH₃ Br Br 1212 CH₃ OCH₃ OCH₃ Br F 1213 CH₃ OCH₃ OCH₃ F H 1214 CH₃ OCH₃ OCH₃ F CH₃ 1215 CH₃ OCH₃ OCH₃ F Cl 1216 CH₃ OCH₃ OCH₃ F Br 1217 CH₃ OCH₃ OCH₃ F F 1218 CH₃ OCH₃ Cl H H 1219 CH₃ OCH₃ Cl H CH₃ 1220 CH₃ OCH₃ Cl H OCH₃ 1221 CH₃ OCH₃ Cl H Cl 1222 CH₃ OCH₃ Cl H Br 1223 CH₃ OCH₃ Cl H F 1224 CH₃ OCH₃ Cl CH₃ H 1225 CH₃ OCH₃ Cl CH₃ CH₃ 1226 CH₃ OCH₃ Cl CH₃ OCH₃ 1227 CH₃ OCH₃ Cl CH₃ Br 1228 CH₃ OCH₃ Cl CH₃ F 1229 CH₃ OCH₃ Cl OCH₃ H 1230 CH₃ OCH₃ Cl OCH₃ CH₃ 1231 CH₃ OCH₃ Cl OCH₃ OCH₃ 1232 CH₃ OCH₃ Cl OCH₃ Br 1233 CH₃ OCH₃ Cl OCH₃ F 1234 CH₃ OCH₃ Cl Cl H 1235 CH₃ OCH₃ Cl Cl CH₃ 1236 CH₃ OCH₃ Cl Cl OCH₃ 1237 CH₃ OCH₃ Cl Cl Cl 1238 CH₃ OCH₃ Cl Cl Br 1239 CH₃ OCH₃ Cl Cl F 1240 CH₃ OCH₃ Cl Br H 1241 CH₃ OCH₃ Cl Br CH₃ 1242 CH₃ OCH₃ Cl Br OCH₃ 1243 CH₃ OCH₃ Cl Br Br 1244 CH₃ OCH₃ Cl F H 1245 CH₃ OCH₃ Cl F CH₃ 1246 CH₃ OCH₃ Cl F OCH₃ 1247 CH₃ OCH₃ Cl F Br 1248 CH₃ OCH₃ Cl F F 1249 CH₃ OCH₃ Br H H 1250 CH₃ OCH₃ Br H CH₃ 1251 CH₃ OCH₃ Br H OCH₃ 1252 CH₃ OCH₃ Br H Cl 1253 CH₃ OCH₃ Br H Br 1254 CH₃ OCH₃ Br H F 1255 CH₃ OCH₃ Br CH₃ H 1256 CH₃ OCH₃ Br CH₃ CH₃ 1257 CH₃ OCH₃ Br CH₃ OCH₃ 1258 CH₃ OCH₃ Br CH₃ Cl 1259 CH₃ OCH₃ Br CH₃ F 1260 CH₃ OCH₃ Br OCH₃ H 1261 CH₃ OCH₃ Br OCH₃ CH₃ 1262 CH₃ OCH₃ Br OCH₃ OCH₃ 1263 CH₃ OCH₃ Br OCH₃ Cl 1264 CH₃ OCH₃ Br OCH₃ F 1265 CH₃ OCH₃ Br Cl H 1266 CH₃ OCH₃ Br Cl CH₃ 1267 CH₃ OCH₃ Br Cl OCH₃ 1268 CH₃ OCH₃ Br Cl Cl 1269 CH₃ OCH₃ Br Cl F 1270 CH₃ OCH₃ Br Br H 1271 CH₃ OCH₃ Br Br CH₃ 1272 CH₃ OCH₃ Br Br OCH₃ 1273 CH₃ OCH₃ Br Br Cl 1274 CH₃ OCH₃ Br Br Br 1275 CH₃ OCH₃ Br Br F 1276 CH₃ OCH₃ Br F H 1277 CH₃ OCH₃ Br F CH₃ 1278 CH₃ OCH₃ Br F OCH₃ 1279 CH₃ OCH₃ Br F Cl 1280 CH₃ OCH₃ Br F F 1281 CH₃ OCH₃ F H H 1282 CH₃ OCH₃ F H CH₃ 1283 CH₃ OCH₃ F H OCH₃ 1284 CH₃ OCH₃ F H Cl 1285 CH₃ OCH₃ F H Br 1286 CH₃ OCH₃ F H F 1287 CH₃ OCH₃ F CH₃ H 1288 CH₃ OCH₃ F CH₃ CH₃ 1289 CH₃ OCH₃ F CH₃ OCH₃ 1290 CH₃ OCH₃ F CH₃ Cl 1291 CH₃ OCH₃ F CH₃ Br 1292 CH₃ OCH₃ F OCH₃ H 1293 CH₃ OCH₃ F OCH₃ CH₃ 1294 CH₃ OCH₃ F OCH₃ OCH₃ 1295 CH₃ OCH₃ F OCH₃ Cl 1296 CH₃ OCH₃ F OCH₃ Br 1297 CH₃ OCH₃ F Cl H 1298 CH₃ OCH₃ F Cl CH₃ 1299 CH₃ OCH₃ F Cl OCH₃ 1300 CH₃ OCH₃ F Cl Cl 1301 CH₃ OCH₃ F Cl Br 1302 CH₃ OCH₃ F Br H 1303 CH₃ OCH₃ F Br CH₃ 1304 CH₃ OCH₃ F Br OCH₃ 1305 CH₃ OCH₃ F Br Cl 1306 CH₃ OCH₃ F Br Br 1307 CH₃ OCH₃ F F H 1308 CH₃ OCH₃ F F CH₃ 1309 CH₃ OCH₃ F F OCH₃ 1310 CH₃ OCH₃ F F Cl 1311 CH₃ OCH₃ F F Br 1312 CH₃ OCH₃ F F F 1313 CH₃ Cl CH₃ H H 1314 CH₃ Cl CH₃ H CH₃ 1315 CH₃ Cl CH₃ H OCH₃ 1316 CH₃ Cl CH₃ H Cl 1317 CH₃ Cl CH₃ H Br 1318 CH₃ Cl CH₃ H F 1319 CH₃ Cl CH₃ CH₃ H 1320 CH₃ Cl CH₃ CH₃ CH₃ 1321 CH₃ Cl CH₃ CH₃ OCH₃ 1322 CH₃ Cl CH₃ CH₃ Cl 1323 CH₃ Cl CH₃ CH₃ Br 1324 CH₃ Cl CH₃ CH₃ F 1325 CH₃ Cl CH₃ OCH₃ H 1326 CH₃ Cl CH₃ OCH₃ OCH₃ 1327 CH₃ Cl CH₃ OCH₃ Cl 1328 CH₃ Cl CH₃ OCH₃ Br 1329 CH₃ Cl CH₃ OCH₃ F 1330 CH₃ Cl CH₃ Cl H 1331 CH₃ Cl CH₃ Cl OCH₃ 1332 CH₃ Cl CH₃ Cl Cl 1333 CH₃ Cl CH₃ Cl Br 1334 CH₃ Cl CH₃ Cl F 1335 CH₃ Cl CH₃ Br H 1336 CH₃ Cl CH₃ Br OCH₃ 1337 CH₃ Cl CH₃ Br Cl 1338 CH₃ Cl CH₃ Br Br 1339 CH₃ Cl CH₃ Br F 1340 CH₃ Cl CH₃ F H 1341 CH₃ Cl CH₃ F OCH₃ 1342 CH₃ Cl CH₃ F Cl 1343 CH₃ Cl CH₃ F Br 1344 CH₃ Cl CH₃ F F 1345 CH₃ Cl OCH₃ H H 1346 CH₃ Cl OCH₃ H CH₃ 1347 CH₃ Cl OCH₃ H OCH₃ 1348 CH₃ Cl OCH₃ H Cl 1349 CH₃ Cl OCH₃ H Br 1350 CH₃ Cl OCH₃ H F 1351 CH₃ Cl OCH₃ CH₃ H 1352 CH₃ Cl OCH₃ CH₃ CH₃ 1353 CH₃ Cl OCH₃ CH₃ Cl 1354 CH₃ Cl OCH₃ CH₃ Br 1355 CH₃ Cl OCH₃ CH₃ F 1356 CH₃ Cl OCH₃ OCH₃ H 1357 CH₃ Cl OCH₃ OCH₃ CH₃ 1358 CH₃ Cl OCH₃ OCH₃ OCH₃ 1359 CH₃ Cl OCH₃ OCH₃ Cl 1360 CH₃ Cl OCH₃ OCH₃ Br 1361 CH₃ Cl OCH₃ OCH₃ F 1362 CH₃ Cl OCH₃ Cl H 1363 CH₃ Cl OCH₃ Cl CH₃ 1364 CH₃ Cl OCH₃ Cl Cl 1365 CH₃ Cl OCH₃ Cl Br 1366 CH₃ Cl OCH₃ Cl F 1367 CH₃ Cl OCH₃ Br H 1368 CH₃ Cl OCH₃ Br CH₃ 1369 CH₃ Cl OCH₃ Br Cl 1370 CH₃ Cl OCH₃ Br Br 1371 CH₃ Cl OCH₃ Br F 1372 CH₃ Cl OCH₃ F H 1373 CH₃ Cl OCH₃ F CH₃ 1374 CH₃ Cl OCH₃ F Cl 1375 CH₃ Cl OCH₃ F Br 1376 CH₃ Cl OCH₃ F F 1377 CH₃ Cl Cl H H 1378 CH₃ Cl Cl H CH₃ 1379 CH₃ Cl Cl H OCH₃ 1380 CH₃ Cl Cl H Cl 1381 CH₃ Cl Cl H Br 1382 CH₃ Cl Cl H F 1383 CH₃ Cl Cl CH₃ H 1384 CH₃ Cl Cl CH₃ CH₃ 1385 CH₃ Cl Cl CH₃ OCH₃ 1386 CH₃ Cl Cl CH₃ Br 1387 CH₃ Cl Cl CH₃ F 1388 CH₃ Cl Cl OCH₃ H 1389 CH₃ Cl Cl OCH₃ CH₃ 1390 CH₃ Cl Cl OCH₃ OCH₃ 1391 CH₃ Cl Cl OCH₃ Br 1392 CH₃ Cl Cl OCH₃ F 1393 CH₃ Cl Cl Cl H 1394 CH₃ Cl Cl Cl CH₃ 1395 CH₃ Cl Cl Cl OCH₃ 1396 CH₃ Cl Cl Cl Cl 1397 CH₃ Cl Cl Cl Br 1398 CH₃ Cl Cl Cl F 1399 CH₃ Cl Cl Br H 1400 CH₃ Cl Cl Br CH₃ 1401 CH₃ Cl Cl Br OCH₃ 1402 CH₃ Cl Cl Br Br 1403 CH₃ Cl Cl F H 1404 CH₃ Cl Cl F CH₃ 1405 CH₃ Cl Cl F OCH₃ 1406 CH₃ Cl Cl F Br 1407 CH₃ Cl Cl F F 1408 CH₃ Cl Br H H 1409 CH₃ Cl Br H CH₃ 1410 CH₃ Cl Br H OCH₃ 1411 CH₃ Cl Br H Cl 1412 CH₃ Cl Br H Br 1413 CH₃ Cl Br H F 1414 CH₃ Cl Br CH₃ H 1415 CH₃ Cl Br CH₃ CH₃ 1416 CH₃ Cl Br CH₃ OCH₃ 1417 CH₃ Cl Br CH₃ Cl 1418 CH₃ Cl Br CH₃ F 1419 CH₃ Cl Br OCH₃ H 1420 CH₃ Cl Br OCH₃ CH₃ 1421 CH₃ Cl Br OCH₃ OCH₃ 1422 CH₃ Cl Br OCH₃ Cl 1423 CH₃ Cl Br OCH₃ F 1424 CH₃ Cl Br Cl H 1425 CH₃ Cl Br Cl CH₃ 1426 CH₃ Cl Br Cl OCH₃ 1427 CH₃ Cl Br Cl Cl 1428 CH₃ Cl Br Cl F 1429 CH₃ Cl Br Br H 1430 CH₃ Cl Br Br CH₃ 1431 CH₃ Cl Br Br OCH₃ 1432 CH₃ Cl Br Br Cl 1433 CH₃ Cl Br Br Br 1434 CH₃ Cl Br Br F 1435 CH₃ Cl Br F H 1436 CH₃ Cl Br F CH₃ 1437 CH₃ Cl Br F OCH₃ 1438 CH₃ Cl Br F Cl 1439 CH₃ Cl Br F F 1440 CH₃ Cl F H H 1441 CH₃ Cl F H CH₃ 1442 CH₃ Cl F H OCH₃ 1443 CH₃ Cl F H Cl 1444 CH₃ Cl F H Br 1445 CH₃ Cl F H F 1446 CH₃ Cl F CH₃ H 1447 CH₃ Cl F CH₃ CH₃ 1448 CH₃ Cl F CH₃ OCH₃ 1449 CH₃ Cl F CH₃ Cl 1450 CH₃ Cl F CH₃ Br 1451 CH₃ Cl F OCH₃ H 1452 CH₃ Cl F OCH₃ CH₃ 1453 CH₃ Cl F OCH₃ OCH₃ 1454 CH₃ Cl F OCH₃ Cl 1455 CH₃ Cl F OCH₃ Br 1456 CH₃ Cl F Cl H 1457 CH₃ Cl F Cl CH₃ 1458 CH₃ Cl F Cl OCH₃ 1459 CH₃ Cl F Cl Cl 1460 CH₃ Cl F Cl Br 1461 CH₃ Cl F Br H 1462 CH₃ Cl F Br CH₃ 1463 CH₃ Cl F Br OCH₃ 1464 CH₃ Cl F Br Cl 1465 CH₃ Cl F Br Br 1466 CH₃ Cl F F H 1467 CH₃ Cl F F CH₃ 1468 CH₃ Cl F F OCH₃ 1469 cH₃ Cl F F Cl 1470 CH₃ Cl F F Br 1471 CH₃ Cl F F F 1472 CH₃ Br CH₃ H H 1473 CH₃ Br CH₃ H CH₃ 1474 CH₃ Br CH₃ H OCH₃ 1475 CH₃ Br CH₃ H Cl 1476 CH₃ Br CH₃ H Br 1477 CH₃ Br CH₃ H F 1478 CH₃ Br CH₃ CH₃ H 1479 CH₃ Br CH₃ CH₃ CH₃ 1480 CH₃ Br CH₃ CH₃ OCH₃ 1481 CH₃ Br CH₃ CH₃ Cl 1482 CH₃ Br CH₃ CH₃ Br 1483 CH₃ Br CH₃ CH₃ F 1484 CH₃ Br CH₃ OCH₃ H 1485 CH₃ Br CH₃ OCH₃ OCH₃ 1486 CH₃ Br CH₃ OCH₃ Cl 1487 CH₃ Br CH₃ OCH₃ Br 1488 CH₃ Br CH₃ OCH₃ F 1489 CH₃ Br CH₃ Cl H 1490 CH₃ Br CH₃ Cl OCH₃ 1491 CH₃ Br CH₃ Cl Cl 1492 CH₃ Br CH₃ Cl Br 1493 CH₃ Br CH₃ Cl F 1494 CH₃ Br CH₃ Br H 1495 CH₃ Br CH₃ Br OCH₃ 1496 CH₃ Br CH₃ Br Cl 1497 CH₃ Br CH₃ Br Br 1498 CH₃ Br CH₃ Br F 1499 CH₃ Br CH₃ F H 1500 CH₃ Br CH₃ F OCH₃ 1501 CH₃ Br CH₃ F Cl 1502 CH₃ Br CH₃ F Br 1503 CH₃ Br CH₃ F F 1504 CH₃ Br OCH₃ H H 1505 CH₃ Br OCH₃ H CH₃ 1506 CH₃ Br OCH₃ H OCH₃ 1507 CH₃ Br OCH₃ H Cl 1508 CH₃ Br OCH₃ H Br 1509 CH₃ Br OCH₃ H F 1510 CH₃ Br OCH₃ CH₃ H 1511 CH₃ Br OCH₃ CH₃ CH₃ 1512 CH₃ Br OCH₃ CH₃ Cl 1513 CH₃ Br OCH₃ CH₃ Br 1514 CH₃ Br OCH₃ CH₃ F 1515 CH₃ Br OCH₃ OCH₃ H 1516 CH₃ Br OCH₃ OCH₃ CH₃ 1517 CH₃ Br OCH₃ OCH₃ OCH₃ 1518 CH₃ Br OCH₃ OCH₃ Cl 1519 CH₃ Br OCH₃ OCH₃ Br 1520 CH₃ Br OCH₃ OCH₃ F 1521 CH₃ Br OCH₃ Cl H 1522 CH₃ Br OCH₃ Cl CH₃ 1523 CH₃ Br OCH₃ Cl Cl 1524 CH₃ Br OCH₃ Cl Br 1525 CH₃ Br OCH₃ Cl F 1526 CH₃ Br OCH₃ Br H 1527 CH₃ Br OCH₃ Br CH₃ 1528 CH₃ Br OCH₃ Br Cl 1529 CH₃ Br OCH₃ Br Br 1530 CH₃ Br OCH₃ Br F 1531 CH₃ Br OCH₃ F H 1532 CH₃ Br OCH₃ F CH₃ 1533 CH₃ Br OCH₃ F Cl 1534 CH₃ Br OCH₃ F Br 1535 CH₃ Br OCH₃ F F 1536 CH₃ Br Cl H H 1537 CH₃ Br Cl H CH₃ 1538 CH₃ Br Cl H OCH₃ 1539 CH₃ Br Cl H Cl 1540 CH₃ Br Cl H Br 1541 CH₃ Br Cl H F 1542 CH₃ Br Cl CH₃ H 1543 CH₃ Br Cl CH₃ CH₃ 1544 CH₃ Br Cl CH₃ OCH₃ 1545 CH₃ Br Cl CH₃ Br 1546 CH₃ Br Cl CH₃ F 1547 CH₃ Br Cl OCH₃ H 1548 CH₃ Br Cl OCH₃ CH₃ 1549 CH₃ Br Cl OCH₃ OCH₃ 1550 CH₃ Br Cl OCH₃ Br 1551 CH₃ Br Cl OCH₃ F 1552 CH₃ Br Cl Cl H 1553 CH₃ Br Cl Cl CH₃ 1554 CH₃ Br Cl Cl OCH₃ 1555 CH₃ Br Cl Cl Cl 1556 CH₃ Br Cl Cl Br 1557 CH₃ Br Cl Cl F 1558 CH₃ Br Cl Br H 1559 CH₃ Br Cl Br CH₃ 1560 CH₃ Br Cl Br OCH₃ 1561 CH₃ Br Cl Br Br 1562 CH₃ Br Cl F H 1563 CH₃ Br Cl F CH₃ 1564 CH₃ Br Cl F OCH₃ 1565 CH₃ Br Cl F Br 1566 CH₃ Br Cl F F 1567 CH₃ Br Br H H 1568 CH₃ Br Br H CH₃ 1569 CH₃ Br Br H OCH₃ 1570 CH₃ Br Br H Cl 1571 CH₃ Br Br H Br 1572 CH₃ Br Br H F 1573 CH₃ Br Br CH₃ H 1574 CH₃ Br Br CH₃ CH₃ 1575 CH₃ Br Br CH₃ OCH₃ 1576 CH₃ Br Br CH₃ Cl 1577 CH₃ Br Br CH₃ F 1578 CH₃ Br Br OCH₃ H 1579 CH₃ Br Br OCH₃ CH₃ 1580 CH₃ Br Br OCH₃ OCH₃ 1581 CH₃ Br Br OCH₃ Cl 1582 CH₃ Br Br OCH₃ F 1583 CH₃ Br Br Cl H 1584 CH₃ Br Br Cl CH₃ 1585 CH₃ Br Br Cl OCH₃ 1586 CH₃ Br Br Cl Cl 1587 CH₃ Br Br Cl F 1588 CH₃ Br Br Br H 1589 CH₃ Br Br Br CH₃ 1590 CH₃ Br Br Br OCH₃ 1591 CH₃ Br Br Br Cl 1592 CH₃ Br Br Br Br 1593 CH₃ Br Br Br F 1594 CH₃ Br Br F H 1595 CH₃ Br Br F CH₃ 1596 CH₃ Br Br F OCH₃ 1597 CH₃ Br Br F Cl 1598 CH₃ Br Br F F 1599 CH₃ Br F H H 1600 CH₃ Br F H CH₃ 1601 CH₃ Br F H OCH₃ 1602 CH₃ Br F H Cl 1603 CH₃ Br F H Br 1604 CH₃ Br F H F 1605 CH₃ Br F CH₃ H 1606 CH₃ Br F CH₃ CH₃ 1607 CH₃ Br F CH₃ OCH₃ 1608 CH₃ Br F CH₃ Cl 1609 CH₃ Br F CH₃ Br 1610 CH₃ Br F OCH₃ H 1611 CH₃ Br F OCH₃ CH₃ 1612 CH₃ Br F OCH₃ OCH₃ 1613 CH₃ Br F OCH₃ Cl 1614 CH₃ Br F OCH₃ Br 1615 CH₃ Br F Cl H 1616 CH₃ Br F Cl CH₃ 1617 CH₃ Br F Cl OCH₃ 1618 CH₃ Br F Cl Cl 1619 CH₃ Br F Cl Br 1620 CH₃ Br F Br H 1621 CH₃ Br F Br CH₃ 1622 CH₃ Br F Br OCH₃ 1623 CH₃ Br F Br Cl 1624 CH₃ Br F Br Br 1625 CH₃ Br F F H 1626 CH₃ Br F F CH₃ 1627 CH₃ Br F F OCH₃ 1628 CH₃ Br F F Cl 1629 CH₃ Br F F Br 1630 CH₃ Br F F F 1631 CH₃ F CH₃ H H 1632 CH₃ F CH₃ H CH₃ 1633 CH₃ F CH₃ H OCH₃ 1634 CH₃ F CH₃ H Cl 1635 CH₃ F CH₃ H Br 1636 CH₃ F CH₃ H F 1637 CH₃ F CH₃ CH₃ H 1638 CH₃ F CH₃ CH₃ CH₃ 1639 CH₃ F CH₃ CH₃ OCH₃ 1640 CH₃ F CH₃ CH₃ Cl 1641 CH₃ F CH₃ CH₃ Br 1642 CH₃ F CH₃ CH₃ F 1643 CH₃ F CH₃ OCH₃ H 1644 CH₃ F CH₃ OCH₃ OCH₃ 1645 CH₃ F CH₃ OCH₃ Cl 1646 CH₃ F CH₃ OCH₃ Br 1647 CH₃ F CH₃ OCH₃ F 1648 CH₃ F CH₃ Cl H 1649 CH₃ F CH₃ Cl OCH₃ 1650 CH₃ F CH₃ Cl Cl 1651 CH₃ F CH₃ Cl Br 1652 CH₃ F CH₃ Cl F 1653 CH₃ F CH₃ Br H 1654 CH₃ F CH₃ Br OCH₃ 1655 CH₃ F CH₃ Br Cl 1656 CH₃ F CH₃ Br Br 1657 CH₃ F CH₃ Br F 1658 CH₃ F CH₃ F H 1659 CH₃ F CH₃ F OCH₃ 1660 CH₃ F CH₃ F Cl 1661 CH₃ F CH₃ F Br 1662 CH₃ F CH₃ F F 1663 CH₃ F OCH₃ H H 1664 CH₃ F OCH₃ H CH₃ 1665 CH₃ F OCH₃ H OCH₃ 1666 CH₃ F OCH₃ H Cl 1667 CH₃ F OCH₃ H Br 1668 CH₃ F OCH₃ H F 1669 CH₃ F OCH₃ CH₃ H 1670 CH₃ F OCH₃ CH₃ CH₃ 1671 CH₃ F OCH₃ CH₃ Cl 1672 CH₃ F OCH₃ CH₃ Br 1673 CH₃ F OCH₃ CH₃ F 1674 CH₃ F OCH₃ OCH₃ H 1675 CH₃ F OCH₃ OCH₃ CH₃ 1676 CH₃ F OCH₃ OCH₃ OCH₃ 1677 CH₃ F OCH₃ OCH₃ Cl 1678 CH₃ F OCH₃ OCH₃ Br 1679 CH₃ F OCH₃ OCH₃ F 1680 CH₃ F OCH₃ Cl H 1681 CH₃ F OCH₃ Cl CH₃ 1682 CH₃ F OCH₃ Cl Cl 1683 CH₃ F OCH₃ Cl Br 1684 CH₃ F OCH₃ Cl F 1685 CH₃ F OCH₃ Br H 1686 CH₃ F OCH₃ Br CH₃ 1687 CH₃ F OCH₃ Br Cl 1688 CH₃ F OCH₃ Br Br 1689 CH₃ F OCH₃ Br F 1690 CH₃ F OCH₃ F H 1691 CH₃ F OCH₃ F CH₃ 1692 CH₃ F OCH₃ F Cl 1693 CH₃ F OCH₃ F Br 1694 CH₃ F OCH₃ F F 1695 CH₃ F Cl H H 1696 CH₃ F Cl H CH₃ 1697 CH₃ F Cl H OCH₃ 1698 CH₃ F Cl H Cl 1699 CH₃ F Cl H Br 1700 CH₃ F Cl H F 1701 CH₃ F Cl CH₃ H 1702 CH₃ F Cl CH₃ CH₃ 1703 CH₃ F Cl CH₃ OCH₃ 1704 CH₃ F Cl CH₃ Br 1705 CH₃ F Cl CH₃ F 1706 CH₃ F Cl OCH₃ H 1707 CH₃ F Cl OCH₃ CH₃ 1708 CH₃ F Cl OCH₃ OCH₃ 1709 CH₃ F Cl OCH₃ Br 1710 CH₃ F Cl OCH₃ F 1711 CH₃ F Cl Cl H 1712 CH₃ F Cl Cl CH₃ 1713 CH₃ F Cl Cl OCH₃ 1714 CH₃ F Cl Cl Cl 1715 CH₃ F Cl Cl Br 1716 CH₃ F Cl Cl F 1717 CH₃ F Cl Br H 1718 CH₃ F Cl Br CH₃ 1719 CH₃ F Cl Br OCH₃ 1720 CH₃ F Cl Br Br 1721 CH₃ F Cl F H 1722 CH₃ F Cl F CH₃ 1723 CH₃ F Cl F OCH₃ 1724 CH₃ F Cl F Br 1725 CH₃ F Cl F F 1726 CH₃ F Br H H 1727 CH₃ F Br H CH₃ 1728 CH₃ F Br H OCH₃ 1729 CH₃ F Br H Cl 1730 CH₃ F Br H Br 1731 CH₃ F Br H F 1732 CH₃ F Br CH₃ H 1733 CH₃ F Br CH₃ CH₃ 1734 CH₃ F Br CH₃ OCH₃ 1735 CH₃ F Br CH₃ Cl 1736 CH₃ F Br CH₃ F 1737 CH₃ F Br OCH₃ H 1738 CH₃ F Br OCH₃ CH₃ 1739 CH₃ F Br OCH₃ OCH₃ 1740 CH₃ F Br OCH₃ Cl 1741 CH₃ F Br OCH₃ F 1742 CH₃ F Br Cl H 1743 CH₃ F Br Cl CH₃ 1744 CH₃ F Br Cl OCH₃ 1745 CH₃ F Br Cl Cl 1746 CH₃ F Br Cl F 1747 CH₃ F Br Br H 1748 CH₃ F Br Br CH₃ 1749 CH₃ F Br Br OCH₃ 1750 CH₃ F Br Br Cl 1751 CH₃ F Br Br Br 1752 CH₃ F Br Br F 1753 CH₃ F Br F H 1754 CH₃ F Br F CH₃ 1755 CH₃ F Br F OCH₃ 1756 CH₃ F Br F Cl 1757 CH₃ F Br F F 1758 CH₃ F F H H 1759 CH₃ F F H CH₃ 1760 CH₃ F F H OCH₃ 1761 CH₃ F F H Cl 1762 CH₃ F F H Br 1763 CH₃ F F H F 1764 CH₃ F F CH₃ H 1765 CH₃ F F CH₃ CH₃ 1766 CH₃ F F CH₃ OCH₃ 1767 CH₃ F F CH₃ Cl 1768 CH₃ F F CH₃ Br 1769 CH₃ F F OCH₃ H 1770 CH₃ F F OCH₃ CH₃ 1771 CH₃ F F OCH₃ OCH₃ 1772 CH₃ F F OCH₃ Cl 1773 CH₃ F F OCH₃ Br 1774 CH₃ F F Cl H 1775 CH₃ F F Cl CH₃ 1776 CH₃ F F Cl OCH₃ 1777 CH₃ F F Cl Cl 1778 CH₃ F F Cl Br 1779 CH₃ F F Br H 1780 CH₃ F F Br CH₃ 1781 CH₃ F F Br OCH₃ 1782 CH₃ F F Br Cl 1783 CH₃ F F Br Br 1784 CH₃ F F F H 1785 CH₃ F F F CH₃ 1786 CH₃ F F F OCH₃ 1787 CH₃ F F F Cl 1788 CH₃ F F F Br 1789 CH₃ F F F F 1790 OCH₃ CH₃ CH₃ H H 1791 OCH₃ CH₃ CH₃ CH₃ H 1792 OCH₃ CH₃ CH₃ OCH₃ H 1793 OCH₃ CH₃ CH₃ Cl H 1794 OCH₃ CH₃ CH₃ Br H 1795 OCH₃ CH₃ CH₃ F H 1796 OCH₃ CH₃ CH₃ H CH₃ 1797 OCH₃ CH₃ CH₃ CH₃ CH₃ 1798 OCH₃ CH₃ CH₃ H OCH₃ 1799 OCH₃ CH₃ CH₃ CH₃ OCH₃ 1800 OCH₃ CH₃ CH₃ OCH₃ OCH₃ 1801 OCH₃ CH₃ CH₃ Cl OCH₃ 1802 OCH₃ CH₃ CH₃ Br OCH₃ 1803 OCH₃ CH₃ CH₃ F OCH₃ 1804 OCH₃ CH₃ CH₃ H Cl 1805 OCH₃ CH₃ CH₃ CH₃ Cl 1806 OCH₃ CH₃ CH₃ OCH₃ Cl 1807 OCH₃ CH₃ CH₃ Cl Cl 1808 OCH₃ CH₃ CH₃ Br Cl 1809 OCH₃ CH₃ CH₃ F Cl 1810 OCH₃ CH₃ CH₃ H Br 1811 OCH₃ CH₃ CH₃ CH₃ Br 1812 OCH₃ CH₃ CH₃ OCH₃ Br 1813 OCH₃ CH₃ CH₃ Cl Br 1814 OCH₃ CH₃ CH₃ Br Br 1815 OCH₃ CH₃ CH₃ F Br 1816 OCH₃ CH₃ CH₃ H F 1817 OCH₃ CH₃ CH₃ CH₃ F 1818 OCH₃ CH₃ CH₃ OCH₃ F 1819 OCH₃ CH₃ CH₃ Cl F 1820 OCH₃ CH₃ CH₃ Br F 1821 OCH₃ CH₃ CH₃ F F 1822 OCH₃ CH₃ OCH₃ H H 1823 OCH₃ CH₃ OCH₃ CH₃ H 1824 OCH₃ CH₃ OCH₃ OCH₃ H 1825 OCH₃ CH₃ OCH₃ Cl H 1826 OCH₃ CH₃ OCH₃ Br H 1827 OCH₃ CH₃ OCH₃ F H 1828 OCH₃ CH₃ OCH₃ H CH₃ 1829 OCH₃ CH₃ OCH₃ CH₃ CH₃ 1830 OCH₃ CH₃ OCH₃ OCH₃ CH₃ 1831 OCH₃ CH₃ OCH₃ Cl CH₃ 1832 OCH₃ CH₃ OCH₃ Br CH₃ 1833 OCH₃ CH₃ OCH₃ F CH₃ 1834 OCH₃ CH₃ OCH₃ H OCH₃ 1835 OCH₃ CH₃ OCH₃ OCH₃ OCH₃ 1836 OCH₃ CH₃ OCH₃ H Cl 1837 OCH₃ CH₃ OCH₃ CH₃ Cl 1838 OCH₃ CH₃ OCH₃ OCH₃ Cl 1839 OCH₃ CH₃ OCH₃ Cl Cl 1840 OCH₃ CH₃ OCH₃ Br Cl 1841 OCH₃ CH₃ OCH₃ F Cl 1842 OCH₃ CH₃ OCH₃ H Br 1843 OCH₃ CH₃ OCH₃ CH₃ Br 1844 OCH₃ CH₃ OCH₃ OCH₃ Br 1845 OCH₃ CH₃ OCH₃ Cl Br 1846 OCH₃ CH₃ OCH₃ Br Br 1847 OCH₃ CH₃ OCH₃ F Br 1848 OCH₃ CH₃ OCH₃ H F 1849 OCH₃ CH₃ OCH₃ CH₃ F 1850 OCH₃ CH₃ OCH₃ OCH₃ F 1851 OCH₃ CH₃ OCH₃ Cl F 1852 OCH₃ CH₃ OCH₃ Br F 1853 OCH₃ CH₃ OCH₃ F F 1854 OCH₃ CH₃ Cl H H 1855 OCH₃ CH₃ Cl CH₃ H 1856 OCH₃ CH₃ Cl OCH₃ H 1857 OCH₃ CH₃ Cl Cl H 1858 OCH₃ CH₃ Cl Br H 1859 OCH₃ CH₃ Cl F H 1860 OCH₃ CH₃ Cl H CH₃ 1861 OCH₃ CH₃ Cl CH₃ CH₃ 1862 OCH₃ CH₃ Cl OCH₃ CH₃ 1863 OCH₃ CH₃ Cl Cl CH₃ 1864 OCH₃ CH₃ Cl Br CH₃ 1865 OCH₃ CH₃ Cl F CH₃ 1866 OCH₃ CH₃ Cl H OCH₃ 1867 OCH₃ CH₃ Cl CH₃ OCH₃ 1868 OCH₃ CH₃ Cl OCH₃ OCH₃ 1869 OCH₃ CH₃ Cl Cl OCH₃ 1870 OCH₃ CH₃ Cl Br OCH₃ 1871 OCH₃ CH₃ Cl F OCH₃ 1872 OCH₃ CH₃ Cl H Cl 1873 OCH₃ CH₃ Cl Cl Cl 1874 OCH₃ CH₃ Cl H Br 1875 OCH₃ CH₃ Cl CH₃ Br 1876 OCH₃ CH₃ Cl OCH₃ Br 1877 OCH₃ CH₃ Cl Cl Br 1878 OCH₃ CH₃ Cl Br Br 1879 OCH₃ CH₃ Cl F Br 1880 OCH₃ CH₃ Cl H F 1881 OCH₃ CH₃ Cl CH₃ F 1882 OCH₃ CH₃ Cl OCH₃ F 1883 OCH₃ CH₃ Cl Cl F 1884 OCH₃ CH₃ Cl F F 1885 OCH₃ CH₃ Br H H 1886 OCH₃ CH₃ Br CH₃ H 1887 OCH₃ CH₃ Br OCH₃ H 1888 OCH₃ CH₃ Br Cl H 1889 OCH₃ CH₃ Br Br H 1890 OCH₃ CH₃ Br F H 1891 OCH₃ CH₃ Br H CH₃ 1892 OCH₃ CH₃ Br CH₃ CH₃ 1893 OCH₃ CH₃ Br OCH₃ CH₃ 1894 OCH₃ CH₃ Br Cl CH₃ 1895 OCH₃ CH₃ Br Br CH₃ 1896 OCH₃ CH₃ Br F CH₃ 1897 OCH₃ CH₃ Br H OCH₃ 1898 OCH₃ CH₃ Br CH₃ OCH₃ 1899 OCH₃ CH₃ Br OCH₃ OCH₃ 1900 OCH₃ CH₃ Br Cl OCH₃ 1901 OCH₃ CH₃ Br Br OCH₃ 1902 OCH₃ CH₃ Br F OCH₃ 1903 OCH₃ CH₃ Br H Cl 1904 OCH₃ CH₃ Br CH₃ Cl 1905 OCH₃ CH₃ Br OCH₃ Cl 1906 OCH₃ CH₃ Br Cl Cl 1907 OCH₃ CH₃ Br Br Cl 1908 OCH₃ CH₃ Br F Cl 1909 OCH₃ CH₃ Br H Br 1910 OCH₃ CH₃ Br Br Br 1911 OCH₃ CH₃ Br H F 1912 OCH₃ CH₃ Br CH₃ F 1913 OCH₃ CH₃ Br OCH₃ F 1914 OCH₃ CH₃ Br Cl F 1915 OCH₃ CH₃ Br Br F 1916 OCH₃ CH₃ Br F F 1917 OCH₃ CH₃ F H H 1918 OCH₃ CH₃ F CH₃ H 1919 OCH₃ CH₃ F OCH₃ H 1920 OCH₃ CH₃ F Cl H 1921 OCH₃ CH₃ F Br H 1922 OCH₃ CH₃ F F H 1923 OCH₃ CH₃ F H CH₃ 1924 OCH₃ CH₃ F CH₃ CH₃ 1925 OCH₃ CH₃ F OCH₃ CH₃ 1926 OCH₃ CH₃ F Cl CH₃ 1927 OCH₃ CH₃ F Br CH₃ 1928 OCH₃ CH₃ F F CH₃ 1929 OCH₃ CH₃ F H OCH₃ 1930 OCH₃ CH₃ F CH₃ OCH₃ 1931 OCH₃ CH₃ F OCH₃ OCH₃ 1932 OCH₃ CH₃ F Cl OCH₃ 1933 OCH₃ CH₃ F Br OCH₃ 1934 OCH₃ CH₃ F F OCH₃ 1935 OCH₃ CH₃ F H Cl 1936 OCH₃ CH₃ F CH₃ Cl 1937 OCH₃ CH₃ F OCH₃ Cl 1938 OCH₃ CH₃ F Cl Cl 1939 OCH₃ CH₃ F Br Cl 1940 OCH₃ CH₃ F F Cl 1941 OCH₃ CH₃ F H Br 1942 OCH₃ CH₃ F CH₃ Br 1943 OCH₃ CH₃ F OCH₃ Br 1944 OCH₃ CH₃ F Cl Br 1945 OCH₃ CH₃ F Br Br 1946 OCH₃ CH₃ F F Br 1947 OCH₃ CH₃ F H F 1948 OCH₃ CH₃ F F F 1949 OCH₃ OCH₃ CH₃ H H 1950 OCH₃ OCH₃ CH₃ H CH₃ 1951 OCH₃ OCH₃ CH₃ H OCH₃ 1952 OCH₃ OCH₃ CH₃ H Cl 1953 OCH₃ OCH₃ CH₃ H Br 1954 OCH₃ OCH₃ CH₃ H F 1955 OCH₃ OCH₃ CH₃ CH₃ H 1956 OCH₃ OCH₃ CH₃ CH₃ CH₃ 1957 OCH₃ OCH₃ CH₃ CH₃ OCH₃ 1958 OCH₃ OCH₃ CH₃ CH₃ Cl 1959 OCH₃ OCH₃ CH₃ CH₃ Br 1960 OCH₃ OCH₃ CH₃ CH₃ F 1961 OCH₃ OCH₃ CH₃ OCH₃ H 1962 OCH₃ OCH₃ CH₃ OCH₃ OCH₃ 1963 OCH₃ OCH₃ CH₃ OCH₃ Cl 1964 OCH₃ OCH₃ CH₃ OCH₃ Br 1965 OCH₃ OCH₃ CH₃ OCH₃ F 1966 OCH₃ OCH₃ CH₃ Cl H 1967 OCH₃ OCH₃ CH₃ Cl OCH₃ 1968 OCH₃ OCH₃ CH₃ Cl Cl 1969 OCH₃ OCH₃ CH₃ Cl Br 1970 OCH₃ OCH₃ CH₃ Cl F 1971 OCH₃ OCH₃ CH₃ Br H 1972 OCH₃ OCH₃ CH₃ Br OCH₃ 1973 OCH₃ OCH₃ CH₃ Br Cl 1974 OCH₃ OCH₃ CH₃ Br Br 1975 OCH₃ OCH₃ CH₃ Br F 1976 OCH₃ OCH₃ CH₃ F H 1977 OCH₃ OCH₃ CH₃ F OCH₃ 1978 OCH₃ OCH₃ CH₃ F Cl 1979 OCH₃ OCH₃ CH₃ F Br 1980 OCH₃ OCH₃ CH₃ F F 1981 OCH₃ OCH₃ OCH₃ H H 1982 OCH₃ OCH₃ OCH₃ H CH₃ 1983 OCH₃ OCH₃ OCH₃ H OCH₃ 1984 OCH₃ OCH₃ OCH₃ H Cl 1985 OCH₃ OCH₃ OCH₃ H Br 1986 OCH₃ OCH₃ OCH₃ H F 1987 OCH₃ OCH₃ OCH₃ CH₃ H 1988 OCH₃ OCH₃ OCH₃ CH₃ CH₃ 1989 OCH₃ OCH₃ OCH₃ CH₃ Cl 1990 OCH₃ OCH₃ OCH₃ CH₃ Br 1991 OCH₃ OCH₃ OCH₃ CH₃ F 1992 OCH₃ OCH₃ OCH₃ OCH₃ H 1993 OCH₃ OCH₃ OCH₃ OCH₃ CH₃ 1994 OCH₃ OCH₃ OCH₃ OCH₃ OCH₃ 1995 OCH₃ OCH₃ OCH₃ OCH₃ Cl 1996 OCH₃ OCH₃ OCH₃ OCH₃ Br 1997 OCH₃ OCH₃ OCH₃ OCH₃ F 1998 OCH₃ OCH₃ OCH₃ Cl H 1999 OCH₃ OCH₃ OCH₃ Cl CH₃ 2000 OCH₃ OCH₃ OCH₃ Cl Cl 2001 OCH₃ OCH₃ OCH₃ Cl Br 2002 OCH₃ OCH₃ OCH₃ Cl F 2003 OCH₃ OCH₃ OCH₃ Br H 2004 OCH₃ OCH₃ OCH₃ Br CH₃ 2005 OCH₃ OCH₃ OCH₃ Br Cl 2006 OCH₃ OCH₃ OCH₃ Br Br 2007 OCH₃ OCH₃ OCH₃ Br F 2008 OCH₃ OCH₃ OCH₃ F H 2009 OCH₃ OCH₃ OCH₃ F CH₃ 2010 OCH₃ OCH₃ OCH₃ F Cl 2011 OCH₃ OCH₃ OCH₃ F Br 2012 OCH₃ OCH₃ OCH₃ F F 2013 OCH₃ OCH₃ Cl H H 2014 OCH₃ OCH₃ Cl H CH₃ 2015 OCH₃ OCH₃ Cl H OCH₃ 2016 OCH₃ OCH₃ Cl H Cl 2017 OCH₃ OCH₃ Cl H Br 2018 OCH₃ OCH₃ Cl H F 2019 OCH₃ OCH₃ Cl CH₃ H 2020 OCH₃ OCH₃ Cl CH₃ CH₃ 2021 OCH₃ OCH₃ Cl CH₃ OCH₃ 2022 OCH₃ OCH₃ Cl CH₃ Br 2023 OCH₃ OCH₃ Cl CH₃ F 2024 OCH₃ OCH₃ Cl OCH₃ H 2025 OCH₃ OCH₃ Cl OCH₃ CH₃ 2026 OCH₃ OCH₃ Cl OCH₃ OCH₃ 2027 OCH₃ OCH₃ Cl OCH₃ Br 2028 OCH₃ OCH₃ Cl OCH₃ F 2029 OCH₃ OCH₃ Cl Cl H 2030 OCH₃ OCH₃ Cl Cl CH₃ 2031 OCH₃ OCH₃ Cl Cl OCH₃ 2032 OCH₃ OCH₃ Cl Cl Cl 2033 OCH₃ OCH₃ Cl Cl Br 2034 OCH₃ OCH₃ Cl Cl F 2035 OCH₃ OCH₃ Cl Br H 2036 OCH₃ OCH₃ Cl Br CH₃ 2037 OCH₃ OCH₃ Cl Br OCH₃ 2038 OCH₃ OCH₃ Cl Br Br 2039 OCH₃ OCH₃ Cl F H 2040 OCH₃ OCH₃ Cl F CH₃ 2041 OCH₃ OCH₃ Cl F OCH₃ 2042 OCH₃ OCH₃ Cl F Br 2043 OCH₃ OCH₃ Cl F F 2044 OCH₃ OCH₃ Br H H 2045 OCH₃ OCH₃ Br H CH₃ 2046 OCH₃ OCH₃ Br H OCH₃ 2047 OCH₃ OCH₃ Br H Cl 2048 OCH₃ OCH₃ Br H Br 2049 OCH₃ OCH₃ Br H F 2050 OCH₃ OCH₃ Br CH₃ H 2051 OCH₃ OCH₃ Br CH₃ CH₃ 2052 OCH₃ OCH₃ Br CH₃ OCH₃ 2053 OCH₃ OCH₃ Br CH₃ Cl 2054 OCH₃ OCH₃ Br CH₃ F 2055 OCH₃ OCH₃ Br OCH₃ H 2056 OCH₃ OCH₃ Br OCH₃ CH₃ 2057 OCH₃ OCH₃ Br OCH₃ OCH₃ 2058 OCH₃ OCH₃ Br OCH₃ Cl 2059 OCH₃ OCH₃ Br OCH₃ F 2060 OCH₃ OCH₃ Br Cl H 2061 OCH₃ OCH₃ Br Cl CH₃ 2062 OCH₃ OCH₃ Br Cl OCH₃ 2063 OCH₃ OCH₃ Br Cl Cl 2064 OCH₃ OCH₃ Br Cl F 2065 OCH₃ OCH₃ Br Br H 2066 OCH₃ OCH₃ Br Br CH₃ 2067 OCH₃ OCH₃ Br Br OCH₃ 2068 OCH₃ OCH₃ Br Br Cl 2069 OCH₃ OCH₃ Br Br Br 2070 OCH₃ OCH₃ Br Br F 2071 OCH₃ OCH₃ Br F H 2072 OCH₃ OCH₃ Br F CH₃ 2073 OCH₃ OCH₃ Br F OCH₃ 2074 OCH₃ OCH₃ Br F Cl 2075 OCH₃ OCH₃ Br F F 2076 OCH₃ OCH₃ F H H 2077 OCH₃ OCH₃ F H CH₃ 2078 OCH₃ OCH₃ F H OCH₃ 2079 OCH₃ OCH₃ F H Cl 2080 OCH₃ OCH₃ F H Br 2081 OCH₃ OCH₃ F H F 2082 OCH₃ OCH₃ F CH₃ H 2083 OCH₃ OCH₃ F CH₃ CH₃ 2084 OCH₃ OCH₃ F CH₃ OCH₃ 2085 OCH₃ OCH₃ F CH₃ Cl 2086 OCH₃ OCH₃ F CH₃ Br 2087 OCH₃ OCH₃ F OCH₃ H 2088 OCH₃ OCH₃ F OCH₃ CH₃ 2089 OCH₃ OCH₃ F OCH₃ OCH₃ 2090 OCH₃ OCH₃ F OCH₃ Cl 2091 OCH₃ OCH₃ F OCH₃ Br 2092 OCH₃ OCH₃ F Cl H 2093 OCH₃ OCH₃ F Cl CH₃ 2094 OCH₃ OCH₃ F Cl OCH₃ 2095 OCH₃ OCH₃ F Cl Cl 2096 OCH₃ OCH₃ F Cl Br 2097 OCH₃ OCH₃ F Br H 2098 OCH₃ OCH₃ F Br CH₃ 2099 OCH₃ OCH₃ F Br OCH₃ 2100 OCH₃ OCH₃ F Br Cl 2101 OCH₃ OCH₃ F Br Br 2102 OCH₃ OCH₃ F F H 2103 OCH₃ OCH₃ F F CH₃ 2104 OCH₃ OCH₃ F F OCH₃ 2105 OCH₃ OCH₃ F F Cl 2106 OCH₃ OCH₃ F F Br 2107 OCH₃ OCH₃ F F F 2108 OCH₃ Cl CH₃ H H 2109 OCH₃ Cl CH₃ H CH₃ 2110 OCH₃ Cl CH₃ H OCH₃ 2111 OCH₃ Cl CH₃ H Cl 2112 OCH₃ Cl CH₃ H Br 2113 OCH₃ Cl CH₃ H F 2114 OCH₃ Cl CH₃ CH₃ H 2115 OCH₃ Cl CH₃ CH₃ CH₃ 2116 OCH₃ Cl CH₃ CH₃ OCH₃ 2117 OCH₃ Cl CH₃ CH₃ Cl 2118 OCH₃ Cl CH₃ CH₃ Br 2119 OCH₃ Cl CH₃ CH₃ F 2120 OCH₃ Cl CH₃ OCH₃ H 2121 OCH₃ Cl CH₃ OCH₃ OCH₃ 2122 OCH₃ Cl CH₃ OCH₃ Cl 2123 OCH₃ Cl CH₃ OCH₃ Br 2124 OCH₃ Cl CH₃ OCH₃ F 2125 OCH₃ Cl CH₃ Cl H 2126 OCH₃ Cl CH₃ Cl OCH₃ 2127 OCH₃ Cl CH₃ Cl Cl 2128 OCH₃ Cl CH₃ Cl Br 2129 OCH₃ Cl CH₃ Cl F 2130 OCH₃ Cl CH₃ Br H 2131 OCH₃ Cl CH₃ Br OCH₃ 2132 OCH₃ Cl CH₃ Br Cl 2133 OCH₃ Cl CH₃ Br Br 2134 OCH₃ Cl CH₃ Br F 2135 OCH₃ Cl CH₃ F H 2136 OCH₃ Cl CH₃ F OCH₃ 2137 OCH₃ Cl CH₃ F Cl 2138 OCH₃ Cl CH₃ F Br 2139 OCH₃ Cl CH₃ F F 2140 OCH₃ Cl OCH₃ H H 2141 OCH₃ Cl OCH₃ H CH₃ 2142 OCH₃ Cl OCH₃ H OCH₃ 2143 OCH₃ Cl OCH₃ H Cl 2144 OCH₃ Cl OCH₃ H Br 2145 OCH₃ Cl OCH₃ H F 2146 OCH₃ Cl OCH₃ CH₃ H 2147 OCH₃ Cl OCH₃ CH₃ CH₃ 2148 OCH₃ Cl OCH₃ CH₃ Cl 2149 OCH₃ Cl OCH₃ CH₃ Br 2150 OCH₃ Cl OCH₃ CH₃ F 2151 OCH₃ Cl OCH₃ OCH₃ H 2152 OCH₃ Cl OCH₃ OCH₃ CH₃ 2153 OCH₃ Cl OCH₃ OCH₃ OCH₃ 2154 OCH₃ Cl OCH₃ OCH₃ Cl 2155 OCH₃ Cl OCH₃ OCH₃ Br 2156 OCH₃ Cl OCH₃ OCH₃ F 2157 OCH₃ Cl OCH₃ Cl H 2158 OCH₃ Cl OCH₃ Cl CH₃ 2159 OCH₃ Cl OCH₃ Cl Cl 2160 OCH₃ Cl OCH₃ Cl Br 2161 OCH₃ Cl OCH₃ Cl F 2162 OCH₃ Cl OCH₃ Br H 2163 OCH₃ Cl OCH₃ Br CH₃ 2164 OCH₃ Cl OCH₃ Br Cl 2165 OCH₃ Cl OCH₃ Br Br 2166 OCH₃ Cl OCH₃ Br F 2167 OCH₃ Cl OCH₃ F H 2168 OCH₃ Cl OCH₃ F CH₃ 2169 OCH₃ Cl OCH₃ F Cl 2170 OCH₃ Cl OCH₃ F Br 2171 OCH₃ Cl OCH₃ F F 2172 OCH₃ Cl Cl H H 2173 OCH₃ Cl Cl H CH₃ 2174 OCH₃ Cl Cl H OCH₃ 2175 OCH₃ Cl Cl H Cl 2176 OCH₃ Cl Cl H Br 2177 OCH₃ Cl Cl H F 2178 OCH₃ Cl Cl CH₃ H 2179 OCH₃ Cl Cl CH₃ CH₃ 2180 OCH₃ Cl Cl CH₃ OCH₃ 2181 OCH₃ Cl Cl CH₃ Br 2182 OCH₃ Cl Cl CH₃ F 2183 OCH₃ Cl Cl OCH₃ H 2184 OCH₃ Cl Cl OCH₃ CH₃ 2185 OCH₃ Cl Cl OCH₃ OCH₃ 2186 OCH₃ Cl Cl OCH₃ Br 2187 OCH₃ Cl Cl OCH₃ F 2188 OCH₃ Cl Cl Cl H 2189 OCH₃ Cl Cl Cl CH₃ 2190 OCH₃ Cl Cl Cl OCH₃ 2191 OCH₃ Cl Cl Cl Cl 2192 OCH₃ Cl Cl Cl Br 2193 OCH₃ Cl Cl Cl F 2194 OCH₃ Cl Cl Br H 2195 OCH₃ Cl Cl Br CH₃ 2196 OCH₃ Cl Cl Br OCH₃ 2197 OCH₃ Cl Cl Br Br 2198 OCH₃ Cl Cl F H 2199 OCH₃ Cl Cl F CH₃ 2200 OCH₃ Cl Cl F OCH₃ 2201 OCH₃ Cl Cl F Br 2202 OCH₃ Cl Cl F F 2203 OCH₃ Cl Br H H 2204 OCH₃ Cl Br H CH₃ 2205 OCH₃ Cl Br H OCH₃ 2206 OCH₃ Cl Br H Cl 2207 OCH₃ Cl Br H Br 2208 OCH₃ Cl Br H F 2209 OCH₃ Cl Br CH₃ H 2210 OCH₃ Cl Br CH₃ CH₃ 2211 OCH₃ Cl Br CH₃ OCH₃ 2212 OCH₃ Cl Br CH₃ Cl 2213 OCH₃ Cl Br CH₃ F 2214 OCH₃ Cl Br OCH₃ H 2215 OCH₃ Cl Br OCH₃ CH₃ 2216 OCH₃ Cl Br OCH₃ OCH₃ 2217 OCH₃ Cl Br OCH₃ Cl 2218 OCH₃ Cl Br OCH₃ F 2219 OCH₃ Cl Br Cl H 2220 OCH₃ Cl Br Cl CH₃ 2221 OCH₃ Cl Br Cl OCH₃ 2222 OCH₃ Cl Br Cl Cl 2223 OCH₃ Cl Br Cl F 2224 OCH₃ Cl Br Br H 2225 OCH₃ Cl Br Br CH₃ 2226 OCH₃ Cl Br Br OCH₃ 2227 OCH₃ Cl Br Br Cl 2228 OCH₃ Cl Br Br Br 2229 OCH₃ Cl Br Br F 2230 OCH₃ Cl Br F H 2231 OCH₃ Cl Br F CH₃ 2232 OCH₃ Cl Br F OCH₃ 2233 OCH₃ Cl Br F Cl 2234 OCH₃ Cl Br F F 2235 OCH₃ Cl F H H 2236 OCH₃ Cl F H CH₃ 2237 OCH₃ Cl F H OCH₃ 2238 OCH₃ Cl F H Cl 2239 OCH₃ Cl F H Br 2240 OCH₃ Cl F H F 2241 OCH₃ Cl F CH₃ H 2242 OCH₃ Cl F CH₃ CH₃ 2243 OCH₃ Cl F CH₃ OCH₃ 2244 OCH₃ Cl F CH₃ Cl 2245 OCH₃ Cl F CH₃ Br 2246 OCH₃ Cl F OCH₃ H 2247 OCH₃ Cl F OCH₃ CH₃ 2248 OCH₃ Cl F OCH₃ OCH₃ 2249 OCH₃ Cl F OCH₃ Cl 2250 OCH₃ Cl F OCH₃ Br 2251 OCH₃ Cl F Cl H 2252 OCH₃ Cl F Cl CH₃ 2253 OCH₃ Cl F Cl OCH₃ 2254 OCH₃ Cl F Cl Cl 2255 OCH₃ Cl F Cl Br 2256 OCH₃ Cl F Br H 2257 OCH₃ Cl F Br CH₃ 2258 OCH₃ Cl F Br OCH₃ 2259 OCH₃ Cl F Br Cl 2260 OCH₃ Cl F Br Br 2261 OCH₃ Cl F F H 2262 OCH₃ Cl F F CH₃ 2263 OCH₃ Cl F F OCH₃ 2264 OCH₃ Cl F F Cl 2265 OCH₃ Cl F F Br 2266 OCH₃ Cl F F F 2267 OCH₃ Br CH₃ H H 2268 OCH₃ Br CH₃ H CH₃ 2269 OCH₃ Br CH₃ H OCH₃ 2270 OCH₃ Br CH₃ H Cl 2271 OCH₃ Br CH₃ H Br 2272 OCH₃ Br CH₃ H F 2273 OCH₃ Br CH₃ CH₃ H 2274 OCH₃ Br CH₃ CH₃ CH₃ 2275 OCH₃ Br CH₃ CH₃ OCH₃ 2276 OCH₃ Br CH₃ CH₃ Cl 2277 OCH₃ Br CH₃ CH₃ Br 2278 OCH₃ Br CH₃ CH₃ F 2279 OCH₃ Br CH₃ OCH₃ H 2280 OCH₃ Br CH₃ OCH₃ OCH₃ 2281 OCH₃ Br CH₃ OCH₃ Cl 2282 OCH₃ Br CH₃ OCH₃ Br 2283 OCH₃ Br CH₃ OCH₃ F 2284 OCH₃ Br CH₃ Cl H 2285 OCH₃ Br CH₃ Cl OCH₃ 2286 OCH₃ Br CH₃ Cl Cl 2287 OCH₃ Br CH₃ Cl Br 2288 OCH₃ Br CH₃ Cl F 2289 OCH₃ Br CH₃ Br H 2290 OCH₃ Br CH₃ Br OCH₃ 2291 OCH₃ Br CH₃ Br Cl 2292 OCH₃ Br CH₃ Br Br 2293 OCH₃ Br CH₃ Br F 2294 OCH₃ Br CH₃ F H 2295 OCH₃ Br CH₃ F OCH₃ 2296 OCH₃ Br CH₃ F Cl 2297 OCH₃ Br CH₃ F Br 2298 OCH₃ Br CH₃ F F 2299 OCH₃ Br OCH₃ H H 2300 OCH₃ Br OCH₃ H CH₃ 2301 OCH₃ Br OCH₃ H OCH₃ 2302 OCH₃ Br OCH₃ H Cl 2303 OCH₃ Br OCH₃ H Br 2304 OCH₃ Br OCH₃ H F 2305 OCH₃ Br OCH₃ CH₃ H 2306 OCH₃ Br OCH₃ CH₃ CH₃ 2307 OCH₃ Br OCH₃ CH₃ Cl 2308 OCH₃ Br OCH₃ CH₃ Br 2309 OCH₃ Br OCH₃ CH₃ F 2310 OCH₃ Br OCH₃ OCH₃ H 2311 OCH₃ Br OCH₃ OCH₃ CH₃ 2312 OCH₃ Br OCH₃ OCH₃ OCH₃ 2313 OCH₃ Br OCH₃ OCH₃ Cl 2314 OCH₃ Br OCH₃ OCH₃ Br 2315 OCH₃ Br OCH₃ OCH₃ F 2316 OCH₃ Br OCH₃ Cl H 2317 OCH₃ Br OCH₃ Cl CH₃ 2318 OCH₃ Br OCH₃ Cl Cl 2319 OCH₃ Br OCH₃ Cl Br 2320 OCH₃ Br OCH₃ Cl F 2321 OCH₃ Br OCH₃ Br H 2322 OCH₃ Br OCH₃ Br CH₃ 2323 OCH₃ Br OCH₃ Br Cl 2324 OCH₃ Br OCH₃ Br Br 2325 OCH₃ Br OCH₃ Br F 2326 OCH₃ Br OCH₃ F H 2327 OCH₃ Br OCH₃ F CH₃ 2328 OCH₃ Br OCH₃ F Cl 2329 OCH₃ Br OCH₃ F Br 2330 OCH₃ Br OCH₃ F F 2331 OCH₃ Br Cl H H 2332 OCH₃ Br Cl H CH₃ 2333 OCH₃ Br Cl H OCH₃ 2334 OCH₃ Br Cl H Cl 2335 OCH₃ Br Cl H Br 2336 OCH₃ Br Cl H F 2337 OCH₃ Br Cl CH₃ H 2338 OCH₃ Br Cl CH₃ CH₃ 2339 OCH₃ Br Cl CH₃ OCH₃ 2340 OCH₃ Br Cl CH₃ Br 2341 OCH₃ Br Cl CH₃ F 2342 OCH₃ Br Cl OCH₃ H 2343 OCH₃ Br Cl OCH₃ CH₃ 2344 OCH₃ Br Cl OCH₃ OCH₃ 2345 OCH₃ Br Cl OCH₃ Br 2346 OCH₃ Br Cl OCH₃ F 2347 OCH₃ Br Cl Cl H 2348 OCH₃ Br Cl Cl CH₃ 2349 OCH₃ Br Cl Cl OCH₃ 2350 OCH₃ Br Cl Cl Cl 2351 OCH₃ Br Cl Cl Br 2352 OCH₃ Br Cl Cl F 2353 OCH₃ Br Cl Br H 2354 OCH₃ Br Cl Br CH₃ 2355 OCH₃ Br Cl Br OCH₃ 2356 OCH₃ Br Cl Br Br 2357 OCH₃ Br Cl F H 2358 OCH₃ Br Cl F CH₃ 2359 OCH₃ Br Cl F OCH₃ 2360 OCH₃ Br Cl F Br 2361 OCH₃ Br Cl F F 2362 OCH₃ Br Br H H 2363 OCH₃ Br Br H CH₃ 2364 OCH₃ Br Br H OCH₃ 2365 OCH₃ Br Br H Cl 2366 OCH₃ Br Br H Br 2367 OCH₃ Br Br H F 2368 OCH₃ Br Br CH₃ H 2369 OCH₃ Br Br CH₃ CH₃ 2370 OCH₃ Br Br CH₃ OCH₃ 2371 OCH₃ Br Br CH₃ Cl 2372 OCH₃ Br Br CH₃ F 2373 OCH₃ Br Br OCH₃ H 2374 OCH₃ Br Br OCH₃ CH₃ 2375 OCH₃ Br Br OCH₃ OCH₃ 2376 OCH₃ Br Br OCH₃ Cl 2377 OCH₃ Br Br OCH₃ F 2378 OCH₃ Br Br Cl H 2379 OCH₃ Br Br Cl CH₃ 2380 OCH₃ Br Br Cl OCH₃ 2381 OCH₃ Br Br Cl Cl 2382 OCH₃ Br Br Cl F 2383 OCH₃ Br Br Br H 2384 OCH₃ Br Br Br CH₃ 2385 OCH₃ Br Br Br OCH₃ 2386 OCH₃ Br Br Br Cl 2387 OCH₃ Br Br Br Br 2388 OCH₃ Br Br Br F 2389 OCH₃ Br Br F H 2390 OCH₃ Br Br F CH₃ 2391 OCH₃ Br Br F OCH₃ 2392 OCH₃ Br Br F Cl 2393 OCH₃ Br Br F F 2394 OCH₃ Br F H H 2395 OCH₃ Br F H CH₃ 2396 OCH₃ Br F H OCH₃ 2397 OCH₃ Br F H Cl 2398 OCH₃ Br F H Br 2399 OCH₃ Br F H F 2400 OCH₃ Br F CH₃ H 2401 OCH₃ Br F CH₃ CH₃ 2402 OCH₃ Br F CH₃ OCH₃ 2403 OCH₃ Br F CH₃ Cl 2404 OCH₃ Br F CH₃ Br 2405 OCH₃ Br F OCH₃ H 2406 OCH₃ Br F OCH₃ CH₃ 2407 OCH₃ Br F OCH₃ OCH₃ 2408 OCH₃ Br F OCH₃ Cl 2409 OCH₃ Br F OCH₃ Br 2410 OCH₃ Br F Cl H 2411 OCH₃ Br F Cl CH₃ 2412 OCH₃ Br F Cl OCH₃ 2413 OCH₃ Br F Cl Cl 2414 OCH₃ Br F Cl Br 2415 OCH₃ Br F Br H 2416 OCH₃ Br F Br CH₃ 2417 OCH₃ Br F Br OCH₃ 2418 OCH₃ Br F Br Cl 2419 OCH₃ Br F Br Br 2420 OCH₃ Br F F H 2421 OCH₃ Br F F CH₃ 2422 OCH₃ Br F F OCH₃ 2423 OCH₃ Br F F Cl 2424 OCH₃ Br F F Br 2425 OCH₃ Br F F F 2426 OCH₃ F CH₃ H H 2427 OCH₃ F CH₃ H CH₃ 2428 OCH₃ F CH₃ H OCH₃ 2429 OCH₃ F CH₃ H Cl 2430 OCH₃ F CH₃ H Br 2431 OCH₃ F CH₃ H F 2432 OCH₃ F CH₃ CH₃ H 2433 OCH₃ F CH₃ CH₃ CH₃ 2434 OCH₃ F CH₃ CH₃ OCH₃ 2435 OCH₃ F CH₃ CH₃ Cl 2436 OCH₃ F CH₃ CH₃ Br 2437 OCH₃ F CH₃ CH₃ F 2438 OCH₃ F CH₃ OCH₃ H 2439 OCH₃ F CH₃ OCH₃ OCH₃ 2440 OCH₃ F CH₃ OCH₃ Cl 2441 OCH₃ F CH₃ OCH₃ Br 2442 OCH₃ F CH₃ OCH₃ F 2443 OCH₃ F CH₃ Cl H 2444 OCH₃ F CH₃ Cl OCH₃ 2445 OCH₃ F CH₃ Cl Cl 2446 OCH₃ F CH₃ Cl Br 2447 OCH₃ F CH₃ Cl F 2448 OCH₃ F CH₃ Br H 2449 OCH₃ F CH₃ Br OCH₃ 2450 OCH₃ F CH₃ Br Cl 2451 OCH₃ F CH₃ Br Br 2452 OCH₃ F CH₃ Br F 2453 OCH₃ F CH₃ F H 2454 OCH₃ F CH₃ F OCH₃ 2455 OCH₃ F CH₃ F Cl 2456 OCH₃ F CH₃ F Br 2457 OCH₃ F CH₃ F F 2458 OCH₃ F OCH₃ H H 2459 OCH₃ F OCH₃ H CH₃ 2460 OCH₃ F OCH₃ H OCH₃ 2461 OCH₃ F OCH₃ H Cl 2462 OCH₃ F OCH₃ H Br 2463 OCH₃ F OCH₃ H F 2464 OCH₃ F OCH₃ CH₃ H 2465 OCH₃ F OCH₃ CH₃ CH₃ 2466 OCH₃ F OCH₃ CH₃ Cl 2467 OCH₃ F OCH₃ CH₃ Br 2468 OCH₃ F OCH₃ CH₃ F 2469 OCH₃ F OCH₃ OCH₃ H 2470 OCH₃ F OCH₃ OCH₃ CH₃ 2471 OCH₃ F OCH₃ OCH₃ OCH₃ 2472 OCH₃ F OCH₃ OCH₃ Cl 2473 OCH₃ F OCH₃ OCH₃ Br 2474 OCH₃ F OCH₃ OCH₃ F 2475 OCH₃ F OCH₃ Cl H 2476 OCH₃ F OCH₃ Cl CH₃ 2477 OCH₃ F OCH₃ Cl Cl 2478 OCH₃ F OCH₃ Cl Br 2479 OCH₃ F OCH₃ Cl F 2480 OCH₃ F OCH₃ Br H 2481 OCH₃ F OCH₃ Br CH₃ 2482 OCH₃ F OCH₃ Br Cl 2483 OCH₃ F OCH₃ Br Br 2484 OCH₃ F OCH₃ Br F 2485 OCH₃ F OCH₃ F H 2486 OCH₃ F OCH₃ F CH₃ 2487 OCH₃ F OCH₃ F Cl 2488 OCH₃ F OCH₃ F Br 2489 OCH₃ F OCH₃ F F 2490 OCH₃ F Cl H H 2491 OCH₃ F Cl H CH₃ 2492 OCH₃ F Cl H OCH₃ 2493 OCH₃ F Cl H Cl 2494 OCH₃ F Cl H Br 2495 OCH₃ F Cl H F 2496 OCH₃ F Cl CH₃ H 2497 OCH₃ F Cl CH₃ CH₃ 2498 OCH₃ F Cl CH₃ OCH₃ 2499 OCH₃ F Cl CH₃ Br 2500 OCH₃ F Cl CH₃ F 2501 OCH₃ F Cl OCH₃ H 2502 OCH₃ F Cl OCH₃ CH₃ 2503 OCH₃ F Cl OCH₃ OCH₃ 2504 OCH₃ F Cl OCH₃ Br 2505 OCH₃ F Cl OCH₃ F 2506 OCH₃ F Cl Cl H 2507 OCH₃ F Cl Cl CH₃ 2508 OCH₃ F Cl Cl OCH₃ 2509 OCH₃ F Cl Cl Cl 2510 OCH₃ F Cl Cl Br 2511 OCH₃ F Cl Cl F 2512 OCH₃ F Cl Br H 2513 OCH₃ F Cl Br CH₃ 2514 OCH₃ F Cl Br OCH₃ 2515 OCH₃ F Cl Br Br 2516 OCH₃ F Cl F H 2517 OCH₃ F Cl F CH₃ 2518 OCH₃ F Cl F OCH₃ 2519 OCH₃ F Cl F Br 2520 OCH₃ F Cl F F 2521 OCH₃ F Br H H 2522 OCH₃ F Br H CH₃ 2523 OCH₃ F Br H OCH₃ 2524 OCH₃ F Br H Cl 2525 OCH₃ F Br H Br 2526 OCH₃ F Br H F 2527 OCH₃ F Br CH₃ H 2528 OCH₃ F Br CH₃ CH₃ 2529 OCH₃ F Br CH₃ OCH₃ 2530 OCH₃ F Br CH₃ Cl 2531 OCH₃ F Br CH₃ F 2532 OCH₃ F Br OCH₃ H 2533 OCH₃ F Br OCH₃ CH₃ 2534 OCH₃ F Br OCH₃ OCH₃ 2535 OCH₃ F Br OCH₃ Cl 2536 OCH₃ F Br OCH₃ F 2537 OCH₃ F Br Cl H 2538 OCH₃ F Br Cl CH₃ 2539 OCH₃ F Br Cl OCH₃ 2540 OCH₃ F Br Cl Cl 2541 OCH₃ F Br Cl F 2542 OCH₃ F Br Br H 2543 OCH₃ F Br Br CH₃ 2544 OCH₃ F Br Br OCH₃ 2545 OCH₃ F Br Br Cl 2546 OCH₃ F Br Br Br 2547 OCH₃ F Br Br F 2548 OCH₃ F Br F H 2549 OCH₃ F Br F CH₃ 2550 OCH₃ F Br F OCH₃ 2551 OCH₃ F Br F Cl 2552 OCH₃ F Br F F 2553 OCH₃ F F H H 2554 OCH₃ F F H CH₃ 2555 OCH₃ F F H OCH₃ 2556 OCH₃ F F H Cl 2557 OCH₃ F F H Br 2558 OCH₃ F F H F 2559 OCH₃ F F CH₃ H 2560 OCH₃ F F CH₃ CH₃ 2561 OCH₃ F F CH₃ OCH₃ 2562 OCH₃ F F CH₃ Cl 2563 OCH₃ F F CH₃ Br 2564 OCH₃ F F OCH₃ H 2565 OCH₃ F F OCH₃ CH₃ 2566 OCH₃ F F OCH₃ OCH₃ 2567 OCH₃ F F OCH₃ Cl 2568 OCH₃ F F OCH₃ Br 2569 OCH₃ F F Cl H 2570 OCH₃ F F Cl CH₃ 2571 OCH₃ F F Cl OCH₃ 2572 OCH₃ F F Cl Cl 2573 OCH₃ F F Cl Br 2574 OCH₃ F F Br H 2575 OCH₃ F F Br CH₃ 2576 OCH₃ F F Br OCH₃ 2577 OCH₃ F F Br Cl 2578 OCH₃ F F Br Br 2579 OCH₃ F F F H 2580 OCH₃ F F F CH₃ 2581 OCH₃ F F F OCH₃ 2582 OCH₃ F F F Cl 2583 OCH₃ F F F Br 2584 OCH₃ F F F F 2585 Cl CH₃ CH₃ H H 2586 Cl CH₃ CH₃ CH₃ H 2587 Cl CH₃ CH₃ OCH₃ H 2588 Cl CH₃ CH₃ Cl H 2589 Cl CH₃ CH₃ Br H 2590 Cl CH₃ CH₃ F H 2591 Cl CH₃ CH₃ H CH₃ 2592 Cl CH₃ CH₃ CH₃ CH₃ 2593 Cl CH₃ CH₃ H OCH₃ 2594 Cl CH₃ CH₃ CH₃ OCH₃ 2595 Cl CH₃ CH₃ OCH₃ OCH₃ 2596 Cl CH₃ CH₃ Cl OCH₃ 2597 Cl CH₃ CH₃ Br OCH₃ 2598 Cl CH₃ CH₃ F OCH₃ 2599 Cl CH₃ CH₃ H Cl 2600 Cl CH₃ CH₃ CH₃ Cl 2601 Cl CH₃ CH₃ OCH₃ Cl 2602 Cl CH₃ CH₃ Cl Cl 2603 Cl CH₃ CH₃ Br Cl 2604 Cl CH₃ CH₃ F Cl 2605 Cl CH₃ CH₃ H Br 2606 Cl CH₃ CH₃ CH₃ Br 2607 Cl CH₃ CH₃ OCH₃ Br 2608 Cl CH₃ CH₃ Cl Br 2609 Cl CH₃ CH₃ Br Br 2610 Cl CH₃ CH₃ F Br 2611 Cl CH₃ CH₃ H F 2612 Cl CH₃ CH₃ CH₃ F 2613 Cl CH₃ CH₃ OCH₃ F 2614 Cl CH₃ CH₃ Cl F 2615 Cl CH₃ CH₃ Br F 2616 Cl CH₃ CH₃ F F 2617 Cl CH₃ OCH₃ H H 2618 Cl CH₃ OCH₃ CH₃ H 2619 Cl CH₃ OCH₃ OCH₃ H 2620 Cl CH₃ OCH₃ Cl H 2621 Cl CH₃ OCH₃ Br H 2622 Cl CH₃ OCH₃ F H 2623 Cl CH₃ OCH₃ H CH₃ 2624 Cl CH₃ OCH₃ CH₃ CH₃ 2625 Cl CH₃ OCH₃ OCH₃ CH₃ 2626 Cl CH₃ OCH₃ Cl CH₃ 2627 Cl CH₃ OCH₃ Br CH₃ 2628 Cl CH₃ OCH₃ F CH₃ 2629 Cl CH₃ OCH₃ H OCH₃ 2630 Cl CH₃ OCH₃ OCH₃ OCH₃ 2631 Cl CH₃ OCH₃ H Cl 2632 Cl CH₃ OCH₃ CH₃ Cl 2633 Cl CH₃ OCH₃ OCH₃ Cl 2634 Cl CH₃ OCH₃ Cl Cl 2635 Cl CH₃ OCH₃ Br Cl 2636 Cl CH₃ OCH₃ F Cl 2637 Cl CH₃ OCH₃ H Br 2638 Cl CH₃ OCH₃ CH₃ Br 2639 Cl CH₃ OCH₃ OCH₃ Br 2640 Cl CH₃ OCH₃ Cl Br 2641 Cl CH₃ OCH₃ Br Br 2642 Cl CH₃ OCH₃ F Br 2643 Cl CH₃ OCH₃ H F 2644 Cl CH₃ OCH₃ CH₃ F 2645 Cl CH₃ OCH₃ OCH₃ F 2646 Cl CH₃ OCH₃ Cl F 2647 Cl CH₃ OCH₃ Br F 2648 Cl CH₃ OCH₃ F F 2649 Cl CH₃ Cl H H 2650 Cl CH₃ Cl CH₃ H 2651 Cl CH₃ Cl OCH₃ H 2652 Cl CH₃ Cl Cl H 2653 Cl CH₃ Cl Br H 2654 Cl CH₃ Cl F H 2655 Cl CH₃ Cl H CH₃ 2656 Cl CH₃ Cl CH₃ CH₃ 2657 Cl CH₃ Cl OCH₃ CH₃ 2658 Cl CH₃ Cl Cl CH₃ 2659 Cl CH₃ Cl Br CH₃ 2660 Cl CH₃ Cl F CH₃ 2661 Cl CH₃ Cl H OCH₃ 2662 Cl CH₃ Cl CH₃ OCH₃ 2663 Cl CH₃ Cl OCH₃ OCH₃ 2664 Cl CH₃ Cl Cl OCH₃ 2665 Cl CH₃ Cl Br OCH₃ 2666 Cl CH₃ Cl F OCH₃ 2667 Cl CH₃ Cl H Cl 2668 Cl CH₃ Cl Cl Cl 2669 Cl CH₃ Cl H Br 2670 Cl CH₃ Cl CH₃ Br 2671 Cl CH₃ Cl OCH₃ Br 2672 Cl CH₃ Cl Cl Br 2673 Cl CH₃ Cl Br Br 2674 Cl CH₃ Cl F Br 2675 Cl CH₃ Cl H F 2676 Cl CH₃ Cl CH₃ F 2677 Cl CH₃ Cl OCH₃ F 2678 Cl CH₃ Cl Cl F 2679 Cl CH₃ Cl F F 2680 Cl CH₃ Br H H 2681 Cl CH₃ Br CH₃ H 2682 Cl CH₃ Br OCH₃ H 2683 Cl CH₃ Br Cl H 2684 Cl CH₃ Br Br H 2685 Cl CH₃ Br F H 2686 Cl CH₃ Br H CH₃ 2687 Cl CH₃ Br CH₃ CH₃ 2688 Cl CH₃ Br OCH₃ CH₃ 2689 Cl CH₃ Br Cl CH₃ 2690 Cl CH₃ Br Br CH₃ 2691 Cl CH₃ Br F CH₃ 2692 Cl CH₃ Br H OCH₃ 2693 Cl CH₃ Br CH₃ OCH₃ 2694 Cl CH₃ Br OCH₃ OCH₃ 2695 Cl CH₃ Br Cl OCH₃ 2696 Cl CH₃ Br Br OCH₃ 2697 Cl CH₃ Br F OCH₃ 2698 Cl CH₃ Br H Cl 2699 Cl CH₃ Br CH₃ Cl 2700 Cl CH₃ Br OCH₃ Cl 2701 Cl CH₃ Br Cl Cl 2702 Cl CH₃ Br Br Cl 2703 Cl CH₃ Br F Cl 2704 Cl CH₃ Br H Br 2705 Cl CH₃ Br Br Br 2706 Cl CH₃ Br H F 2707 Cl CH₃ Br CH₃ F 2708 Cl CH₃ Br OCH₃ F 2709 Cl CH₃ Br Cl F 2710 Cl CH₃ Br Br F 2711 Cl CH₃ Br F F 2712 Cl CH₃ F H H 2713 Cl CH₃ F CH₃ H 2714 Cl CH₃ F OCH₃ H 2715 Cl CH₃ F Cl H 2716 Cl CH₃ F Br H 2717 Cl CH₃ F F H 2718 Cl CH₃ F H CH₃ 2719 Cl CH₃ F CH₃ CH₃ 2720 Cl CH₃ F OCH₃ CH₃ 2721 Cl CH₃ F Cl CH₃ 2722 Cl CH₃ F Br CH₃ 2723 Cl CH₃ F F CH₃ 2724 Cl CH₃ F H OCH₃ 2725 Cl CH₃ F CH₃ OCH₃ 2726 Cl CH₃ F OCH₃ OCH₃ 2727 Cl CH₃ F Cl OCH₃ 2728 Cl CH₃ F Br OCH₃ 2729 Cl CH₃ F F OCH₃ 2730 Cl CH₃ F H Cl 2731 Cl CH₃ F CH₃ Cl 2732 Cl CH₃ F OCH₃ Cl 2733 Cl CH₃ F Cl Cl 2734 Cl CH₃ F Br Cl 2735 Cl CH₃ F F Cl 2736 Cl CH₃ F H Br 2737 Cl CH₃ F CH₃ Br 2738 Cl CH₃ F OCH₃ Br 2739 Cl CH₃ F Cl Br 2740 Cl CH₃ F Br Br 2741 Cl CH₃ F F Br 2742 Cl CH₃ F H F 2743 Cl CH₃ F F F 2744 Cl OCH₃ CH₃ H H 2745 Cl OCH₃ CH₃ H CH₃ 2746 Cl OCH₃ CH₃ H OCH₃ 2747 Cl OCH₃ CH₃ H Cl 2748 Cl OCH₃ CH₃ H Br 2749 Cl OCH₃ CH₃ H F 2750 Cl OCH₃ CH₃ CH₃ H 2751 Cl OCH₃ CH₃ CH₃ CH₃ 2752 Cl OCH₃ CH₃ CH₃ OCH₃ 2753 Cl OCH₃ CH₃ CH₃ Cl 2754 Cl OCH₃ CH₃ CH₃ Br 2755 Cl OCH₃ CH₃ CH₃ F 2756 Cl OCH₃ CH₃ OCH₃ H 2757 Cl OCH₃ CH₃ OCH₃ OCH₃ 2758 Cl OCH₃ CH₃ OCH₃ Cl 2759 Cl OCH₃ CH₃ OCH₃ Br 2760 Cl OCH₃ CH₃ OCH₃ F 2761 Cl OCH₃ CH₃ Cl H 2762 Cl OCH₃ CH₃ Cl OCH₃ 2763 Cl OCH₃ CH₃ Cl Cl 2764 Cl OCH₃ CH₃ Cl Br 2765 Cl OCH₃ CH₃ Cl F 2766 Cl OCH₃ CH₃ Br H 2767 Cl OCH₃ CH₃ Br OCH₃ 2768 Cl OCH₃ CH₃ Br Cl 2769 Cl OCH₃ CH₃ Br Br 2770 Cl OCH₃ CH₃ Br F 2771 Cl OCH₃ CH₃ F H 2772 Cl OCH₃ CH₃ F OCH₃ 2773 Cl OCH₃ CH₃ F Cl 2774 Cl OCH₃ CH₃ F Br 2775 Cl OCH₃ CH₃ F F 2776 Cl OCH₃ OCH₃ H H 2777 Cl OCH₃ OCH₃ H CH₃ 2778 Cl OCH₃ OCH₃ H OCH₃ 2779 Cl OCH₃ OCH₃ H Cl 2780 Cl OCH₃ OCH₃ H Br 2781 Cl OCH₃ OCH₃ H F 2782 Cl OCH₃ OCH₃ CH₃ H 2783 Cl OCH₃ OCH₃ CH₃ CH₃ 2784 Cl OCH₃ OCH₃ CH₃ Cl 2785 Cl OCH₃ OCH₃ CH₃ Br 2786 Cl OCH₃ OCH₃ CH₃ F 2787 Cl OCH₃ OCH₃ OCH₃ H 2788 Cl OCH₃ OCH₃ OCH₃ CH₃ 2789 Cl OCH₃ OCH₃ OCH₃ OCH₃ 2790 Cl OCH₃ OCH₃ OCH₃ Cl 2791 Cl OCH₃ OCH₃ OCH₃ Br 2792 Cl OCH₃ OCH₃ OCH₃ F 2793 Cl OCH₃ OCH₃ Cl H 2794 Cl OCH₃ OCH₃ Cl CH₃ 2795 Cl OCH₃ OCH₃ Cl Cl 2796 Cl OCH₃ OCH₃ Cl Br 2797 Cl OCH₃ OCH₃ Cl F 2798 Cl OCH₃ OCH₃ Br H 2799 Cl OCH₃ OCH₃ Br CH₃ 2800 Cl OCH₃ OCH₃ Br Cl 2801 Cl OCH₃ OCH₃ Br Br 2802 Cl OCH₃ OCH₃ Br F 2803 Cl OCH₃ OCH₃ F H 2804 Cl OCH₃ OCH₃ F CH₃ 2805 Cl OCH₃ OCH₃ F Cl 2806 Cl OCH₃ OCH₃ F Br 2807 Cl OCH₃ OCH₃ F F 2808 Cl OCH₃ Cl H H 2809 Cl OCH₃ Cl H CH₃ 2810 Cl OCH₃ Cl H OCH₃ 2811 Cl OCH₃ Cl H Cl 2812 Cl OCH₃ Cl H Br 2813 Cl OCH₃ Cl H F 2814 Cl OCH₃ Cl CH₃ H 2815 Cl OCH₃ Cl CH₃ CH₃ 2816 Cl OCH₃ Cl CH₃ OCH₃ 2817 Cl OCH₃ Cl CH₃ Br 2818 Cl OCH₃ Cl CH₃ F 2819 Cl OCH₃ Cl OCH₃ H 2820 Cl OCH₃ Cl OCH₃ CH₃ 2821 Cl OCH₃ Cl OCH₃ OCH₃ 2822 Cl OCH₃ Cl OCH₃ Br 2823 Cl OCH₃ Cl OCH₃ F 2824 Cl OCH₃ Cl Cl H 2825 Cl OCH₃ Cl Cl CH₃ 2826 Cl OCH₃ Cl Cl OCH₃ 2827 Cl OCH₃ Cl Cl Cl 2828 Cl OCH₃ Cl Cl Br 2829 Cl OCH₃ Cl Cl F 2830 Cl OCH₃ Cl Br H 2831 Cl OCH₃ Cl Br CH₃ 2832 Cl OCH₃ Cl Br OCH₃ 2833 Cl OCH₃ Cl Br Br 2834 Cl OCH₃ Cl F H 2835 Cl OCH₃ Cl F CH₃ 2836 Cl OCH₃ Cl F OCH₃ 2837 Cl OCH₃ Cl F Br 2838 Cl OCH₃ Cl F F 2839 Cl OCH₃ Br H H 2840 Cl OCH₃ Br H CH₃ 2841 Cl OCH₃ Br H OCH₃ 2842 Cl OCH₃ Br H Cl 2843 Cl OCH₃ Br H Br 2844 Cl OCH₃ Br H F 2845 Cl OCH₃ Br CH₃ H 2846 Cl OCH₃ Br CH₃ CH₃ 2847 Cl OCH₃ Br CH₃ OCH₃ 2848 Cl OCH₃ Br CH₃ Cl 2849 Cl OCH₃ Br CH₃ F 2850 Cl OCH₃ Br OCH₃ H 2851 Cl OCH₃ Br OCH₃ CH₃ 2852 Cl OCH₃ Br OCH₃ OCH₃ 2853 Cl OCH₃ Br OCH₃ Cl 2854 Cl OCH₃ Br OCH₃ F 2855 Cl OCH₃ Br Cl H 2856 Cl OCH₃ Br Cl CH₃ 2857 Cl OCH₃ Br Cl OCH₃ 2858 Cl OCH₃ Br Cl Cl 2859 Cl OCH₃ Br Cl F 2860 Cl OCH₃ Br Br H 2861 Cl OCH₃ Br Br CH₃ 2862 Cl OCH₃ Br Br OCH₃ 2863 Cl OCH₃ Br Br Cl 2864 Cl OCH₃ Br Br Br 2865 Cl OCH₃ Br Br F 2866 Cl OCH₃ Br F H 2867 Cl OCH₃ Br F CH₃ 2868 Cl OCH₃ Br F OCH₃ 2869 Cl OCH₃ Br F Cl 2870 Cl OCH₃ Br F F 2871 Cl OCH₃ F H H 2872 Cl OCH₃ F H CH₃ 2873 Cl OCH₃ F H OCH₃ 2874 Cl OCH₃ F H Cl 2875 Cl OCH₃ F H Br 2876 Cl OCH₃ F H F 2877 Cl OCH₃ F CH₃ H 2878 Cl OCH₃ F CH₃ CH₃ 2879 Cl OCH₃ F CH₃ OCH₃ 2880 Cl OCH₃ F CH₃ Cl 2881 Cl OCH₃ F CH₃ Br 2882 Cl OCH₃ F OCH₃ H 2883 Cl OCH₃ F OCH₃ CH₃ 2884 Cl OCH₃ F OCH₃ OCH₃ 2885 Cl OCH₃ F OCH₃ Cl 2886 Cl OCH₃ F OCH₃ Br 2887 Cl OCH₃ F Cl H 2888 Cl OCH₃ F Cl CH₃ 2889 Cl OCH₃ F Cl OCH₃ 2890 Cl OCH₃ F Cl Cl 2891 Cl OCH₃ F Cl Br 2892 Cl OCH₃ F Br H 2893 Cl OCH₃ F Br CH₃ 2894 Cl OCH₃ F Br OCH₃ 2895 Cl OCH₃ F Br Cl 2896 Cl OCH₃ F Br Br 2897 Cl OCH₃ F F H 2898 Cl OCH₃ F F CH₃ 2899 Cl OCH₃ F F OCH₃ 2900 Cl OCH₃ F F Cl 2901 Cl OCH₃ F F Br 2902 Cl OCH₃ F F F 2903 Cl Cl CH₃ H H 2904 Cl Cl CH₃ H CH₃ 2905 Cl Cl CH₃ H OCH₃ 2906 Cl Cl CH₃ H Cl 2907 Cl Cl CH₃ H Br 2908 Cl Cl CH₃ H F 2909 Cl Cl CH₃ CH₃ H 2910 Cl Cl CH₃ CH₃ CH₃ 2911 Cl Cl CH₃ CH₃ OCH₃ 2912 Cl Cl CH₃ CH₃ Cl 2913 Cl Cl CH₃ CH₃ Br 2914 Cl Cl CH₃ CH₃ F 2915 Cl Cl CH₃ OCH₃ H 2916 Cl Cl CH₃ OCH₃ OCH₃ 2917 Cl Cl CH₃ OCH₃ Cl 2918 Cl Cl CH₃ OCH₃ Br 2919 Cl Cl CH₃ OCH₃ F 2920 Cl Cl CH₃ Cl H 2921 Cl Cl CH₃ Cl OCH₃ 2922 Cl Cl CH₃ Cl Cl 2923 Cl Cl CH₃ Cl Br 2924 Cl Cl CH₃ Cl F 2925 Cl Cl CH₃ Br H 2926 Cl Cl CH₃ Br OCH₃ 2927 Cl Cl CH₃ Br Cl 2928 Cl Cl CH₃ Br Br 2929 Cl Cl CH₃ Br F 2930 Cl Cl CH₃ F H 2931 Cl Cl CH₃ F OCH₃ 2932 Cl Cl CH₃ F Cl 2933 Cl Cl CH₃ F Br 2934 Cl Cl CH₃ F F 2935 Cl Cl OCH₃ H H 2936 Cl Cl OCH₃ H CH₃ 2937 Cl Cl OCH₃ H OCH₃ 2938 Cl Cl OCH₃ H Cl 2939 Cl Cl OCH₃ H Br 2940 Cl Cl OCH₃ H F 2941 Cl Cl OCH₃ CH₃ H 2942 Cl Cl OCH₃ CH₃ CH₃ 2943 Cl Cl OCH₃ CH₃ Cl 2944 Cl Cl OCH₃ CH₃ Br 2945 Cl Cl OCH₃ CH₃ F 2946 Cl Cl OCH₃ OCH₃ H 2947 Cl Cl OCH₃ OCH₃ CH₃ 2948 Cl Cl OCH₃ OCH₃ OCH₃ 2949 Cl Cl OCH₃ OCH₃ Cl 2950 Cl Cl OCH₃ OCH₃ Br 2951 Cl Cl OCH₃ OCH₃ F 2952 Cl Cl OCH₃ Cl H 2953 Cl Cl OCH₃ Cl CH₃ 2954 Cl Cl OCH₃ Cl Cl 2955 Cl Cl OCH₃ Cl Br 2956 Cl Cl OCH₃ Cl F 2957 Cl Cl OCH₃ Br H 2958 Cl Cl OCH₃ Br CH₃ 2959 Cl Cl OCH₃ Br Cl 2960 Cl Cl OCH₃ Br Br 2961 Cl Cl OCH₃ Br F 2962 Cl Cl OCH₃ F H 2963 Cl Cl OCH₃ F CH₃ 2964 Cl Cl OCH₃ F Cl 2965 Cl Cl OCH₃ F Br 2966 Cl Cl OCH₃ F F 2967 Cl Cl Cl H H 2968 Cl Cl Cl H CH₃ 2969 Cl Cl Cl H OCH₃ 2970 Cl Cl Cl H Cl 2971 Cl Cl Cl H Br 2972 Cl Cl Cl H F 2973 Cl Cl Cl CH₃ H 2974 Cl Cl Cl CH₃ CH₃ 2975 Cl Cl Cl CH₃ OCH₃ 2976 Cl Cl Cl CH₃ Br 2977 Cl Cl Cl CH₃ F 2978 Cl Cl Cl OCH₃ H 2979 Cl Cl Cl OCH₃ CH₃ 2980 Cl Cl Cl OCH₃ OCH₃ 2981 Cl Cl Cl OCH₃ Br 2982 Cl Cl Cl OCH₃ F 2983 Cl Cl Cl Cl H 2984 Cl Cl Cl Cl CH₃ 2985 Cl Cl Cl Cl OCH₃ 2986 Cl Cl Cl Cl Cl 2987 Cl Cl Cl Cl Br 2988 Cl Cl Cl Cl F 2989 Cl Cl Cl Br H 2990 Cl Cl Cl Br CH₃ 2991 Cl Cl Cl Br OCH₃ 2992 Cl Cl Cl Br Br 2993 Cl Cl Cl F H 2994 Cl Cl Cl F CH₃ 2995 Cl Cl Cl F OCH₃ 2996 Cl Cl Cl F Br 2997 Cl Cl Cl F F 2998 Cl Cl Br H H 2999 Cl Cl Br H CH₃ 3000 Cl Cl Br H OCH₃ 3001 Cl Cl Br H Cl 3002 Cl Cl Br H Br 3003 Cl Cl Br H F 3004 Cl Cl Br CH₃ H 3005 Cl Cl Br CH₃ CH₃ 3006 Cl Cl Br CH₃ OCH₃ 3007 Cl Cl Br CH₃ Cl 3008 Cl Cl Br CH₃ F 3009 Cl Cl Br OCH₃ H 3010 Cl Cl Br OCH₃ CH₃ 3011 Cl Cl Br OCH₃ OCH₃ 3012 Cl Cl Br OCH₃ Cl 3013 Cl Cl Br OCH₃ F 3014 Cl Cl Br Cl H 3015 Cl Cl Br Cl CH₃ 3016 Cl Cl Br Cl OCH₃ 3017 Cl Cl Br Cl Cl 3018 Cl Cl Br Cl F 3019 Cl Cl Br Br H 3020 Cl Cl Br Br CH₃ 3021 Cl Cl Br Br OCH₃ 3022 Cl Cl Br Br Cl 3023 Cl Cl Br Br Br 3024 Cl Cl Br Br F 3025 Cl Cl Br F H 3026 Cl Cl Br F CH₃ 3027 Cl Cl Br F OCH₃ 3028 Cl Cl Br F Cl 3029 Cl Cl Br F F 3030 Cl Cl F H H 3031 Cl Cl F H CH₃ 3032 Cl Cl F H OCH₃ 3033 Cl Cl F H Cl 3034 Cl Cl F H Br 3035 Cl Cl F H F 3036 Cl Cl F CH₃ H 3037 Cl Cl F CH₃ CH₃ 3038 Cl Cl F CH₃ OCH₃ 3039 Cl Cl F CH₃ Cl 3040 Cl Cl F CH₃ Br 3041 Cl Cl F OCH₃ H 3042 Cl Cl F OCH₃ CH₃ 3043 Cl Cl F OCH₃ OCH₃ 3044 Cl Cl F OCH₃ Cl 3045 Cl Cl F OCH₃ Br 3046 Cl Cl F Cl H 3047 Cl Cl F Cl CH₃ 3048 Cl Cl F Cl OCH₃ 3049 Cl Cl F Cl Cl 3050 Cl Cl F Cl Br 3051 Cl Cl F Br H 3052 Cl Cl F Br CH₃ 3053 Cl Cl F Br OCH₃ 3054 Cl Cl F Br Cl 3055 Cl Cl F Br Br 3056 Cl Cl F F H 3057 Cl Cl F F CH₃ 3058 Cl Cl F F OCH₃ 3059 Cl Cl F F Cl 3060 Cl Cl F F Br 3061 Cl Cl F F F 3062 Cl Br CH₃ H H 3063 Cl Br CH₃ H CH₃ 3064 Cl Br CH₃ H OCH₃ 3065 Cl Br CH₃ H Cl 3066 Cl Br CH₃ H Br 3067 Cl Br CH₃ H F 3068 Cl Br CH₃ CH₃ H 3069 Cl Br CH₃ CH₃ CH₃ 3070 Cl Br CH₃ CH₃ OCH₃ 3071 Cl Br CH₃ CH₃ Cl 3072 Cl Br CH₃ CH₃ Br 3073 Cl Br CH₃ CH₃ F 3074 Cl Br CH₃ OCH₃ H 3075 Cl Br CH₃ OCH₃ OCH₃ 3076 Cl Br CH₃ OCH₃ Cl 3077 Cl Br CH₃ OCH₃ Br 3078 Cl Br CH₃ OCH₃ F 3079 Cl Br CH₃ Cl H 3080 Cl Br CH₃ Cl OCH₃ 3081 Cl Br CH₃ Cl Cl 3082 Cl Br CH₃ Cl Br 3083 Cl Br CH₃ Cl F 3084 Cl Br CH₃ Br H 3085 Cl Br CH₃ Br OCH₃ 3086 Cl Br CH₃ Br Cl 3087 Cl Br CH₃ Br Br 3088 Cl Br CH₃ Br F 3089 Cl Br CH₃ F H 3090 Cl Br CH₃ F OCH₃ 3091 Cl Br CH₃ F Cl 3092 Cl Br CH₃ F Br 3093 Cl Br CH₃ F F 3094 Cl Br OCH₃ H H 3095 Cl Br OCH₃ H CH₃ 3096 Cl Br OCH₃ H OCH₃ 3097 Cl Br OCH₃ H Cl 3098 Cl Br OCH₃ H Br 3099 Cl Br OCH₃ H F 3100 Cl Br OCH₃ CH₃ H 3101 Cl Br OCH₃ CH₃ CH₃ 3102 Cl Br OCH₃ CH₃ Cl 3103 Cl Br OCH₃ CH₃ Br 3104 Cl Br OCH₃ CH₃ F 3105 Cl Br OCH₃ OCH₃ H 3106 Cl Br OCH₃ OCH₃ CH₃ 3107 Cl Br OCH₃ OCH₃ OCH₃ 3108 Cl Br OCH₃ OCH₃ Cl 3109 Cl Br OCH₃ OCH₃ Br 3110 Cl Br OCH₃ OCH₃ F 3111 Cl Br OCH₃ Cl H 3112 Cl Br OCH₃ Cl CH₃ 3113 Cl Br OCH₃ Cl Cl 3114 Cl Br OCH₃ Cl Br 3115 Cl Br OCH₃ Cl F 3116 Cl Br OCH₃ Br H 3117 Cl Br OCH₃ Br CH₃ 3118 Cl Br OCH₃ Br Cl 3119 Cl Br OCH₃ Br Br 3120 Cl Br OCH₃ Br F 3121 Cl Br OCH₃ F H 3122 Cl Br OCH₃ F CH₃ 3123 Cl Br OCH₃ F Cl 3124 Cl Br OCH₃ F Br 3125 Cl Br OCH₃ F F 3126 Cl Br Cl H H 3127 Cl Br Cl H CH₃ 3128 Cl Br Cl H OCH₃ 3129 Cl Br Cl H Cl 3130 Cl Br Cl H Br 3131 Cl Br Cl H F 3132 Cl Br Cl CH₃ H 3133 Cl Br Cl CH₃ CH₃ 3134 Cl Br Cl CH₃ OCH₃ 3135 Cl Br Cl CH₃ Br 3136 Cl Br Cl CH₃ F 3137 Cl Br Cl OCH₃ H 3138 Cl Br Cl OCH₃ CH₃ 3139 Cl Br Cl OCH₃ OCH₃ 3140 Cl Br Cl OCH₃ Br 3141 Cl Br Cl OCH₃ F 3142 Cl Br Cl Cl H 3143 Cl Br Cl Cl CH₃ 3144 Cl Br Cl Cl OCH₃ 3145 Cl Br Cl Cl Cl 3146 Cl Br Cl Cl Br 3147 Cl Br Cl Cl F 3148 Cl Br Cl Br H 3149 Cl Br Cl Br CH₃ 3150 Cl Br Cl Br OCH₃ 3151 Cl Br Cl Br Br 3152 Cl Br Cl F H 3153 Cl Br Cl F CH₃ 3154 Cl Br Cl F OCH₃ 3155 Cl Br Cl F Br 3156 Cl Br Cl F F 3157 Cl Br Br H H 3158 Cl Br Br H CH₃ 3159 Cl Br Br H OCH₃ 3160 Cl Br Br H Cl 3161 Cl Br Br H Br 3162 Cl Br Br H F 3163 Cl Br Br CH₃ H 3164 Cl Br Br CH₃ CH₃ 3165 Cl Br Br CH₃ OCH₃ 3166 Cl Br Br CH₃ Cl 3167 Cl Br Br CH₃ F 3168 Cl Br Br OCH₃ H 3169 Cl Br Br OCH₃ CH₃ 3170 Cl Br Br OCH₃ OCH₃ 3171 Cl Br Br OCH₃ Cl 3172 Cl Br Br OCH₃ F 3173 Cl Br Br Cl H 3174 Cl Br Br Cl CH₃ 3175 Cl Br Br Cl OCH₃ 3176 Cl Br Br Cl Cl 3177 Cl Br Br Cl F 3178 Cl Br Br Br H 3179 Cl Br Br Br CH₃ 3180 Cl Br Br Br OCH₃ 3181 Cl Br Br Br Cl 3182 Cl Br Br Br Br 3183 Cl Br Br Br F 3184 Cl Br Br F H 3185 Cl Br Br F CH₃ 3186 Cl Br Br F OCH₃ 3187 Cl Br Br F Cl 3188 Cl Br Br F F 3189 Cl Br F H H 3190 Cl Br F H CH₃ 3191 Cl Br F H OCH₃ 3192 Cl Br F H Cl 3193 Cl Br F H Br 3194 Cl Br F H F 3195 Cl Br F CH₃ H 3196 Cl Br F CH₃ CH₃ 3197 Cl Br F CH₃ OCH₃ 3198 Cl Br F CH₃ Cl 3199 Cl Br F CH₃ Br 3200 Cl Br F OCH₃ H 3201 Cl Br F OCH₃ CH₃ 3202 Cl Br F OCH₃ OCH₃ 3203 Cl Br F OCH₃ Cl 3204 Cl Br F OCH₃ Br 3205 Cl Br F Cl H 3206 Cl Br F Cl CH₃ 3207 Cl Br F Cl OCH₃ 3208 Cl Br F Cl Cl 3209 Cl Br F Cl Br 3210 Cl Br F Br H 3211 Cl Br F Br CH₃ 3212 Cl Br F Br OCH₃ 3213 Cl Br F Br Cl 3214 Cl Br F Br Br 3215 Cl Br F F H 3216 Cl Br F F CH₃ 3217 Cl Br F F OCH₃ 3218 Cl Br F F Cl 3219 Cl Br F F Br 3220 Cl Br F F F 3221 Cl F CH₃ H H 3222 Cl F CH₃ H CH₃ 3223 Cl F CH₃ H OCH₃ 3224 Cl F CH₃ H Cl 3225 Cl F CH₃ H Br 3226 Cl F CH₃ H F 3227 Cl F CH₃ CH₃ H 3228 Cl F CH₃ CH₃ CH₃ 3229 Cl F CH₃ CH₃ OCH₃ 3230 Cl F CH₃ CH₃ Cl 3231 Cl F CH₃ CH₃ Br 3232 Cl F CH₃ CH₃ F 3233 Cl F CH₃ OCH₃ H 3234 Cl F CH₃ OCH₃ OCH₃ 3235 Cl F CH₃ OCH₃ Cl 3236 Cl F CH₃ OCH₃ Br 3237 Cl F CH₃ OCH₃ F 3238 Cl F CH₃ Cl H 3239 Cl F CH₃ Cl OCH₃ 3240 Cl F CH₃ Cl Cl 3241 Cl F CH₃ Cl Br 3242 Cl F CH₃ Cl F 3243 Cl F CH₃ Br H 3244 Cl F CH₃ Br OCH₃ 3245 Cl F CH₃ Br Cl 3246 Cl F CH₃ Br Br 3247 Cl F CH₃ Br F 3248 Cl F CH₃ F H 3249 Cl F CH₃ F OCH₃ 3250 Cl F CH₃ F Cl 3251 Cl F CH₃ F Br 3252 Cl F CH₃ F F 3253 Cl F OCH₃ H H 3254 Cl F OCH₃ H CH₃ 3255 Cl F OCH₃ H OCH₃ 3256 Cl F OCH₃ H Cl 3257 Cl F OCH₃ H Br 3258 Cl F OCH₃ H F 3259 Cl F OCH₃ CH₃ H 3260 Cl F OCH₃ CH₃ CH₃ 3261 Cl F OCH₃ CH₃ Cl 3262 Cl F OCH₃ CH₃ Br 3263 Cl F OCH₃ CH₃ F 3264 Cl F OCH₃ OCH₃ H 3265 Cl F OCH₃ OCH₃ CH₃ 3266 Cl F OCH₃ OCH₃ OCH₃ 3267 Cl F OCH₃ OCH₃ Cl 3268 Cl F OCH₃ OCH₃ Br 3269 Cl F OCH₃ OCH₃ F 3270 Cl F OCH₃ Cl H 3271 Cl F OCH₃ Cl CH₃ 3272 Cl F OCH₃ Cl Cl 3273 Cl F OCH₃ Cl Br 3274 Cl F OCH₃ Cl F 3275 Cl F OCH₃ Br H 3276 Cl F OCH₃ Br CH₃ 3277 Cl F OCH₃ Br Cl 3278 Cl F OCH₃ Br Br 3279 Cl F OCH₃ Br F 3280 Cl F OCH₃ F H 3281 Cl F OCH₃ F CH₃ 3282 Cl F OCH₃ F Cl 3283 Cl F OCH₃ F Br 3284 Cl F OCH₃ F F 3285 Cl F Cl H H 3286 Cl F Cl H CH₃ 3287 Cl F Cl H OCH₃ 3288 Cl F Cl H Cl 3289 Cl F Cl H Br 3290 Cl F Cl H F 3291 Cl F Cl CH₃ H 3292 Cl F Cl CH₃ CH₃ 3293 Cl F Cl CH₃ OCH₃ 3294 Cl F Cl CH₃ Br 3295 Cl F Cl CH₃ F 3296 Cl F Cl OCH₃ H 3297 Cl F Cl OCH₃ CH₃ 3298 Cl F Cl OCH₃ OCH₃ 3299 Cl F Cl OCH₃ Br 3300 Cl F Cl OCH₃ F 3301 Cl F Cl Cl H 3302 Cl F Cl Cl CH₃ 3303 Cl F Cl Cl OCH₃ 3304 Cl F Cl Cl Cl 3305 Cl F Cl Cl Br 3306 Cl F Cl Cl F 3307 Cl F Cl Br H 3308 Cl F Cl Br CH₃ 3309 Cl F Cl Br OCH₃ 3310 Cl F Cl Br Br 3311 Cl F Cl F H 3312 Cl F Cl F CH₃ 3313 Cl F Cl F OCH₃ 3314 Cl F Cl F Br 3315 Cl F Cl F F 3316 Cl F Br H H 3317 Cl F Br H CH₃ 3318 Cl F Br H OCH₃ 3319 Cl F Br H Cl 3320 Cl F Br H Br 3321 Cl F Br H F 3322 Cl F Br CH₃ H 3323 Cl F Br CH₃ CH₃ 3324 Cl F Br CH₃ OCH₃ 3325 Cl F Br CH₃ Cl 3326 Cl F Br CH₃ F 3327 Cl F Br OCH₃ H 3328 Cl F Br OCH₃ CH₃ 3329 Cl F Br OCH₃ OCH₃ 3330 Cl F Br OCH₃ Cl 3331 Cl F Br OCH₃ F 3332 Cl F Br Cl H 3333 Cl F Br Cl CH₃ 3334 Cl F Br Cl OCH₃ 3335 Cl F Br Cl Cl 3336 Cl F Br Cl F 3337 Cl F Br Br H 3338 Cl F Br Br CH₃ 3339 Cl F Br Br OCH₃ 3340 Cl F Br Br Cl 3341 Cl F Br Br Br 3342 Cl F Br Br F 3343 Cl F Br F H 3344 Cl F Br F CH₃ 3345 Cl F Br F OCH₃ 3346 Cl F Br F Cl 3347 Cl F Br F F 3348 Cl F F H H 3349 Cl F F H CH₃ 3350 Cl F F H OCH₃ 3351 Cl F F H Cl 3352 Cl F F H Br 3353 Cl F F H F 3354 Cl F F CH₃ H 3355 Cl F F CH₃ CH₃ 3356 Cl F F CH₃ OCH₃ 3357 Cl F F CH₃ Cl 3358 Cl F F CH₃ Br 3359 Cl F F OCH₃ H 3360 Cl F F OCH₃ CH₃ 3361 Cl F F OCH₃ OCH₃ 3362 Cl F F OCH₃ Cl 3363 Cl F F OCH₃ Br 3364 Cl F F Cl H 3365 Cl F F Cl CH₃ 3366 Cl F F Cl OCH₃ 3367 Cl F F Cl Cl 3368 Cl F F Cl Br 3369 Cl F F Br H 3370 Cl F F Br CH₃ 3371 Cl F F Br OCH₃ 3372 Cl F F Br Cl 3373 Cl F F Br Br 3374 Cl F F F H 3375 Cl F F F CH₃ 3376 Cl F F F OCH₃ 3377 Cl F F F Cl 3378 Cl F F F Br 3379 Cl F F F F 3380 Br CH₃ CH₃ H H 3381 Br CH₃ CH₃ CH₃ H 3382 Br CH₃ CH₃ OCH₃ H 3383 Br CH₃ CH₃ Cl H 3384 Br CH₃ CH₃ Br H 3385 Br CH₃ CH₃ F H 3386 Br CH₃ CH₃ H CH₃ 3387 Br CH₃ CH₃ CH₃ CH₃ 3388 Br CH₃ CH₃ H OCH₃ 3389 Br CH₃ CH₃ CH₃ OCH₃ 3390 Br CH₃ CH₃ OCH₃ OCH₃ 3391 Br CH₃ CH₃ Cl OCH₃ 3392 Br CH₃ CH₃ Br OCH₃ 3393 Br CH₃ CH₃ F OCH₃ 3394 Br CH₃ CH₃ H Cl 3395 Br CH₃ CH₃ CH₃ Cl 3396 Br CH₃ CH₃ OCH₃ Cl 3397 Br CH₃ CH₃ Cl Cl 3398 Br CH₃ CH₃ Br Cl 3399 Br CH₃ CH₃ F Cl 3400 Br CH₃ CH₃ H Br 3401 Br CH₃ CH₃ CH₃ Br 3402 Br CH₃ CH₃ OCH₃ Br 3403 Br CH₃ CH₃ Cl Br 3404 Br CH₃ CH₃ Br Br 3405 Br CH₃ CH₃ F Br 3406 Br CH₃ CH₃ H F 3407 Br CH₃ CH₃ CH₃ F 3408 Br CH₃ CH₃ OCH₃ F 3409 Br CH₃ CH₃ Cl F 3410 Br CH₃ CH₃ Br F 3411 Br CH₃ CH₃ F F 3412 Br CH₃ OCH₃ H H 3413 Br CH₃ OCH₃ CH₃ H 3414 Br CH₃ OCH₃ OCH₃ H 3415 Br CH₃ OCH₃ Cl H 3416 Br CH₃ OCH₃ Br H 3417 Br CH₃ OCH₃ F H 3418 Br CH₃ OCH₃ H CH₃ 3419 Br CH₃ OCH₃ CH₃ CH₃ 3420 Br CH₃ OCH₃ OCH₃ CH₃ 3421 Br CH₃ OCH₃ Cl CH₃ 3422 Br CH₃ OCH₃ Br CH₃ 3423 Br CH₃ OCH₃ F CH₃ 3424 Br CH₃ OCH₃ H OCH₃ 3425 Br CH₃ OCH₃ OCH₃ OCH₃ 3426 Br CH₃ OCH₃ H Cl 3427 Br CH₃ OCH₃ CH₃ Cl 3428 Br CH₃ OCH₃ OCH₃ Cl 3429 Br CH₃ OCH₃ Cl Cl 3430 Br CH₃ OCH₃ Br Cl 3431 Br CH₃ OCH₃ F Cl 3432 Br CH₃ OCH₃ H Br 3433 Br CH₃ OCH₃ CH₃ Br 3434 Br CH₃ OCH₃ OCH₃ Br 3435 Br CH₃ OCH₃ Cl Br 3436 Br CH₃ OCH₃ Br Br 3437 Br CH₃ OCH₃ F Br 3438 Br CH₃ OCH₃ H F 3439 Br CH₃ OCH₃ CH₃ F 3440 Br CH₃ OCH₃ OCH₃ F 3441 Br CH₃ OCH₃ Cl F 3442 Br CH₃ OCH₃ Br F 3443 Br CH₃ OCH₃ F F 3444 Br CH₃ Cl H H 3445 Br CH₃ Cl CH₃ H 3446 Br CH₃ Cl OCH₃ H 3447 Br CH₃ Cl Cl H 3448 Br CH₃ Cl Br H 3449 Br CH₃ Cl F H 3450 Br CH₃ Cl H CH₃ 3451 Br CH₃ Cl CH₃ CH₃ 3452 Br CH₃ Cl OCH₃ CH₃ 3453 Br CH₃ Cl Cl CH₃ 3454 Br CH₃ Cl Br CH₃ 3455 Br CH₃ Cl F CH₃ 3456 Br CH₃ Cl H OCH₃ 3457 Br CH₃ Cl CH₃ OCH₃ 3458 Br CH₃ Cl OCH₃ OCH₃ 3459 Br CH₃ Cl Cl OCH₃ 3460 Br CH₃ Cl Br OCH₃ 3461 Br CH₃ Cl F OCH₃ 3462 Br CH₃ Cl H Cl 3463 Br CH₃ Cl Cl Cl 3464 Br CH₃ Cl H Br 3465 Br CH₃ Cl CH₃ Br 3466 Br CH₃ Cl OCH₃ Br 3467 Br CH₃ Cl Cl Br 3468 Br CH₃ Cl Br Br 3469 Br CH₃ Cl F Br 3470 Br CH₃ Cl H F 3471 Br CH₃ Cl CH₃ F 3472 Br CH₃ Cl OCH₃ F 3473 Br CH₃ Cl Cl F 3474 Br CH₃ Cl F F 3475 Br CH₃ Br H H 3476 Br CH₃ Br CH₃ H 3477 Br CH₃ Br OCH₃ H 3478 Br CH₃ Br Cl H 3479 Br CH₃ Br Br H 3480 Br CH₃ Br F H 3481 Br CH₃ Br H CH₃ 3482 Br CH₃ Br CH₃ CH₃ 3483 Br CH₃ Br OCH₃ CH₃ 3484 Br CH₃ Br Cl CH₃ 3485 Br CH₃ Br Br CH₃ 3486 Br CH₃ Br F CH₃ 3487 Br CH₃ Br H OCH₃ 3488 Br CH₃ Br CH₃ OCH₃ 3489 Br CH₃ Br OCH₃ OCH₃ 3490 Br CH₃ Br Cl OCH₃ 3491 Br CH₃ Br Br OCH₃ 3492 Br CH₃ Br F OCH₃ 3493 Br CH₃ Br H Cl 3494 Br CH₃ Br CH₃ Cl 3495 Br CH₃ Br OCH₃ Cl 3496 Br CH₃ Br Cl Cl 3497 Br CH₃ Br Br Cl 3498 Br CH₃ Br F Cl 3499 Br CH₃ Br H Br 3500 Br CH₃ Br Br Br 3501 Br CH₃ Br H F 3502 Br CH₃ Br CH₃ F 3503 Br CH₃ Br OCH₃ F 3504 Br CH₃ Br Cl F 3505 Br CH₃ Br Br F 3506 Br CH₃ Br F F 3507 Br CH₃ F H H 3508 Br CH₃ F CH₃ H 3509 Br CH₃ F OCH₃ H 3510 Br CH₃ F Cl H 3511 Br CH₃ F Br H 3512 Br CH₃ F F H 3513 Br CH₃ F H CH₃ 3514 Br CH₃ F CH₃ CH₃ 3515 Br CH₃ F OCH₃ CH₃ 3516 Br CH₃ F Cl CH₃ 3517 Br CH₃ F Br CH₃ 3518 Br CH₃ F F CH₃ 3519 Br CH₃ F H OCH₃ 3520 Br CH₃ F CH₃ OCH₃ 3521 Br CH₃ F OCH₃ OCH₃ 3522 Br CH₃ F Cl OCH₃ 3523 Br CH₃ F Br OCH₃ 3524 Br CH₃ F F OCH₃ 3525 Br CH₃ F H Cl 3526 Br CH₃ F CH₃ Cl 3527 Br CH₃ F OCH₃ Cl 3528 Br CH₃ F Cl Cl 3529 Br CH₃ F Br Cl 3530 Br CH₃ F F Cl 3531 Br CH₃ F H Br 3532 Br CH₃ F CH₃ Br 3533 Br CH₃ F OCH₃ Br 3534 Br CH₃ F Cl Br 3535 Br CH₃ F Br Br 3536 Br CH₃ F F Br 3537 Br CH₃ F H F 3538 Br CH₃ F F F 3539 Br OCH₃ CH₃ H H 3540 Br OCH₃ CH₃ H CH₃ 3541 Br OCH₃ CH₃ H OCH₃ 3542 Br OCH₃ CH₃ H Cl 3543 Br OCH₃ CH₃ H Br 3544 Br OCH₃ CH₃ H F 3545 Br OCH₃ CH₃ CH₃ H 3546 Br OCH₃ CH₃ CH₃ CH₃ 3547 Br OCH₃ CH₃ CH₃ OCH₃ 3548 Br OCH₃ CH₃ CH₃ Cl 3549 Br OCH₃ CH₃ CH₃ Br 3550 Br OCH₃ CH₃ CH₃ F 3551 Br OCH₃ CH₃ OCH₃ H 3552 Br OCH₃ CH₃ OCH₃ OCH₃ 3553 Br OCH₃ CH₃ OCH₃ Cl 3554 Br OCH₃ CH₃ OCH₃ Br 3555 Br OCH₃ CH₃ OCH₃ F 3556 Br OCH₃ CH₃ Cl H 3557 Br OCH₃ CH₃ Cl OCH₃ 3558 Br OCH₃ CH₃ Cl Cl 3559 Br OCH₃ CH₃ Cl Br 3560 Br OCH₃ CH₃ Cl F 3561 Br OCH₃ CH₃ Br H 3562 Br OCH₃ CH₃ Br OCH₃ 3563 Br OCH₃ CH₃ Br Cl 3564 Br OCH₃ CH₃ Br Br 3565 Br OCH₃ CH₃ Br F 3566 Br OCH₃ CH₃ F H 3567 Br OCH₃ CH₃ F OCH₃ 3568 Br OCH₃ CH₃ F Cl 3569 Br OCH₃ CH₃ F Br 3570 Br OCH₃ CH₃ F F 3571 Br OCH₃ OCH₃ H H 3572 Br OCH₃ OCH₃ H CH₃ 3573 Br OCH₃ OCH₃ H OCH₃ 3574 Br OCH₃ OCH₃ H Cl 3575 Br OCH₃ OCH₃ H Br 3576 Br OCH₃ OCH₃ H F 3577 Br OCH₃ OCH₃ CH₃ H 3578 Br OCH₃ OCH₃ CH₃ CH₃ 3579 Br OCH₃ OCH₃ CH₃ Cl 3580 Br OCH₃ OCH₃ CH₃ Br 3581 Br OCH₃ OCH₃ CH₃ F 3582 Br OCH₃ OCH₃ OCH₃ H 3583 Br OCH₃ OCH₃ OCH₃ CH₃ 3584 Br OCH₃ OCH₃ OCH₃ OCH₃ 3585 Br OCH₃ OCH₃ OCH₃ Cl 3586 Br OCH₃ OCH₃ OCH₃ Br 3587 Br OCH₃ OCH₃ OCH₃ F 3588 Br OCH₃ OCH₃ Cl H 3589 Br OCH₃ OCH₃ Cl CH₃ 3590 Br OCH₃ OCH₃ Cl Cl 3591 Br OCH₃ OCH₃ Cl Br 3592 Br OCH₃ OCH₃ Cl F 3593 Br OCH₃ OCH₃ Br H 3594 Br OCH₃ OCH₃ Br CH₃ 3595 Br OCH₃ OCH₃ Br Cl 3596 Br OCH₃ OCH₃ Br Br 3597 Br OCH₃ OCH₃ Br F 3598 Br OCH₃ OCH₃ F H 3599 Br OCH₃ OCH₃ F CH₃ 3600 Br OCH₃ OCH₃ F Cl 3601 Br OCH₃ OCH₃ F Br 3602 Br OCH₃ OCH₃ F F 3603 Br OCH₃ Cl H H 3604 Br OCH₃ Cl H CH₃ 3605 Br OCH₃ Cl H OCH₃ 3606 Br OCH₃ Cl H Cl 3607 Br OCH₃ Cl H Br 3608 Br OCH₃ Cl H F 3609 Br OCH₃ Cl CH₃ H 3610 Br OCH₃ Cl CH₃ CH₃ 3611 Br OCH₃ Cl CH₃ OCH₃ 3612 Br OCH₃ Cl CH₃ Br 3613 Br OCH₃ Cl CH₃ F 3614 Br OCH₃ Cl OCH₃ H 3615 Br OCH₃ Cl OCH₃ CH₃ 3616 Br OCH₃ Cl OCH₃ OCH₃ 3617 Br OCH₃ Cl OCH₃ Br 3618 Br OCH₃ Cl OCH₃ F 3619 Br OCH₃ Cl Cl H 3620 Br OCH₃ Cl Cl CH₃ 3621 Br OCH₃ Cl Cl OCH₃ 3622 Br OCH₃ Cl Cl Cl 3623 Br OCH₃ Cl Cl Br 3624 Br OCH₃ Cl Cl F 3625 Br OCH₃ Cl Br H 3626 Br OCH₃ Cl Br CH₃ 3627 Br OCH₃ Cl Br OCH₃ 3628 Br OCH₃ Cl Br Br 3629 Br OCH₃ Cl F H 3630 Br OCH₃ Cl F CH₃ 3631 Br OCH₃ Cl F OCH₃ 3632 Br OCH₃ Cl F Br 3633 Br OCH₃ Cl F F 3634 Br OCH₃ Br H H 3635 Br OCH₃ Br H CH₃ 3636 Br OCH₃ Br H OCH₃ 3637 Br OCH₃ Br H Cl 3638 Br OCH₃ Br H Br 3639 Br OCH₃ Br H F 3640 Br OCH₃ Br CH₃ H 3641 Br OCH₃ Br CH₃ CH₃ 3642 Br OCH₃ Br CH₃ OCH₃ 3643 Br OCH₃ Br CH₃ Cl 3644 Br OCH₃ Br CH₃ F 3645 Br OCH₃ Br OCH₃ H 3646 Br OCH₃ Br OCH₃ CH₃ 3647 Br OCH₃ Br OCH₃ OCH₃ 3648 Br OCH₃ Br OCH₃ Cl 3649 Br OCH₃ Br OCH₃ F 3650 Br OCH₃ Br Cl H 3651 Br OCH₃ Br Cl CH₃ 3652 Br OCH₃ Br Cl OCH₃ 3653 Br OCH₃ Br Cl Cl 3654 Br OCH₃ Br Cl F 3655 Br OCH₃ Br Br H 3656 Br OCH₃ Br Br CH₃ 3657 Br OCH₃ Br Br OCH₃ 3658 Br OCH₃ Br Br Cl 3659 Br OCH₃ Br Br Br 3660 Br OCH₃ Br Br F 3661 Br OCH₃ Br F H 3662 Br OCH₃ Br F CH₃ 3663 Br OCH₃ Br F OCH₃ 3664 Br OCH₃ Br F Cl 3665 Br OCH₃ Br F F 3666 Br OCH₃ F H H 3667 Br OCH₃ F H CH₃ 3668 Br OCH₃ F H OCH₃ 3669 Br OCH₃ F H Cl 3670 Br OCH₃ F H Br 3671 Br OCH₃ F H F 3672 Br OCH₃ F CH₃ H 3673 Br OCH₃ F CH₃ CH₃ 3674 Br OCH₃ F CH₃ OCH₃ 3675 Br OCH₃ F CH₃ Cl 3676 Br OCH₃ F CH₃ Br 3677 Br OCH₃ F OCH₃ H 3678 Br OCH₃ F OCH₃ CH₃ 3679 Br OCH₃ F OCH₃ OCH₃ 3680 Br OCH₃ F OCH₃ Cl 3681 Br OCH₃ F OCH₃ Br 3682 Br OCH₃ F Cl H 3683 Br OCH₃ F Cl CH₃ 3684 Br OCH₃ F Cl OCH₃ 3685 Br OCH₃ F Cl Cl 3686 Br OCH₃ F Cl Br 3687 Br OCH₃ F Br H 3688 Br OCH₃ F Br CH₃ 3689 Br OCH₃ F Br OCH₃ 3690 Br OCH₃ F Br Cl 3691 Br OCH₃ F Br Br 3692 Br OCH₃ F F H 3693 Br OCH₃ F F CH₃ 3694 Br OCH₃ F F OCH₃ 3695 Br OCH₃ F F Cl 3696 Br OCH₃ F F Br 3697 Br OCH₃ F F F 3698 Br Cl CH₃ H H 3699 Br Cl CH₃ H CH₃ 3700 Br Cl CH₃ H OCH₃ 3701 Br Cl CH₃ H Cl 3702 Br Cl CH₃ H Br 3703 Br Cl CH₃ H F 3704 Br Cl CH₃ CH₃ H 3705 Br Cl CH₃ CH₃ CH₃ 3706 Br Cl CH₃ CH₃ OCH₃ 3707 Br Cl CH₃ CH₃ Cl 3708 Br Cl CH₃ CH₃ Br 3709 Br Cl CH₃ CH₃ F 3710 Br Cl CH₃ OCH₃ H 3711 Br Cl CH₃ OCH₃ OCH₃ 3712 Br Cl CH₃ OCH₃ Cl 3713 Br Cl CH₃ OCH₃ Br 3714 Br Cl CH₃ OCH₃ F 3715 Br Cl CH₃ Cl H 3716 Br Cl CH₃ Cl OCH₃ 3717 Br Cl CH₃ Cl Cl 3718 Br Cl CH₃ Cl Br 3719 Br Cl CH₃ Cl F 3720 Br Cl CH₃ Br H 3721 Br Cl CH₃ Br OCH₃ 3722 Br Cl CH₃ Br Cl 3723 Br Cl CH₃ Br Br 3724 Br Cl CH₃ Br F 3725 Br Cl CH₃ F H 3726 Br Cl CH₃ F OCH₃ 3727 Br Cl CH₃ F Cl 3728 Br Cl CH₃ F Br 3729 Br Cl CH₃ F F 3730 Br Cl OCH₃ H H 3731 Br Cl OCH₃ H CH₃ 3732 Br Cl OCH₃ H OCH₃ 3733 Br Cl OCH₃ H Cl 3734 Br Cl OCH₃ H Br 3735 Br Cl OCH₃ H F 3736 Br Cl OCH₃ CH₃ H 3737 Br Cl OCH₃ CH₃ CH₃ 3738 Br Cl OCH₃ CH₃ Cl 3739 Br Cl OCH₃ CH₃ Br 3740 Br Cl OCH₃ CH₃ F 3741 Br Cl OCH₃ OCH₃ H 3742 Br Cl OCH₃ OCH₃ CH₃ 3743 Br Cl OCH₃ OCH₃ OCH₃ 3744 Br Cl OCH₃ OCH₃ Cl 3745 Br Cl OCH₃ OCH₃ Br 3746 Br Cl OCH₃ OCH₃ F 3747 Br Cl OCH₃ Cl H 3748 Br Cl OCH₃ Cl CH₃ 3749 Br Cl OCH₃ Cl Cl 3750 Br Cl OCH₃ Cl Br 3751 Br Cl OCH₃ Cl F 3752 Br Cl OCH₃ Br H 3753 Br Cl OCH₃ Br CH₃ 3754 Br Cl OCH₃ Br Cl 3755 Br Cl OCH₃ Br Br 3756 Br Cl OCH₃ Br F 3757 Br Cl OCH₃ F H 3758 Br Cl OCH₃ F CH₃ 3759 Br Cl OCH₃ F Cl 3760 Br Cl OCH₃ F Br 3761 Br Cl OCH₃ F F 3762 Br Cl Cl H H 3763 Br Cl Cl H CH₃ 3764 Br Cl Cl H OCH₃ 3765 Br Cl Cl H Cl 3766 Br Cl Cl H Br 3767 Br Cl Cl H F 3768 Br Cl Cl CH₃ H 3769 Br Cl Cl CH₃ CH₃ 3770 Br Cl Cl CH₃ OCH₃ 3771 Br Cl Cl CH₃ Br 3772 Br Cl Cl CH₃ F 3773 Br Cl Cl OCH₃ H 3774 Br Cl Cl OCH₃ CH₃ 3775 Br Cl Cl OCH₃ OCH₃ 3776 Br Cl Cl OCH₃ Br 3777 Br Cl Cl OCH₃ F 3778 Br Cl Cl Cl H 3779 Br Cl Cl Cl CH₃ 3780 Br Cl Cl Cl OCH₃ 3781 Br Cl Cl Cl Cl 3782 Br Cl Cl Cl Br 3783 Br Cl Cl Cl F 3784 Br Cl Cl Br H 3785 Br Cl Cl Br CH₃ 3786 Br Cl Cl Br OCH₃ 3787 Br Cl Cl Br Br 3788 Br Cl Cl F H 3789 Br Cl Cl F CH₃ 3790 Br Cl Cl F OCH₃ 3791 Br Cl Cl F Br 3792 Br Cl Cl F F 3793 Br Cl Br H H 3794 Br Cl Br H CH₃ 3795 Br Cl Br H OCH₃ 3796 Br Cl Br H Cl 3797 Br Cl Br H Br 3798 Br Cl Br H F 3799 Br Cl Br CH₃ H 3800 Br Cl Br CH₃ CH₃ 3801 Br Cl Br CH₃ OCH₃ 3802 Br Cl Br CH₃ Cl 3803 Br Cl Br CH₃ F 3804 Br Cl Br OCH₃ H 3805 Br Cl Br OCH₃ CH₃ 3806 Br Cl Br OCH₃ OCH₃ 3807 Br Cl Br OCH₃ Cl 3808 Br Cl Br OCH₃ F 3809 Br Cl Br Cl H 3810 Br Cl Br Cl CH₃ 3811 Br Cl Br Cl OCH₃ 3812 Br Cl Br Cl Cl 3813 Br Cl Br Cl F 3814 Br Cl Br Br H 3815 Br Cl Br Br CH₃ 3816 Br Cl Br Br OCH₃ 3817 Br Cl Br Br Cl 3818 Br Cl Br Br Br 3819 Br Cl Br Br F 3820 Br Cl Br F H 3821 Br Cl Br F CH₃ 3822 Br Cl Br F OCH₃ 3823 Br Cl Br F Cl 3824 Br Cl Br F F 3825 Br Cl F H H 3826 Br Cl F H CH₃ 3827 Br Cl F H OCH₃ 3828 Br Cl F H Cl 3829 Br Cl F H Br 3830 Br Cl F H F 3831 Br Cl F CH₃ H 3832 Br Cl F CH₃ CH₃ 3833 Br Cl F CH₃ OCH₃ 3834 Br Cl F CH₃ Cl 3835 Br Cl F CH₃ Br 3836 Br Cl F OCH₃ H 3837 Br Cl F OCH₃ CH₃ 3838 Br Cl F OCH₃ OCH₃ 3839 Br Cl F OCH₃ Cl 3840 Br Cl F OCH₃ Br 3841 Br Cl F Cl H 3842 Br Cl F Cl CH₃ 3843 Br Cl F Cl OCH₃ 3844 Br Cl F Cl Cl 3845 Br Cl F Cl Br 3846 Br Cl F Br H 3847 Br Cl F Br CH₃ 3848 Br Cl F Br OCH₃ 3849 Br Cl F Br Cl 3850 Br Cl F Br Br 3851 Br Cl F F H 3852 Br Cl F F CH₃ 3853 Br Cl F F OCH₃ 3854 Br Cl F F Cl 3855 Br Cl F F Br 3856 Br Cl F F F 3857 Br Br CH₃ H H 3858 Br Br CH₃ H CH₃ 3859 Br Br CH₃ H OCH₃ 3860 Br Br CH₃ H Cl 3861 Br Br CH₃ H Br 3862 Br Br CH₃ H F 3863 Br Br CH₃ CH₃ H 3864 Br Br CH₃ CH₃ CH₃ 3865 Br Br CH₃ CH₃ OCH₃ 3866 Br Br CH₃ CH₃ Cl 3867 Br Br CH₃ CH₃ Br 3868 Br Br CH₃ CH₃ F 3869 Br Br CH₃ OCH₃ H 3870 Br Br CH₃ OCH₃ OCH₃ 3871 Br Br CH₃ OCH₃ Cl 3872 Br Br CH₃ OCH₃ Br 3873 Br Br CH₃ OCH₃ F 3874 Br Br CH₃ Cl H 3875 Br Br CH₃ Cl OCH₃ 3876 Br Br CH₃ Cl Cl 3877 Br Br CH₃ Cl Br 3878 Br Br CH₃ Cl F 3879 Br Br CH₃ Br H 3880 Br Br CH₃ Br OCH₃ 3881 Br Br CH₃ Br Cl 3882 Br Br CH₃ Br Br 3883 Br Br CH₃ Br F 3884 Br Br CH₃ F H 3885 Br Br CH₃ F OCH₃ 3886 Br Br CH₃ F Cl 3887 Br Br CH₃ F Br 3888 Br Br CH₃ F F 3889 Br Br OCH₃ H H 3890 Br Br OCH₃ H CH₃ 3891 Br Br OCH₃ H OCH₃ 3892 Br Br OCH₃ H Cl 3893 Br Br OCH₃ H Br 3894 Br Br OCH₃ H F 3895 Br Br OCH₃ CH₃ H 3896 Br Br OCH₃ CH₃ CH₃ 3897 Br Br OCH₃ CH₃ Cl 3898 Br Br OCH₃ CH₃ Br 3899 Br Br OCH₃ CH₃ F 3900 Br Br OCH₃ OCH₃ H 3901 Br Br OCH₃ OCH₃ CH₃ 3902 Br Br OCH₃ OCH₃ OCH₃ 3903 Br Br OCH₃ OCH₃ Cl 3904 Br Br OCH₃ OCH₃ Br 3905 Br Br OCH₃ OCH₃ F 3906 Br Br OCH₃ Cl H 3907 Br Br OCH₃ Cl CH₃ 3908 Br Br OCH₃ Cl Cl 3909 Br Br OCH₃ Cl Br 3910 Br Br OCH₃ Cl F 3911 Br Br OCH₃ Br H 3912 Br Br OCH₃ Br CH₃ 3913 Br Br OCH₃ Br Cl 3914 Br Br OCH₃ Br Br 3915 Br Br OCH₃ Br F 3916 Br Br OCH₃ F H 3917 Br Br OCH₃ F CH₃ 3918 Br Br OCH₃ F Cl 3919 Br Br OCH₃ F Br 3920 Br Br OCH₃ F F 3921 Br Br Cl H H 3922 Br Br Cl H CH₃ 3923 Br Br Cl H OCH₃ 3924 Br Br Cl H Cl 3925 Br Br Cl H Br 3926 Br Br Cl H F 3927 Br Br Cl CH₃ H 3928 Br Br Cl CH₃ CH₃ 3929 Br Br Cl CH₃ OCH₃ 3930 Br Br Cl CH₃ Br 3931 Br Br Cl CH₃ F 3932 Br Br Cl OCH₃ H 3933 Br Br Cl OCH₃ CH₃ 3934 Br Br Cl OCH₃ OCH₃ 3935 Br Br Cl OCH₃ Br 3936 Br Br Cl OCH₃ F 3937 Br Br Cl Cl H 3938 Br Br Cl Cl CH₃ 3939 Br Br Cl Cl OCH₃ 3940 Br Br Cl Cl Cl 3941 Br Br Cl Cl Br 3942 Br Br Cl Cl F 3943 Br Br Cl Br H 3944 Br Br Cl Br CH₃ 3945 Br Br Cl Br OCH₃ 3946 Br Br Cl Br Br 3947 Br Br Cl F H 3948 Br Br Cl F CH₃ 3949 Br Br Cl F OCH₃ 3950 Br Br Cl F Br 3951 Br Br Cl F F 3952 Br Br Br H H 3953 Br Br Br H CH₃ 3954 Br Br Br H OCH₃ 3955 Br Br Br H Cl 3956 Br Br Br H Br 3957 Br Br Br H F 3958 Br Br Br CH₃ H 3959 Br Br Br CH₃ CH₃ 3960 Br Br Br CH₃ OCH₃ 3961 Br Br Br CH₃ Cl 3962 Br Br Br CH₃ F 3963 Br Br Br OCH₃ H 3964 Br Br Br OCH₃ CH₃ 3965 Br Br Br OCH₃ OCH₃ 3966 Br Br Br OCH₃ Cl 3967 Br Br Br OCH₃ F 3968 Br Br Br Cl H 3969 Br Br Br Cl CH₃ 3970 Br Br Br Cl OCH₃ 3971 Br Br Br Cl Cl 3972 Br Br Br Cl F 3973 Br Br Br Br H 3974 Br Br Br Br CH₃ 3975 Br Br Br Br OCH₃ 3976 Br Br Br Br Cl 3977 Br Br Br Br Br 3978 Br Br Br Br F 3979 Br Br Br F H 3980 Br Br Br F CH₃ 3981 Br Br Br F OCH₃ 3982 Br Br Br F Cl 3983 Br Br Br F F 3984 Br Br F H H 3985 Br Br F H CH₃ 3986 Br Br F H OCH₃ 3987 Br Br F H Cl 3988 Br Br F H Br 3989 Br Br F H F 3990 Br Br F CH₃ H 3991 Br Br F CH₃ CH₃ 3992 Br Br F CH₃ OCH₃ 3993 Br Br F CH₃ Cl 3994 Br Br F CH₃ Br 3995 Br Br F OCH₃ H 3996 Br Br F OCH₃ CH₃ 3997 Br Br F OCH₃ OCH₃ 3998 Br Br F OCH₃ Cl 3999 Br Br F OCH₃ Br 4000 Br Br F Cl H 4001 Br Br F Cl CH₃ 4002 Br Br F Cl OCH₃ 4003 Br Br F Cl Cl 4004 Br Br F Cl Br 4005 Br Br F Br H 4006 Br Br F Br CH₃ 4007 Br Br F Br OCH₃ 4008 Br Br F Br Cl 4009 Br Br F Br Br 4010 Br Br F F H 4011 Br Br F F CH₃ 4012 Br Br F F OCH₃ 4013 Br Br F F Cl 4014 Br Br F F Br 4015 Br Br F F F 4016 Br F CH₃ H H 4017 Br F CH₃ H CH₃ 4018 Br F CH₃ H OCH₃ 4019 Br F CH₃ H Cl 4020 Br F CH₃ H Br 4021 Br F CH₃ H F 4022 Br F CH₃ CH₃ H 4023 Br F CH₃ CH₃ CH₃ 4024 Br F CH₃ CH₃ OCH₃ 4025 Br F CH₃ CH₃ Cl 4026 Br F CH₃ CH₃ Br 4027 Br F CH₃ CH₃ F 4028 Br F CH₃ OCH₃ H 4029 Br F CH₃ OCH₃ OCH₃ 4030 Br F CH₃ OCH₃ Cl 4031 Br F CH₃ OCH₃ Br 4032 Br F CH₃ OCH₃ F 4033 Br F CH₃ Cl H 4034 Br F CH₃ Cl OCH₃ 4035 Br F CH₃ Cl Cl 4036 Br F CH₃ Cl Br 4037 Br F CH₃ Cl F 4038 Br F CH₃ Br H 4039 Br F CH₃ Br OCH₃ 4040 Br F CH₃ Br Cl 4041 Br F CH₃ Br Br 4042 Br F CH₃ Br F 4043 Br F CH₃ F H 4044 Br F CH₃ F OCH₃ 4045 Br F CH₃ F Cl 4046 Br F CH₃ F Br 4047 Br F CH₃ F F 4048 Br F OCH₃ H H 4049 Br F OCH₃ H CH₃ 4050 Br F OCH₃ H OCH₃ 4051 Br F OCH₃ H Cl 4052 Br F OCH₃ H Br 4053 Br F OCH₃ H F 4054 Br F OCH₃ CH₃ H 4055 Br F OCH₃ CH₃ CH₃ 4056 Br F OCH₃ CH₃ Cl 4057 Br F OCH₃ CH₃ Br 4058 Br F OCH₃ CH₃ F 4059 Br F OCH₃ OCH₃ H 4060 Br F OCH₃ OCH₃ CH₃ 4061 Br F OCH₃ OCH₃ OCH₃ 4062 Br F OCH₃ OCH₃ Cl 4063 Br F OCH₃ OCH₃ Br 4064 Br F OCH₃ OCH₃ F 4065 Br F OCH₃ Cl H 4066 Br F OCH₃ Cl CH₃ 4067 Br F OCH₃ Cl Cl 4068 Br F OCH₃ Cl Br 4069 Br F OCH₃ Cl F 4070 Br F OCH₃ Br H 4071 Br F OCH₃ Br CH₃ 4072 Br F OCH₃ Br Cl 4073 Br F OCH₃ Br Br 4074 Br F OCH₃ Br F 4075 Br F OCH₃ F H 4076 Br F OCH₃ F CH₃ 4077 Br F OCH₃ F Cl 4078 Br F OCH₃ F Br 4079 Br F OCH₃ F F 4080 Br F Cl H H 4081 Br F Cl H CH₃ 4082 Br F Cl H OCH₃ 4083 Br F Cl H Cl 4084 Br F Cl H Br 4085 Br F Cl H F 4086 Br F Cl CH₃ H 4087 Br F Cl CH₃ CH₃ 4088 Br F Cl CH₃ OCH₃ 4089 Br F Cl CH₃ Br 4090 Br F Cl CH₃ F 4091 Br F Cl OCH₃ H 4092 Br F Cl OCH₃ CH₃ 4093 Br F Cl OCH₃ OCH₃ 4094 Br F Cl OCH₃ Br 4095 Br F Cl OCH₃ F 4096 Br F Cl Cl H 4097 Br F Cl Cl CH₃ 4098 Br F Cl Cl OCH₃ 4099 Br F Cl Cl Cl 4100 Br F Cl Cl Br 4101 Br F Cl Cl F 4102 Br F Cl Br H 4103 Br F Cl Br CH₃ 4104 Br F Cl Br OCH₃ 4105 Br F Cl Br Br 4106 Br F Cl F H 4107 Br F Cl F CH₃ 4108 Br F Cl F OCH₃ 4109 Br F Cl F Br 4110 Br F Cl F F 4111 Br F Br H H 4112 Br F Br H CH₃ 4113 Br F Br H OCH₃ 4114 Br F Br H Cl 4115 Br F Br H Br 4116 Br F Br H F 4117 Br F Br CH₃ H 4118 Br F Br CH₃ CH₃ 4119 Br F Br CH₃ OCH₃ 4120 Br F Br CH₃ Cl 4121 Br F Br CH₃ F 4122 Br F Br OCH₃ H 4123 Br F Br OCH₃ CH₃ 4124 Br F Br OCH₃ OCH₃ 4125 Br F Br OCH₃ Cl 4126 Br F Br OCH₃ F 4127 Br F Br Cl H 4128 Br F Br Cl CH₃ 4129 Br F Br Cl OCH₃ 4130 Br F Br Cl Cl 4131 Br F Br Cl F 4132 Br F Br Br H 4133 Br F Br Br CH₃ 4134 Br F Br Br OCH₃ 4135 Br F Br Br Cl 4136 Br F Br Br Br 4137 Br F Br Br F 4138 Br F Br F H 4139 Br F Br F CH₃ 4140 Br F Br F OCH₃ 4141 Br F Br F Cl 4142 Br F Br F F 4143 Br F F H H 4144 Br F F H CH₃ 4145 Br F F H OCH₃ 4146 Br F F H Cl 4147 Br F F H Br 4148 Br F F H F 4149 Br F F CH₃ H 4150 Br F F CH₃ CH₃ 4151 Br F F CH₃ OCH₃ 4152 Br F F CH₃ Cl 4153 Br F F CH₃ Br 4154 Br F F OCH₃ H 4155 Br F F OCH₃ CH₃ 4156 Br F F OCH₃ OCH₃ 4157 Br F F OCH₃ Cl 4158 Br F F OCH₃ Br 4159 Br F F Cl H 4160 Br F F Cl CH₃ 4161 Br F F Cl OCH₃ 4162 Br F F Cl Cl 4163 Br F F Cl Br 4164 Br F F Br H 4165 Br F F Br CH₃ 4166 Br F F Br OCH₃ 4167 Br F F Br Cl 4168 Br F F Br Br 4169 Br F F F H 4170 Br F F F CH₃ 4171 Br F F F OCH₃ 4172 Br F F F Cl 4173 Br F F F Br 4174 Br F F F F 4175 F CH₃ CH₃ H H 4176 F CH₃ CH₃ CH₃ H 4177 F CH₃ CH₃ OCH₃ H 4178 F CH₃ CH₃ Cl H 4179 F CH₃ CH₃ Br H 4180 F CH₃ CH₃ F H 4181 F CH₃ CH₃ H CH₃ 4182 F CH₃ CH₃ CH₃ CH₃ 4183 F CH₃ CH₃ H OCH₃ 4184 F CH₃ CH₃ CH₃ OCH₃ 4185 F CH₃ CH₃ OCH₃ OCH₃ 4186 F CH₃ CH₃ Cl OCH₃ 4187 F CH₃ CH₃ Br OCH₃ 4188 F CH₃ CH₃ F OCH₃ 4189 F CH₃ CH₃ H Cl 4190 F CH₃ CH₃ CH₃ Cl 4191 F CH₃ CH₃ OCH₃ Cl 4192 F CH₃ CH₃ Cl Cl 4193 F CH₃ CH₃ Br Cl 4194 F CH₃ CH₃ F Cl 4195 F CH₃ CH₃ H Br 4196 F CH₃ CH₃ CH₃ Br 4197 F CH₃ CH₃ OCH₃ Br 4198 F CH₃ CH₃ Cl Br 4199 F CH₃ CH₃ Br Br 4200 F CH₃ CH₃ F Br 4201 F CH₃ CH₃ H F 4202 F CH₃ CH₃ CH₃ F 4203 F CH₃ CH₃ OCH₃ F 4204 F CH₃ CH₃ Cl F 4205 F CH₃ CH₃ Br F 4206 F CH₃ CH₃ F F 4207 F CH₃ OCH₃ H H 4208 F CH₃ OCH₃ CH₃ H 4209 F CH₃ OCH₃ OCH₃ H 4210 F CH₃ OCH₃ Cl H 4211 F CH₃ OCH₃ Br H 4212 F CH₃ OCH₃ F H 4213 F CH₃ OCH₃ H CH₃ 4214 F CH₃ OCH₃ CH₃ CH₃ 4215 F CH₃ OCH₃ OCH₃ CH₃ 4216 F CH₃ OCH₃ Cl CH₃ 4217 F CH₃ OCH₃ Br CH₃ 4218 F CH₃ OCH₃ F CH₃ 4219 F CH₃ OCH₃ H OCH₃ 4220 F CH₃ OCH₃ OCH₃ OCH₃ 4221 F CH₃ OCH₃ H Cl 4222 F CH₃ OCH₃ CH₃ Cl 4223 F CH₃ OCH₃ OCH₃ Cl 4224 F CH₃ OCH₃ Cl Cl 4225 F CH₃ OCH₃ Br Cl 4226 F CH₃ OCH₃ F Cl 4227 F CH₃ OCH₃ H Br 4228 F CH₃ OCH₃ CH₃ Br 4229 F CH₃ OCH₃ OCH₃ Br 4230 F CH₃ OCH₃ Cl Br 4231 F CH₃ OCH₃ Br Br 4232 F CH₃ OCH₃ F Br 4233 F CH₃ OCH₃ H F 4234 F CH₃ OCH₃ CH₃ F 4235 F CH₃ OCH₃ OCH₃ F 4236 F CH₃ OCH₃ Cl F 4237 F CH₃ OCH₃ Br F 4238 F CH₃ OCH₃ F F 4239 F CH₃ Cl H H 4240 F CH₃ Cl CH₃ H 4241 F CH₃ Cl OCH₃ H 4242 F CH₃ Cl Cl H 4243 F CH₃ Cl Br H 4244 F CH₃ Cl F H 4245 F CH₃ Cl H CH₃ 4246 F CH₃ Cl CH₃ CH₃ 4247 F CH₃ Cl OCH₃ CH₃ 4248 F CH₃ Cl Cl CH₃ 4249 F CH₃ Cl Br CH₃ 4250 F CH₃ Cl F CH₃ 4251 F CH₃ Cl H OCH₃ 4252 F CH₃ Cl CH₃ OCH₃ 4253 F CH₃ Cl OCH₃ OCH₃ 4254 F CH₃ Cl Cl OCH₃ 4255 F CH₃ Cl Br OCH₃ 4256 F CH₃ Cl F OCH₃ 4257 F CH₃ Cl H Cl 4258 F CH₃ Cl Cl Cl 4259 F CH₃ Cl H Br 4260 F CH₃ Cl CH₃ Br 4261 F CH₃ Cl OCH₃ Br 4262 F CH₃ Cl Cl Br 4263 F CH₃ Cl Br Br 4264 F CH₃ Cl F Br 4265 F CH₃ Cl H F 4266 F CH₃ Cl CH₃ F 4267 F CH₃ Cl OCH₃ F 4268 F CH₃ Cl Cl F 4269 F CH₃ Cl F F 4270 F CH₃ Br H H 4271 F CH₃ Br CH₃ H 4272 F CH₃ Br OCH₃ H 4273 F CH₃ Br Cl H 4274 F CH₃ Br Br H 4275 F CH₃ Br F H 4276 F CH₃ Br H CH₃ 4277 F CH₃ Br CH₃ CH₃ 4278 F CH₃ Br OCH₃ CH₃ 4279 F CH₃ Br Cl CH₃ 4280 F CH₃ Br Br CH₃ 4281 F CH₃ Br F CH₃ 4282 F CH₃ Br H OCH₃ 4283 F CH₃ Br CH₃ OCH₃ 4284 F CH₃ Br OCH₃ OCH₃ 4285 F CH₃ Br Cl OCH₃ 4286 F CH₃ Br Br OCH₃ 4287 F CH₃ Br F OCH₃ 4288 F CH₃ Br H Cl 4289 F CH₃ Br CH₃ Cl 4290 F CH₃ Br OCH₃ Cl 4291 F CH₃ Br Cl Cl 4292 F CH₃ Br Br Cl 4293 F CH₃ Br F Cl 4294 F CH₃ Br H Br 4295 F CH₃ Br Br Br 4296 F CH₃ Br H F 4297 F CH₃ Br CH₃ F 4298 F CH₃ Br OCH₃ F 4299 F CH₃ Br Cl F 4300 F CH₃ Br Br F 4301 F CH₃ Br F F 4302 F CH₃ F H H 4303 F CH₃ F CH₃ H 4304 F CH₃ F OCH₃ H 4305 F CH₃ F Cl H 4306 F CH₃ F Br H 4307 F CH₃ F F H 4308 F CH₃ F H CH₃ 4309 F CH₃ F CH₃ CH₃ 4310 F CH₃ F OCH₃ CH₃ 4311 F CH₃ F Cl CH₃ 4312 F CH₃ F Br CH₃ 4313 F CH₃ F F CH₃ 4314 F CH₃ F H OCH₃ 4315 F CH₃ F CH₃ OCH₃ 4316 F CH₃ F OCH₃ OCH₃ 4317 F CH₃ F Cl OCH₃ 4318 F CH₃ F Br OCH₃ 4319 F CH₃ F F OCH₃ 4320 F CH₃ F H Cl 4321 F CH₃ F CH₃ Cl 4322 F CH₃ F OCH₃ Cl 4323 F CH₃ F Cl Cl 4324 F CH₃ F Br Cl 4325 F CH₃ F F Cl 4326 F CH₃ F H Br 4327 F CH₃ F CH₃ Br 4328 F CH₃ F OCH₃ Br 4329 F CH₃ F Cl Br 4330 F CH₃ F Br Br 4331 F CH₃ F F Br 4332 F CH₃ F H F 4333 F CH₃ F F F 4334 F OCH₃ CH₃ H H 4335 F OCH₃ CH₃ H CH₃ 4336 F OCH₃ CH₃ H OCH₃ 4337 F OCH₃ CH₃ H Cl 4338 F OCH₃ CH₃ H Br 4339 F OCH₃ CH₃ H F 4340 F OCH₃ CH₃ CH₃ H 4341 F OCH₃ CH₃ CH₃ CH₃ 4342 F OCH₃ CH₃ CH₃ OCH₃ 4343 F OCH₃ CH₃ CH₃ Cl 4344 F OCH₃ CH₃ CH₃ Br 4345 F OCH₃ CH₃ CH₃ F 4346 F OCH₃ CH₃ OCH₃ H 4347 F OCH₃ CH₃ OCH₃ OCH₃ 4348 F OCH₃ CH₃ OCH₃ Cl 4349 F OCH₃ CH₃ OCH₃ Br 4350 F OCH₃ CH₃ OCH₃ F 4351 F OCH₃ CH₃ Cl H 4352 F OCH₃ CH₃ Cl OCH₃ 4353 F OCH₃ CH₃ Cl Cl 4354 F OCH₃ CH₃ Cl Br 4355 F OCH₃ CH₃ Cl F 4356 F OCH₃ CH₃ Br H 4357 F OCH₃ CH₃ Br OCH₃ 4358 F OCH₃ CH₃ Br Cl 4359 F OCH₃ CH₃ Br Br 4360 F OCH₃ CH₃ Br F 4361 F OCH₃ CH₃ F H 4362 F OCH₃ CH₃ F OCH₃ 4363 F OCH₃ CH₃ F Cl 4364 F OCH₃ CH₃ F Br 4365 F OCH₃ CH₃ F F 4366 F OCH₃ OCH₃ H H 4367 F OCH₃ OCH₃ H CH₃ 4368 F OCH₃ OCH₃ H OCH₃ 4369 F OCH₃ OCH₃ H Cl 4370 F OCH₃ OCH₃ H Br 4371 F OCH₃ OCH₃ H F 4372 F OCH₃ OCH₃ CH₃ H 4373 F OCH₃ OCH₃ CH₃ CH₃ 4374 F OCH₃ OCH₃ CH₃ Cl 4375 F OCH₃ OCH₃ CH₃ Br 4376 F OCH₃ OCH₃ CH₃ F 4377 F OCH₃ OCH₃ OCH₃ H 4378 F OCH₃ OCH₃ OCH₃ CH₃ 4379 F OCH₃ OCH₃ OCH₃ OCH₃ 4380 F OCH₃ OCH₃ OCH₃ Cl 4381 F OCH₃ OCH₃ OCH₃ Br 4382 F OCH₃ OCH₃ OCH₃ F 4383 F OCH₃ OCH₃ Cl H 4384 F OCH₃ OCH₃ Cl CH₃ 4385 F OCH₃ OCH₃ Cl Cl 4386 F OCH₃ OCH₃ Cl Br 4387 F OCH₃ OCH₃ Cl F 4388 F OCH₃ OCH₃ Br H 4389 F OCH₃ OCH₃ Br CH₃ 4390 F OCH₃ OCH₃ Br Cl 4391 F OCH₃ OCH₃ Br Br 4392 F OCH₃ OCH₃ Br F 4393 F OCH₃ OCH₃ F H 4394 F OCH₃ OCH₃ F CH₃ 4395 F OCH₃ OCH₃ F Cl 4396 F OCH₃ OCH₃ F Br 4397 F OCH₃ OCH₃ F F 4398 F OCH₃ Cl H H 4399 F OCH₃ Cl H CH₃ 4400 F OCH₃ Cl H OCH₃ 4401 F OCH₃ Cl H Cl 4402 F OCH₃ Cl H Br 4403 F OCH₃ Cl H F 4404 F OCH₃ Cl CH₃ H 4405 F OCH₃ Cl CH₃ CH₃ 4406 F OCH₃ Cl CH₃ OCH₃ 4407 F OCH₃ Cl CH₃ Br 4408 F OCH₃ Cl CH₃ F 4409 F OCH₃ Cl OCH₃ H 4410 F OCH₃ Cl OCH₃ CH₃ 4411 F OCH₃ Cl OCH₃ OCH₃ 4412 F OCH₃ Cl OCH₃ Br 4413 F OCH₃ Cl OCH₃ F 4414 F OCH₃ Cl Cl H 4415 F OCH₃ Cl Cl CH₃ 4416 F OCH₃ Cl Cl OCH₃ 4417 F OCH₃ Cl Cl Cl 4418 F OCH₃ Cl Cl Br 4419 F OCH₃ Cl Cl F 4420 F OCH₃ Cl Br H 4421 F OCH₃ Cl Br CH₃ 4422 F OCH₃ Cl Br OCH₃ 4423 F OCH₃ Cl Br Br 4424 F OCH₃ Cl F H 4425 F OCH₃ Cl F CH₃ 4426 F OCH₃ Cl F OCH₃ 4427 F OCH₃ Cl F Br 4428 F OCH₃ Cl F F 4429 F OCH₃ Br H H 4430 F OCH₃ Br H CH₃ 4431 F OCH₃ Br H OCH₃ 4432 F OCH₃ Br H Cl 4433 F OCH₃ Br H Br 4434 F OCH₃ Br H F 4435 F OCH₃ Br CH₃ H 4436 F OCH₃ Br CH₃ CH₃ 4437 F OCH₃ Br CH₃ OCH₃ 4438 F OCH₃ Br CH₃ Cl 4439 F OCH₃ Br CH₃ F 4440 F OCH₃ Br OCH₃ H 4441 F OCH₃ Br OCH₃ CH₃ 4442 F OCH₃ Br OCH₃ OCH₃ 4443 F OCH₃ Br OCH₃ Cl 4444 F OCH₃ Br OCH₃ F 4445 F OCH₃ Br Cl H 4446 F OCH₃ Br Cl CH₃ 4447 F OCH₃ Br Cl OCH₃ 4448 F OCH₃ Br Cl Cl 4449 F OCH₃ Br Cl F 4450 F OCH₃ Br Br H 4451 F OCH₃ Br Br CH₃ 4452 F OCH₃ Br Br OCH₃ 4453 F OCH₃ Br Br Cl 4454 F OCH₃ Br Br Br 4455 F OCH₃ Br Br F 4456 F OCH₃ Br F H 4457 F OCH₃ Br F CH₃ 4458 F OCH₃ Br F OCH₃ 4459 F OCH₃ Br F Cl 4460 F OCH₃ Br F F 4461 F OCH₃ F H H 4462 F OCH₃ F H CH₃ 4463 F OCH₃ F H OCH₃ 4464 F OCH₃ F H Cl 4465 F OCH₃ F H Br 4466 F OCH₃ F H F 4467 F OCH₃ F CH₃ H 4468 F OCH₃ F CH₃ CH₃ 4469 F OCH₃ F CH₃ OCH₃ 4470 F OCH₃ F CH₃ Cl 4471 F OCH₃ F CH₃ Br 4472 F OCH₃ F OCH₃ H 4473 F OCH₃ F OCH₃ CH₃ 4474 F OCH₃ F OCH₃ OCH₃ 4475 F OCH₃ F OCH₃ Cl 4476 F OCH₃ F OCH₃ Br 4477 F OCH₃ F Cl H 4478 F OCH₃ F Cl CH₃ 4479 F OCH₃ F Cl OCH₃ 4480 F OCH₃ F Cl Cl 4481 F OCH₃ F Cl Br 4482 F OCH₃ F Br H 4483 F OCH₃ F Br CH₃ 4484 F OCH₃ F Br OCH₃ 4485 F OCH₃ F Br Cl 4486 F OCH₃ F Br Br 4487 F OCH₃ F F H 4488 F OCH₃ F F CH₃ 4489 F OCH₃ F F OCH₃ 4490 F OCH₃ F F Cl 4491 F OCH₃ F F Br 4492 F OCH₃ F F F 4493 F Cl CH₃ H H 4494 F Cl CH₃ H CH₃ 4495 F Cl CH₃ H OCH₃ 4496 F Cl CH₃ H Cl 4497 F Cl CH₃ H Br 4498 F Cl CH₃ H F 4499 F Cl CH₃ CH₃ H 4500 F Cl CH₃ CH₃ CH₃ 4501 F Cl CH₃ CH₃ OCH₃ 4502 F Cl CH₃ CH₃ Cl 4503 F Cl CH₃ CH₃ Br 4504 F Cl CH₃ CH₃ F 4505 F Cl CH₃ OCH₃ H 4506 F Cl CH₃ OCH₃ OCH₃ 4507 F Cl CH₃ OCH₃ Cl 4508 F Cl CH₃ OCH₃ Br 4509 F Cl CH₃ OCH₃ F 4510 F Cl CH₃ Cl H 4511 F Cl CH₃ Cl OCH₃ 4512 F Cl CH₃ Cl Cl 4513 F Cl CH₃ Cl Br 4514 F Cl CH₃ Cl F 4515 F Cl CH₃ Br H 4516 F Cl CH₃ Br OCH₃ 4517 F Cl CH₃ Br Cl 4518 F Cl CH₃ Br Br 4519 F Cl CH₃ Br F 4520 F Cl CH₃ F H 4521 F Cl CH₃ F OCH₃ 4522 F Cl CH₃ F Cl 4523 F Cl CH₃ F Br 4524 F Cl CH₃ F F 4525 F Cl OCH₃ H H 4526 F Cl OCH₃ H CH₃ 4527 F Cl OCH₃ H OCH₃ 4528 F Cl OCH₃ H Cl 4529 F Cl OCH₃ H Br 4530 F Cl OCH₃ H F 4531 F Cl OCH₃ CH₃ H 4532 F Cl OCH₃ CH₃ CH₃ 4533 F Cl OCH₃ CH₃ Cl 4534 F Cl OCH₃ CH₃ Br 4535 F Cl OCH₃ CH₃ F 4536 F Cl OCH₃ OCH₃ H 4537 F Cl OCH₃ OCH₃ CH₃ 4538 F Cl OCH₃ OCH₃ OCH₃ 4539 F Cl OCH₃ OCH₃ Cl 4540 F Cl OCH₃ OCH₃ Br 4541 F Cl OCH₃ OCH₃ F 4542 F Cl OCH₃ Cl H 4543 F Cl OCH₃ Cl CH₃ 4544 F Cl OCH₃ Cl Cl 4545 F Cl OCH₃ Cl Br 4546 F Cl OCH₃ Cl F 4547 F Cl OCH₃ Br H 4548 F Cl OCH₃ Br CH₃ 4549 F Cl OCH₃ Br Cl 4550 F Cl OCH₃ Br Br 4551 F Cl OCH₃ Br F 4552 F Cl OCH₃ F H 4553 F Cl OCH₃ F CH₃ 4554 F Cl OCH₃ F Cl 4555 F Cl OCH₃ F Br 4556 F Cl OCH₃ F F 4557 F Cl Cl H H 4558 F Cl Cl H CH₃ 4559 F Cl Cl H OCH₃ 4560 F Cl Cl H Cl 4561 F Cl Cl H Br 4562 F Cl Cl H F 4563 F Cl Cl CH₃ H 4564 F Cl Cl CH₃ CH₃ 4565 F Cl Cl CH₃ OCH₃ 4566 F Cl Cl CH₃ Br 4567 F Cl Cl CH₃ F 4568 F Cl Cl OCH₃ H 4569 F Cl Cl OCH₃ CH₃ 4570 F Cl Cl OCH₃ OCH₃ 4571 F Cl Cl OCH₃ Br 4572 F Cl Cl OCH₃ F 4573 F Cl Cl Cl H 4574 F Cl Cl Cl CH₃ 4575 F Cl Cl Cl OCH₃ 4576 F Cl Cl Cl Cl 4577 F Cl Cl Cl Br 4578 F Cl Cl Cl F 4579 F Cl Cl Br H 4580 F Cl Cl Br CH₃ 4581 F Cl Cl Br OCH₃ 4582 F Cl Cl Br Br 4583 F Cl Cl F H 4584 F Cl Cl F CH₃ 4585 F Cl Cl F OCH₃ 4586 F Cl Cl F Br 4587 F Cl Cl F F 4588 F Cl Br H H 4589 F Cl Br H CH₃ 4590 F Cl Br H OCH₃ 4591 F Cl Br H Cl 4592 F Cl Br H Br 4593 F Cl Br H F 4594 F Cl Br CH₃ H 4595 F Cl Br CH₃ CH₃ 4596 F Cl Br CH₃ OCH₃ 4597 F Cl Br CH₃ Cl 4598 F Cl Br CH₃ F 4599 F Cl Br OCH₃ H 4600 F Cl Br OCH₃ CH₃ 4601 F Cl Br OCH₃ OCH₃ 4602 F Cl Br OCH₃ Cl 4603 F Cl Br OCH₃ F 4604 F Cl Br Cl H 4605 F Cl Br Cl CH₃ 4606 F Cl Br Cl OCH₃ 4607 F Cl Br Cl Cl 4608 F Cl Br Cl F 4609 F Cl Br Br H 4610 F Cl Br Br CH₃ 4611 F Cl Br Br OCH₃ 4612 F Cl Br Br Cl 4613 F Cl Br Br Br 4614 F Cl Br Br F 4615 F Cl Br F H 4616 F Cl Br F CH₃ 4617 F Cl Br F OCH₃ 4618 F Cl Br F Cl 4619 F Cl Br F F 4620 F Cl F H H 4621 F Cl F H CH₃ 4622 F Cl F H OCH₃ 4623 F Cl F H Cl 4624 F Cl F H Br 4625 F Cl F H F 4626 F Cl F CH₃ H 4627 F Cl F CH₃ CH₃ 4628 F Cl F CH₃ OCH₃ 4629 F Cl F CH₃ Cl 4630 F Cl F CH₃ Br 4631 F Cl F OCH₃ H 4632 F Cl F OCH₃ CH₃ 4633 F Cl F OCH₃ OCH₃ 4634 F Cl F OCH₃ Cl 4635 F Cl F OCH₃ Br 4636 F Cl F Cl H 4637 F Cl F Cl CH₃ 4638 F Cl F Cl OCH₃ 4639 F Cl F Cl Cl 4640 F Cl F Cl Br 4641 F Cl F Br H 4642 F Cl F Br CH₃ 4643 F Cl F Br OCH₃ 4644 F Cl F Br Cl 4645 F Cl F Br Br 4646 F Cl F F H 4647 F Cl F F CH₃ 4648 F Cl F F OCH₃ 4649 F Cl F F Cl 4650 F Cl F F Br 4651 F Cl F F F 4652 F Br CH₃ H H 4653 F Br CH₃ H CH₃ 4654 F Br CH₃ H OCH₃ 4655 F Br CH₃ H Cl 4656 F Br CH₃ H Br 4657 F Br CH₃ H F 4658 F Br CH₃ CH₃ H 4659 F Br CH₃ CH₃ CH₃ 4660 F Br CH₃ CH₃ OCH₃ 4661 F Br CH₃ CH₃ Cl 4662 F Br CH₃ CH₃ Br 4663 F Br CH₃ CH₃ F 4664 F Br CH₃ OCH₃ H 4665 F Br CH₃ OCH₃ OCH₃ 4666 F Br CH₃ OCH₃ Cl 4667 F Br CH₃ OCH₃ Br 4668 F Br CH₃ OCH₃ F 4669 F Br CH₃ Cl H 4670 F Br CH₃ Cl OCH₃ 4671 F Br CH₃ Cl Cl 4672 F Br CH₃ Cl Br 4673 F Br CH₃ Cl F 4674 F Br CH₃ Br H 4675 F Br CH₃ Br OCH₃ 4676 F Br CH₃ Br Cl 4677 F Br CH₃ Br Br 4678 F Br CH₃ Br F 4679 F Br CH₃ F H 4680 F Br CH₃ F OCH₃ 4681 F Br CH₃ F Cl 4682 F Br CH₃ F Br 4683 F Br CH₃ F F 4684 F Br OCH₃ H H 4685 F Br OCH₃ H CH₃ 4686 F Br OCH₃ H OCH₃ 4687 F Br OCH₃ H Cl 4688 F Br OCH₃ H Br 4689 F Br OCH₃ H F 4690 F Br OCH₃ CH₃ H 4691 F Br OCH₃ CH₃ CH₃ 4692 F Br OCH₃ CH₃ Cl 4693 F Br OCH₃ CH₃ Br 4694 F Br OCH₃ CH₃ F 4695 F Br OCH₃ OCH₃ H 4696 F Br OCH₃ OCH₃ CH₃ 4697 F Br OCH₃ OCH₃ OCH₃ 4698 F Br OCH₃ OCH₃ Cl 4699 F Br OCH₃ OCH₃ Br 4700 F Br OCH₃ OCH₃ F 4701 F Br OCH₃ Cl H 4702 F Br OCH₃ Cl CH₃ 4703 F Br OCH₃ Cl Cl 4704 F Br OCH₃ Cl Br 4705 F Br OCH₃ Cl F 4706 F Br OCH₃ Br H 4707 F Br OCH₃ Br CH₃ 4708 F Br OCH₃ Br Cl 4709 F Br OCH₃ Br Br 4710 F Br OCH₃ Br F 4711 F Br OCH₃ F H 4712 F Br OCH₃ F CH₃ 4713 F Br OCH₃ F Cl 4714 F Br OCH₃ F Br 4715 F Br OCH₃ F F 4716 F Br Cl H H 4717 F Br Cl H CH₃ 4718 F Br Cl H OCH₃ 4719 F Br Cl H Cl 4720 F Br Cl H Br 4721 F Br Cl H F 4722 F Br Cl CH₃ H 4723 F Br Cl CH₃ CH₃ 4724 F Br Cl CH₃ OCH₃ 4725 F Br Cl CH₃ Br 4726 F Br Cl CH₃ F 4727 F Br Cl OCH₃ H 4728 F Br Cl OCH₃ CH₃ 4729 F Br Cl OCH₃ OCH₃ 4730 F Br Cl OCH₃ Br 4731 F Br Cl OCH₃ F 4732 F Br Cl Cl H 4733 F Br Cl Cl CH₃ 4734 F Br Cl Cl OCH₃ 4735 F Br Cl Cl Cl 4736 F Br Cl Cl Br 4737 F Br Cl Cl F 4738 F Br Cl Br H 4739 F Br Cl Br CH₃ 4740 F Br Cl Br OCH₃ 4741 F Br Cl Br Br 4742 F Br Cl F H 4743 F Br Cl F CH₃ 4744 F Br Cl F OCH₃ 4745 F Br Cl F Br 4746 F Br Cl F F 4747 F Br Br H H 4748 F Br Br H CH₃ 4749 F Br Br H OCH₃ 4750 F Br Br H Cl 4751 F Br Br H Br 4752 F Br Br H F 4753 F Br Br CH₃ H 4754 F Br Br CH₃ CH₃ 4755 F Br Br CH₃ OCH₃ 4756 F Br Br CH₃ Cl 4757 F Br Br CH₃ F 4758 F Br Br OCH₃ H 4759 F Br Br OCH₃ CH₃ 4760 F Br Br OCH₃ OCH₃ 4761 F Br Br OCH₃ Cl 4762 F Br Br OCH₃ F 4763 F Br Br Cl H 4764 F Br Br Cl CH₃ 4765 F Br Br Cl OCH₃ 4766 F Br Br Cl Cl 4767 F Br Br Cl F 4768 F Br Br Br H 4769 F Br Br Br CH₃ 4770 F Br Br Br OCH₃ 4771 F Br Br Br Cl 4772 F Br Br Br Br 4773 F Br Br Br F 4774 F Br Br F H 4775 F Br Br F CH₃ 4776 F Br Br F OCH₃ 4777 F Br Br F Cl 4778 F Br Br F F 4779 F Br F H H 4780 F Br F H CH₃ 4781 F Br F H OCH₃ 4782 F Br F H Cl 4783 F Br F H Br 4784 F Br F H F 4785 F Br F CH₃ H 4786 F Br F CH₃ CH₃ 4787 F Br F CH₃ OCH₃ 4788 F Br F CH₃ Cl 4789 F Br F CH₃ Br 4790 F Br F OCH₃ H 4791 F Br F OCH₃ CH₃ 4792 F Br F OCH₃ OCH₃ 4793 F Br F OCH₃ Cl 4794 F Br F OCH₃ Br 4795 F Br F Cl H 4796 F Br F Cl CH₃ 4797 F Br F Cl OCH₃ 4798 F Br F Cl Cl 4799 F Br F Cl Br 4800 F Br F Br H 4801 F Br F Br CH₃ 4802 F Br F Br OCH₃ 4803 F Br F Br Cl 4804 F Br F Br Br 4805 F Br F F H 4806 F Br F F CH₃ 4807 F Br F F OCH₃ 4808 F Br F F Cl 4809 F Br F F Br 4810 F Br F F F 4811 F F CH₃ H H 4812 F F CH₃ H CH₃ 4813 F F CH₃ H OCH₃ 4814 F F CH₃ H Cl 4815 F F CH₃ H Br 4816 F F CH₃ H F 4817 F F CH₃ CH₃ H 4818 F F CH₃ CH₃ CH₃ 4819 F F CH₃ CH₃ OCH₃ 4820 F F CH₃ CH₃ Cl 4821 F F CH₃ CH₃ Br 4822 F F CH₃ CH₃ F 4823 F F CH₃ OCH₃ H 4824 F F CH₃ OCH₃ OCH₃ 4825 F F CH₃ OCH₃ Cl 4826 F F CH₃ OCH₃ Br 4827 F F CH₃ OCH₃ F 4828 F F CH₃ Cl H 4829 F F CH₃ Cl OCH₃ 4830 F F CH₃ Cl Cl 4831 F F CH₃ Cl Br 4832 F F CH₃ Cl F 4833 F F CH₃ Br H 4834 F F CH₃ Br OCH₃ 4835 F F CH₃ Br Cl 4836 F F CH₃ Br Br 4837 F F CH₃ Br F 4838 F F CH₃ F H 4839 F F CH₃ F OCH₃ 4840 F F CH₃ F Cl 4841 F F CH₃ F Br 4842 F F CH₃ F F 4843 F F OCH₃ H H 4844 F F OCH₃ H CH₃ 4845 F F OCH₃ H OCH₃ 4846 F F OCH₃ H Cl 4847 F F OCH₃ H Br 4848 F F OCH₃ H F 4849 F F OCH₃ CH₃ H 4850 F F OCH₃ CH₃ CH₃ 4851 F F OCH₃ CH₃ Cl 4852 F F OCH₃ CH₃ Br 4853 F F OCH₃ CH₃ F 4854 F F OCH₃ OCH₃ H 4855 F F OCH₃ OCH₃ CH₃ 4856 F F OCH₃ OCH₃ OCH₃ 4857 F F OCH₃ OCH₃ Cl 4858 F F OCH₃ OCH₃ Br 4859 F F OCH₃ OCH₃ F 4860 F F OCH₃ Cl H 4861 F F OCH₃ Cl CH₃ 4862 F F OCH₃ Cl Cl 4863 F F OCH₃ Cl Br 4864 F F OCH₃ Cl F 4865 F F OCH₃ Br H 4866 F F OCH₃ Br CH₃ 4867 F F OCH₃ Br Cl 4868 F F OCH₃ Br Br 4869 F F OCH₃ Br F 4870 F F OCH₃ F H 4871 F F OCH₃ F CH₃ 4872 F F OCH₃ F Cl 4873 F F OCH₃ F Br 4874 F F OCH₃ F F 4875 F F Cl H H 4876 F F Cl H CH₃ 4877 F F Cl H OCH₃ 4878 F F Cl H Cl 4879 F F Cl H Br 4880 F F Cl H F 4881 F F Cl CH₃ H 4882 F F Cl CH₃ CH₃ 4883 F F Cl CH₃ OCH₃ 4884 F F Cl CH₃ Br 4885 F F Cl CH₃ F 4886 F F Cl OCH₃ H 4887 F F Cl OCH₃ CH₃ 4888 F F Cl OCH₃ OCH₃ 4889 F F Cl OCH₃ Br 4890 F F Cl OCH₃ F 4891 F F Cl Cl H 4892 F F Cl Cl CH₃ 4893 F F Cl Cl OCH₃ 4894 F F Cl Cl Cl 4895 F F Cl Cl Br 4896 F F Cl Cl F 4897 F F Cl Br H 4898 F F Cl Br CH₃ 4899 F F Cl Br OCH₃ 4900 F F Cl Br Br 4901 F F Cl F H 4902 F F Cl F CH₃ 4903 F F Cl F OCH₃ 4904 F F Cl F Br 4905 F F Cl F F 4906 F F Br H H 4907 F F Br H CH₃ 4908 F F Br H OCH₃ 4909 F F Br H Cl 4910 F F Br H Br 4911 F F Br H F 4912 F F Br CH₃ H 4913 F F Br CH₃ CH₃ 4914 F F Br CH₃ OCH₃ 4915 F F Br CH₃ Cl 4916 F F Br CH₃ F 4917 F F Br OCH₃ H 4918 F F Br OCH₃ CH₃ 4919 F F Br OCH₃ OCH₃ 4920 F F Br OCH₃ Cl 4921 F F Br OCH₃ F 4922 F F Br Cl H 4923 F F Br Cl CH₃ 4924 F F Br Cl OCH₃ 4925 F F Br Cl Cl 4926 F F Br Cl F 4927 F F Br Br H 4928 F F Br Br CH₃ 4929 F F Br Br OCH₃ 4930 F F Br Br Cl 4931 F F Br Br Br 4932 F F Br Br F 4933 F F Br F H 4934 F F Br F CH₃ 4935 F F Br F OCH₃ 4936 F F Br F Cl 4937 F F Br F F 4938 F F F H H 4939 F F F H CH₃ 4940 F F F H OCH₃ 4941 F F F H Cl 4942 F F F H Br 4943 F F F H F 4944 F F F CH₃ H 4945 F F F CH₃ CH₃ 4946 F F F CH₃ OCH₃ 4947 F F F CH₃ Cl 4948 F F F CH₃ Br 4949 F F F OCH₃ H 4950 F F F OCH₃ CH₃ 4951 F F F OCH₃ OCH₃ 4952 F F F OCH₃ Cl 4953 F F F OCH₃ Br 4954 F F F Cl H 4955 F F F Cl CH₃ 4956 F F F Cl OCH₃ 4957 F F F Cl Cl 4958 F F F Cl Br 4959 F F F Br H 4960 F F F Br CH₃ 4961 F F F Br OCH₃ 4962 F F F Br Cl 4963 F F F Br Br 4964 F F F F H 4965 F F F F CH₃ 4966 F F F F OCH₃ 4967 F F F F Cl 4968 F F F F Br 4969 F F F F F

The compounds of Formulas I, II, III, IV, and V are MCH receptor antagonists, as demonstrated by the ligand binding assays described hereinbelow. MCH receptor antagonist activity has been correlated with pharmaceutical activity for the treatment of eating disorders such as obesity and hyperphagia, and diabetes. Compounds of Formula I exhibit good activity in standard in vitro MCH calcium mobilization assays and/or receptor binding assays, specifically in the assays described hereinbelow, see Examples 6 and 7. Generally, compounds of Formula I have a K_(i) of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 μM or less, as determined by a standard in vitro MCH receptor mediated calcium mobilization assay as exemplified by Example 6, hereinbelow. Generally compounds of Formula I are MCH receptor antagonists and exhibit IC₅₀ values of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vitro MCH receptor binding assay such as is described hereinbelow in Example 7.

Preferably, the MCH receptor antagonists of Formula I bind specifically, and still more preferably with high affinity, to MCH receptors.

General Synthetic Procedures

The compounds described herein may be synthesized according to the following procedures of Schemes 1-3, wherein A, W, X, Z, and R¹-R⁸ are as defined for Formulas I-V, above.

Compounds of Formula I can be prepared by the methods of generic scheme 1. Coupling of carbonyl compounds such as aldehydes or ketones 1 with amines 2 and compounds 3 (where A′ is a ring precursor) forms an intermediate precursor that is then cyclized to form the compounds 4 of Formula I.

Compounds of Formula II-V can be prepared by general scheme 2. Using a modified Ugi synthesis, [(a) Ugi, I., Angew. Chem. Int. Ed. Engl. 1962, 1, 8; (b) Ugi, I. and Steinbruckner, C., Chem Ber. 1961, 94, 734; (c) Ugi, I. et al., Endeavor 1994, 18, 115; (d) Domling, A., Combinatorial Chemistry & High Throughput Screening 1998, 1, 1] carbonyl compounds such as aldehydes or ketones 1 with piperazines 5 and isocyanides 6 forms an intermediate precursor that is cyclized, such as with TMSN₃, to form tetrazoles 7.

Isoxazoles compounds can be prepared by general scheme 3. Cycloaddition reactions of substituted propynyl piperazines 8, such as with nitrile oxide, form isoxazoles 9.

The following examples illustrate the invention.

EXAMPLE 1

Benzaldehyde (102 mL, 1 mmol), trans-cinnamylpiperazine (202 mg, 1 mmol), 2,6-dimethylphenylisocyanide (131 mg, 1 mmol), and TMSN₃ (132 mL, 1 mmol) were added to 40 mL methanol in order of their participation in the Ugi reaction. After 18 hours the solution was concentrated to yield a colorless oil. The product was purified by FCC (2% MeOH/CHCl₃) to yield a colorless oil.

EXAMPLE 2

Biphenylcarboxaldehyde (182 mg, 1 mmol), TMSN₃ (132 mL, 1 mmol), 2,6-dimethylphenylisocyanide (131 mg, 1 mmol) and trans-cinnamylpiperazine (202 mg, 1 mmol) were added to 40 mL methanol in order of their participation in the Ugi reaction. After 18 hours, the solution was concentrated to yield a colorless oil, which was purified by FCC (1% MeOH/CHCl₃). Because of rapid elution of product in 1% MeOH/CHCl₃, only one fraction was pure. Other fractions were combined and evaporated. The product was a light yellow oil, which was briefly a white solid during evaporation.

EXAMPLE 3

The compound of Example 2 (168 mg, 0.359 mmol) was dissolved in 5 mL DCM and 1.0 M HCl/ether (0.72 mL) was added. After 1 hour, the resulting white precipitate was filtered.

EXAMPLE 4

Amine (0.93 g, 5 mmol), aldehyde (0.51 mL, 5 mmol), TMSN₃ (0.66 mL, 5 mmol) and isocyanide (0.66 g, 5 mmol) were dissolved in 200 mL MeOH in order of participation in the Ugi reaction. After 4 days, the reaction solution was about 75% evaporated, and the white precipitate was filtered, washed with cold MeOH, and air dried.

EXAMPLE 5

The compound of Example 4 (37 mg) and 2 mL 10% TFA/DCE were shaken for 18 hours and concentrated to give a colorless oil. The product was purified by LC.

EXAMPLE 6 Functional Assays

Human embryonic kidney cells (293 total) expressing either human, rat, or mouse MCH receptor were harvested from 150 mm culture dishes using PBS. Spinning at 1500 rpm for 2 minutes initially pelleted cells. The resulting pellet was then homogenized in 15 mL ice cold sucrose buffer (25 mM HEPES, 0.3 M sucrose, pH 7.4) with a motorized, glass fitted, Teflon® homogenizer. The homogenate was centrifuged at 48,000×g at 4° C. for 10 minutes, resuspended in 15 mL assay buffer (25 mM HEPES, 10 mM mgCl₂, 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc®, 1 μM Phosphoramidon, pH 7.4) with a Tissue-Tearor® (Biospec Products) and centrifuged again at 48,000×g for 10 minutes. The pellet was homogenized for a third time in 15 mL assay buffer using the Tissue-Tearor® and again centrifuged at 48,000×g for 10 minutes. The resulting pellet was resuspended in assay buffer at a wet weight concentration of 10-20 mg/mL.

Pharmacological analyses were conducted using either a HT-PS100 device (Axiom Biotechnologies, San Diego, Calif.), which provides high-resolution dose-response fluorometric measurements of [Ca⁺⁺]_(i) mobilization, or using a FLIPR® device (Molecular Devices, Sunnyvale, Calif.).

HT-PS100 Protocol:

Materials: HEK 293 cells were stably transfected with the rat MCH1 receptor and maintained under G418 antibiotic pressure. HT-PS100 assay buffer consisted of Physiological Saline Solution (145 mM NaCl, 5.4 mM KCL, 1.0 mM NaH₂PO₄, 1.8 mM CaCl₂, 0.8 mM mgSO₄, 15.0 mM HEPES, pH 7.4, 11.2 mM glucose)+50 μM Pluronic-F127. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 100 μM in 96 well plates.

Methods: HEK 293 stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, Md.) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by 10′ treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4° C.) hybridoma medium (Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, Mo.) and resuspended at 2×10⁶ cells/mL in the same medium. The resuspended cells were loaded with the fluorescent calcium indicator Fura-2 by incubating with Fura-2AM (Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature. The loaded cells were then washed twice with hybridoma medium, adjusted to 2×10⁵ cells/mL and kept at ambient temperature in a spinner flask under gentle stirring for up to 6 hours during the experiment.

Receptor-stimulated intracellular calcium responses were detected in the flow-through detector cuvette of the HT-PS100 by monitoring increases in the ratio of Fura-2 fluorescence intensities R_(340/380) measured at alternating 340/380 nm excitation and 510 nm emission.

Preliminary static experiments, conducted to determine the kinetics of MCHlR's dose response to MCH peptide, indicated the optimum time point to capture the maximum Ca⁺⁺ transients was 30 s. No interference with DMSO was seen up to 1%. Based on these observations, subsequent experiments were conducted on the HT-PS100 to generate high resolution dose response curves, characterize agonist/antagonist properties, and evaluate antagonist potencies via Schild experiments. During HT-PS100 validation, reproducible EC₅₀s for MCH of 10 nM were generated within a broad range of cell passage and harvest density. HT-PS100 gradient generation was calibrated with a standardized stock of fluorescein.

Test compounds were screened for MCH1R activity in the HT-PS100 for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 100 μM. Antagonist activity was tested by 30 s pre-incubation of cells at a compound concentration of 100 μM, with subsequent introduction of MCH at a concentration 5-fold of EC₅₀ as determined in preliminary experiments. Compounds that showed inhibition of the MCH-induced Ca⁺⁺ response were automatically tagged for re-interrogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the HT-PS100 for selected compounds by 30 s pre-incubation of cells with antagonist compounds prior to administering MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells 30 s before introducing a gradient of increasing MCH concentration. Values for compound pA₂ were calculated by linear regression of Log(DR−1) MCH EC₅₀ as a function of Log(antagonist concentration), where DR is the dose ratio of MCH EC₅₀ values determined in the presence and absence of antagonist.

The following compounds had K_(i) values of 100 nM or less in the HT-PS100 assay: Compound Nos. 1, 4, 48, 53, 55, 56, 57, 60, 61, 62, 64, 70, 76, 77, 78, 79, 82, 83, and 84.

FLIPR® Protocol:

Materials: Pharmacological analysis was conducted using a FLIPR® device (Molecular Devices, Sunnyvale, Calif.). CHOK1-Gqi cells were stably transfected with the rat MCH1 receptor and maintained under G418 antibiotic pressure. FLIPR® assay buffer consisted of phenol red-free DMEM+2.5 mM probenecid. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 10 μM in 96 well black, flat bottom, collagen-I coated plates (Becton Dickinson, Bedford, Mass.).

Methods: CHOK1-Gqi cells stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, Md.) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by 10′ treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4° C.) hybridoma medium (Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, Mo.) and replated onto 96 well black, flat bottom, collagen-I coated plates to a density of 10,000 cells/well. The cells were then loaded with the fluorescent calcium indicator Fura-2 (Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature. The loaded cells were then washed twice with 90 μl/well of wash buffer (1×HBSS, 20 mM HEPES, 2.5 mM probenecid).

Receptor-stimulated intracellular calcium responses were detected using FLIPR® by monitoring increases in the Fura-2 fluorescence response.

Test compounds were screened for MCH1R activity in the FLIPR® for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 1 μM. Antagonist activity was tested by 10 min pre-incubation of cells at a compound concentration of defined to be 300× the EC₅₀ of MCH (typically 1 μM), with subsequent introduction of MCH at a concentration 5-fold of EC₅₀ as determined in preliminary experiments. Compounds that showed inhibition of MCH induced MCH1R dependant Ca⁺⁺ responses were automatically tagged for re-interogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the FLIPR® for selected compounds by co-administering antagonist compounds together with MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells in a gradient of increasing MCH concentration. Values for compound pA₂ were calculated by linear regression of MCH EC₅₀s as a function of antagonist concentration.

The following compounds had K_(i) values of 100 μM or less in the rMCH FLIPR® assay: Compound Nos. 1, 4, 11, 12, 20, 48, 53, 55, 56, 57, 60, 61, 62, 64, 70, 76, 77, 78, 79, 82, 83, 84, 86, 87, 92, 133, 134, 135, 143, 144, 145, 145, 147, 148, 150, and 151. Of these, Compound Nos. 11 and 56 had K_(i) values of 100 nM or less in this assay.

The following compounds had K_(i) values of 100 μM or less in the hMCH FLIPR® assay: Compound Nos. 1, 4, 20, 48, 53, 55, 56, 57, 60, 61, 62, 70, 77, 78, 79, 82, 83, 84, 86, 87, 133, 134, 135, 143, 144, 145, 147, 148, 150, and 151. Of these, Compound Nos. 4, 48, 53, 55, 56, 70, 79, and 82 had K_(i) values of 100 nM or less in this assay.

EXAMPLE 7 Ligand Binding Assay

Binding assays were determined as described below using mouse, rat or human MCH 1 receptors (mMCH1R, rMCH1R, and hMCH1R, respectively) expressed in HEK 293; IC₅₀ values were calculated.

Binding assays were performed in 96-well U-bottom plates. Membranes (100 μg tissue) were incubated at 30° C. for 90 minutes in assay buffer with various peptides in the presence of 0.2 nM ¹²⁵I native-MCH (Perkin-Elmer Life Sciences, Boston, Mass.) in 100 μL total volume. Non-specific binding was assessed in the presence of 1 μM cold native-MCH. The reaction was terminated by rapid filtration through Unfilter-96 GF/C glass fiber filter plates (FilterMate® 196 Harvester, Packard Instrument Co., Meriden, Conn.) pre-soaked in PBS/0.5% BSA, followed by three washes with 300 μL ice-cold water. Bound radioactivity was determined using a TopCount® microplate scintillation and luminescence counter (Packard Instrument Co., Meriden, Conn.). Nonlinear regression analyses of drug concentration curves were performed using GraphPad Prism® (GraphPad Software, Inc., San Diego, Calif.).

The following compounds had IC₅₀ values of 100 μM or less in the rMCH assay: Compound Nos. 1, 4, 11, 12, 14, 15, 19, 20, 21, 22, 24, 26, 27, 28, 29, 29, 30, 31, 33, 35, 36, 37, 38, 39, 46, 48, 52, 53, 55, 56, 57, 58, 60, 61, 62, 63, 64, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 92, 99, 118, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 142, 143, 144, 145, 147, 148, 150, 151, 154, 156, 162, 163, and 164. Of these, Compound Nos. 1, 11, 56, 70, 79, 84, 129, 134, 136, 137, 138, 139, 140, 142, 144, and 163 had IC₅₀ values of 100 nM or less in the rMCH assay.

The following compounds had IC₅₀ values of 100 μM or less in the hMCH assay: Compound Nos. 1, 4, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 26, 29, 30, 31, 33, 35, 36, 37, 38, 39, 42, 46, 48, 52, 53, 55, 56, 57, 58, 60, 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 91, 92, 133, 134, 135, 142, 143, 144, 145, 147, 148, 150, 151, and 164. Of these, Compound Nos. 1, 4, 20, 55, 56, 62, 64, 70, 76, 77, 78, 84, 134, 142, and 144 had IC₅₀ values of 100 nM or less in the hMCH assay.

In view of the above, it will be seen that the several objects of the invention are achieved.

The above description of the embodiments and examples are intended only to acquaint others skilled in the art with the invention, its principles, and its practical application, so that others skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. The present invention, therefore, is not limited to the above embodiments, and may be variously modified.

With reference to the use of the word(s) “comprise” or “comprises” or “comprising” or “including” or “having” in the above description and/or in the following claims, it should be noted that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that each of those words is to be so interpreted in construing the above description and/or the following claims. When introducing elements of the present invention or the preferred embodiment(s) thereof, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements.

In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.

As various changes could be made in the above compounds and methods without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.

The entire texts of all U.S. Patents and other references cited herein are hereby incorporated by reference into this patent. 

1. A compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof:

wherein A is selected from the group consisting of heteroaryl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, alkyl, alkenyl, aryl, aralkenyl and heterocyclo; X is selected from the group consisting of:

Z is selected from the group consisting of a bond, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo; R¹ is selected from the group consisting of alkyl, aryl, aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² is optionally substituted by one or more substituents selected from the group consisting of alkoxy, aryloxy, haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy, alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group consiting of hydrogen, alkyl, and halo; and R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group; provided that Z is not methyl when X is XB or XC, further provided that W is not pyrrolidyl when X is XC, and further provided that R³ is not aryl- or haloaryl-substituted indolyl.
 2. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein A is selected from the group consisting of 5- or 6-membered heteroaryl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, lower alkyl, lower alkenyl, aryl, aralkenyl and 3-to 10-membered heterocyclo; Z is selected from the group consisting of a bond, lower alkyl, lower cycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo; R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to 10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of lower alkoxy, aryloxy, lower haloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(lower alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, and (3-to 10-membered heterocyclo)carbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group consiting of hydrogen, lower alkyl, and halo; and R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group.
 3. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; Z is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate, dimethylphosphonate, monoethylphosphonate, diethylphosphonate, monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and keto; R² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl, trichloromethylphenyl, bis(fluoromethyl)phenyl, bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl, bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl, bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy, difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy, diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino, N-(propylcarbonyl)amino, N-(butylcarbonyl)amino, N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl, dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl, difluorophenyl, chlorobromophenyl, chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy; R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, isoamyl, hexyl, fluoro, chloro, bromo, and iodo; and R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.
 4. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—.
 5. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—.
 6. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula II

wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, alkyl, alkenyl, aryl, aralkenyl and heterocyclo; Z is selected from the group consisting of a bond, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo; R¹ is selected from the group consisting of alkyl, aryl, aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of alkoxy, aryloxy, haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy, alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consiting of hydrogen, alkyl, and halo; and R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group; provided that R³ is not aryl- or haloaryl-substituted indolyl.
 7. The compound, pharmaceutically-acceptable salt or tautomer of claim 6, wherein A is selected from the group consisting of 5- or 6-membered heteroaryl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, lower alkyl, lower alkenyl, aryl, aralkenyl and 3-to 10-membered heterocyclo; Z is selected from the group consisting of a bond, lower alkyl, lower cycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo; R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to 10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of lower alkoxy, aryloxy, lower haloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(lower alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, and (3-to 10-membered heterocyclo)carbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consiting of hydrogen, lower alkyl, and halo; and R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group.
 8. The compound, pharmaceutically-acceptable salt or tautomer of claim 6, wherein A is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—; W is selected from the group consisting of a bond, —C(═O)—, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; Z is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate, dimethylphosphonate, monoethylphosphonate, diethylphosphonate, monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and keto; R² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl, trichloromethylphenyl, bis(fluoromethyl)phenyl, bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl, bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl, bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy, difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy, diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino, N-(propylcarbonyl) amino, N-(butylcarbonyl) amino, N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl, dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl, difluorophenyl, chlorobromophenyl, chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy; R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoro, chloro, bromo, and iodo; and R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.
 9. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula III

wherein W is selected from the group consisting of a bond, —C(═O)—, alkyl, alkenyl, aryl, aralkenyl and heterocyclo; Z is selected from the group consisting of a bond, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclo; R¹ is selected from the group consisting of alkyl, aryl, aralkyl, alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of alkoxy, aryloxy, haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy, alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, alkoxy, aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consiting of hydrogen, alkyl, and halo; and R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group; provided that R³ is not aryl- or haloaryl-substituted indolyl.
 10. The compound, pharmaceutically-acceptable salt or tautomer of claim 9, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen.
 11. The compound, pharmaceutically-acceptable salt or tautomer of claim 10, wherein W is selected from the group consisting of a bond, —C(═O)—, lower alkyl, lower alkenyl, aryl, aralkenyl and 3- to 10-membered heterocyclo; Z is selected from the group consisting of a bond, lower alkyl, lower cycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo; R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl, lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to 10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, hydroxy, carboxyl, halo, cyano and keto; R² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to 10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of lower alkoxy, aryloxy, lower haloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl, haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy, lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(lower alkylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, aryl, lower alkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, and (3-to 10-membered heterocyclo)carbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl, carboxyl, aryloxy, keto, and hydroxy; R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group.
 12. The compound, pharmaceutically-acceptable salt or tautomer of claim 11, wherein W is selected from the group consisting of a bond, —C(═O)—, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; Z is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl; R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate, dimethylphosphonate, monoethylphosphonate, diethylphosphonate, monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, carboxyl, fluoro, chloro, bromo, iodo, cyano and keto; R² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl, biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl, chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl, trichloromethylphenyl, bis(fluoromethyl)phenyl, bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl, bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl, bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy, bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy, difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy, bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy, dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy, ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy, diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy, ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy, diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy, hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino, N-(propylcarbonyl)amino, N-(butylcarbonyl)amino, N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro; R³ is selected from the group consisting of hydrogen, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl, dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, and tetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one or more substituents selected from the group consisting of fluoro, chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl, difluorophenyl, chlorobromophenyl, chlorofluorophenyl, bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, keto, and hydroxy; R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.
 13. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula IV

wherein Z is selected from the group consisting of a bond, alkyl, aryl, aralkyl, heteroaralkyl, and heterocyclo; R¹ is selected from the group consisting of alkoxycarbonyl, alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, and heterocyclo, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, and keto; R² is selected from the group consisting of alkyl, aryl, heterocyclo, and heteroaryl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of alkoxy, alkyl, alkylaryloxy, alkylthio, aralkenyl, aralkoxy, aralkyl, aryloxy, cyano, halo, haloalkyl, haloalkylaryl, haloaryloxy, heteroaryl, hydroxy, hydroxyalkoxy, N-(alkylcarbonyl)amino, and nitro; R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen, alkyl and halo; and R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independently selected from the group consisting of hydrogen, alkyl, hydroxy, and alkoxy.
 14. The compound, pharmaceutically-acceptable salt or tautomer of claim 13, wherein Z is selected from the group consisting of a bond, lower alkyl, aryl, lower aralkyl, lower heteroaralkyl, and 3- to 10-membered heterocyclo; R¹ is selected from the group consisting of lower alkoxycarbonyl, lower alkyl, lower cycloalkyl, lower aralkyl, aryl, 3- to 10-membered heteroaryl, and 3- to 10-membered heterocyclo, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, halo, and keto; R² is selected from the group consisting of lower alkyl, aryl, 3- to 10-membered heterocyclo, and 3- to 10-membered heteroaryl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of lower alkoxy, lower alkyl, lower alkylaryloxy, lower alkylthio, lower aralkenyl, lower aralkoxy, lower aralkyl, aryloxy, cyano, halo, lower haloalkyl, lower haloalkylaryl, haloaryloxy, 3- to 10-membered heteroaryl, hydroxy, lower hydroxyalkoxy, N-(lower alkylcarbonyl)amino, and nitro; R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group consiting of hydrogen, lower alkyl, and halo; and R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy, and lower alkoxy.
 15. The compound, pharmaceutically-acceptable salt or tautomer of claim 14, wherein Z is selected from the group consisting of a bond, methyl, ethyl, propyl, t-butyl, phenyl, tetrahydronaphthyl, biphenyl, naphthyl, phenylpropyl, indolylethyl, and piperidyl; R¹ is selected from the group consisting of methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenyl, tetrahydronaphthyl, indolyl, tetrahydrofuryl, pyrrolidinyl, and morpholinyl, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, bromo, fluoro, chloro, and keto; R² is selected from the group consisting of methyl, phenyl, biphenyl, naphthyl, tetrahydrofuryl, pyrrolidinyl, morpholinyl, piperidyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together with the atom to which they are both attached form a piperidyl or cyclohexyl group, wherein R² or the piperidyl or cyclohexyl group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl, methylphenoxy, methylthio, phenylethenyl, benzyloxy, phenylethoxy, benzyl, phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl, trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole, hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro; R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, fluoro, chloro, and bromo; and R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independently selected from the group consisting of hydrogen, methyl, hydroxy, and methoxy.
 16. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula V

wherein Z is selected from the group consisting of a bond, alkyl, aralkyl, heteroaralkyl, and heterocyclo; R¹ is selected from the group consisting of alkoxycarbonyl, alkyl, aralkyl, aryl, heteroaryl, and heterocyclo, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, and keto; R² is selected from the group consisting of alkyl, aryl, and heteroaryl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of alkoxy, alkyl, alkylaryloxy, alkylthio, aralkenyl, aralkoxy, aralkyl, aryloxy, cyano, halo, haloalkyl, haloalkylaryl, haloaryloxy, heteroaryl, hydroxy, hydroxyalkoxy, N-(alkylcarbonyl)amino, and nitro; R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independently selected from the group consisting of hydrogen, alkyl, hydroxy, and alkoxy.
 17. The compound, pharmaceutically-acceptable salt or tautomer of claim 16, wherein Z is selected from the group consisting of a bond, lower alkyl, lower aralkyl, lower heteroaralkyl, and 3- to 10-membered heterocyclo; R¹ is selected from the group consisting of lower alkoxycarbonyl, lower alkyl, lower aralkyl, aryl, 3- to 10-membered heteroaryl, and 3- to 10-membered heterocyclo, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, halo, and keto; R² is selected from the group consisting of lower alkyl, aryl, and 3- to 10-membered heteroaryl, or R² and R⁸ together with the atom to which they are both attached form a 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of lower alkoxy, lower alkyl, lower alkylaryloxy, lower alkylthio, lower aralkenyl, lower aralkoxy, lower aralkyl, aryloxy, cyano, halo, lower haloalkyl, lower haloalkylaryl, haloaryloxy, 3- to 10-membered heteroaryl, hydroxy, lower hydroxyalkoxy, N-(lower alkylcarbonyl)amino, and nitro; R^(10a), R^(10b), R^(10c), R^(11d), and R^(10e) are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy, and lower alkoxy.
 18. The compound, pharmaceutically-acceptable salt or tautomer of claim 17, wherein Z is selected from the group consisting of a bond, methyl, ethyl, propyl, t-butyl, phenylpropyl, indolylethyl, and piperidyl; R¹ is selected from the group consisting of methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl, benzyl, phenyl, tetrahydronaphthyl, indolyl, tetrahydrofuryl, pyrrolidinyl, and morpholinyl, wherein R¹ is optionally substituted by one or more substituents selected from the group consisting of methyl, chloro, and keto; R² is selected from the group consisting of methyl, phenyl, biphenyl, naphthyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together with the atom to which they are both attached form a piperidyl or cyclohexyl group, wherein R² or the piperidyl or cyclohexyl group formed with R⁸ is optionally substituted by one or more substituents selected from the group consisting of methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl, methylphenoxy, methylthio, phenylethenyl, benzyloxy, phenylethoxy, benzyl, phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl, trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole, hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro; R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independently selected from the group consisting of hydrogen, methyl, hydroxy, and methoxy.
 19. The compound, pharmaceutically-acceptable salt or tautomer of claim 18, wherein the compound is selected from the group consisting of 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine, 1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[(1-tert-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine, 1-[(1-benzyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine, (5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)acetic acid methyl ester, 1-[(1-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine, 1-[(1-isopropyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine, 5-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)-1H-indole, (5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)acetic acid ethyl ester, 1-(3-phenylallyl)-4-{phenyl-[1-(1,1,3,3-tetramethylbutyl)-1H-tetrazol-5-yl]methyl}piperazine, (5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)acetic acid tert-butyl ester, 3-phenyl-2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propionic acid methyl ester, 1-{[1-(3,3-diphenylpropyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine, 1-{[1-(1-benzylpiperidin-4-yl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine, 3-[2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)ethyl]-1H-indole, 1-{[1-(3,4-dichlorobenzyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine, 3-(1H-indol-3-yl)-2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propionic acid methyl ester, 1-(3-phenylallyl)-4-{phenyl-[1-(tetrahydrofuran-2-ylmethyl)-1H-tetrazol-5-yl]methyl}piperazine, 1-[(1-phenethyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine, 1-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]pyrrolidin-2-one, 1-({1-[2-(1-methyl-pyrrolidin-2-yl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3-phenylallyl)piperazine, 1-(3-phenylallyl)-4-{phenyl-[1-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-tetrazol-5-yl]methyl}piperazine, 1-({1-[2-(4-chlorophenyl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3-phenylallyl)piperazine, 4-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]morpholine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]naphthalen-1-ylmethyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-styrylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]thiophen-2-ylmethyl}-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-p-tolylmethyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(4-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(3,4-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-m-tolylmethyl}-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]naphthalen-2-ylmethyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(1-methyl-1H-pyrrol-2-yl)methyl]-4-(3-phenylallyl)piperazine, 1-{(2-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(2-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[5-(3-trifluoromethylphenyl)furan-2-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{2-benzyloxy-1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]ethyl}-4-(3-phenylallyl)piperazine, 1-{(4-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(6-methylpyridin-2-yl)methyl]-4-(3-phenylallyl)piperazine, 1-{[3-(3,4-dichlorophenoxy)phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-p-tolyloxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-3-ylmethyl}-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-2-ylmethyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3-phenylallyl)piperazine, 3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile, 2-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile, 1-{benzo[1,3]dioxol-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenol, 1-{benzo[1,3]dioxol-5-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 2-(3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenoxy)ethanol, 1-{1-[1-[(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-2-phenethyloxyethyl}-4-(3-phenylallyl)piperazine, 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-4-ylmethyl}-4-(3-phenylallyl)piperazine, 1-{[3-(3,5-dichloro-phenoxy)-phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{1-benzyl-4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]piperidin-4-yl}-4-(3-phenylallyl)piperazine, 1-{1-[1-[(2,6-dimethylphenyl)-1H-tetrazol-5-yl]cyclohexyl}-4-(3-phenylallyl)piperazine, 1-{4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-1-methylpiperidin-4-yl}-4-(3-phenylallyl)piperazine, 1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{(4-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-(3-phenylallyl)-4-[phenyl-(1-phenyl-1H-tetrazol-5-yl)methyl]piperazine, 1-[(4-imidazol-1-ylphenyl)-(1-phenyl-1H-tetrazol-5-yl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(3,4-dimethylphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{(3,4-difluorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isopropylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methylsulfanylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(3,4-dimethoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{(4-benzyloxy-3-methoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isobutylphenyl)methyl]-4-(3-phenylallyl)piperazine, n-(4-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenyl)acetamide, 3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethoxyphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(3,5-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-nitrophenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{(3-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-{(3-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine, 1-{biphenyl-3-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3,3-diphenylallyl)piperazine, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-[3-(4-methoxyphenyl)allyl]piperazine, 2-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-ylmethyl}-1-methyl-1H-indole, 3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-ylmethyl}-1H-indole, 2-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-yl}propenyl)phenol, 1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylpropyl)piperazine, 1-benzo[1,3]dioxol-5-ylmethyl-4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazine, (1-benzylpyrrolidin-3-yl)-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]ethylamine, 4-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-yl}propenyl)-2-methoxyphenol, and 1-[[1-(2,6-dichlorophenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine.
 20. A pharmaceutical composition comprising a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 6, 9, 13, 16, and 19 and a pharmaceutically acceptable carrier, adjuvant, or diluent.
 21. A method of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, the method comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 6, 9, 13, 16, and
 19. 22. A method of treating or preventing a condition selected from the group consisting of feeding disorders, sexual disorders, reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, and sleep disturbances, comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 6, 9, 13, 16, and
 19. 23. The method of claim 22 wherein the condition being treated or prevented is a feeding disorder.
 24. The method of claim 23 wherein the feeding disorder is selected from the group consisting of obesity, bulimia and bulimia nervosa.
 25. A method of treating or preventing obesity, comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer, or prodrug of any of claims 1, 6, 9, 13, 16, and
 19. 